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WHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary, University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1  See pages 141–6 for a full list of Witness Seminars held, details of the published volumes, and other 
related publications.
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funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the Seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting.  Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our Group’s website at www.histmodbiomed.org 
vii
ACKNOWLEDGEMENTS
Many thanks to Professor Peter Harper for suggesting this meeting, and to 
Professor Sue Povey and Professor Ian Craig who also advised us in planning 
the seminar. Additionally, Sue Povey generously lent us her precious copies of 
many of the HGM volumes. 
Professor Sir Walter Bodmer kindly provided a photograph of the participants 
at the EMBO 1973 conference that he convened in Oxford, and we are very 
grateful to him and Professor Veronica van Heyningen for identifying many of 
its participants; and to other Witness Seminar participants who have engaged 
enthusiastically and helpfully in the editorial process.
As with all our meetings, we depend a great deal on Wellcome Trust staff to 
ensure their smooth running: the Audiovisual Department, Catering, Reception, 
Security, and Wellcome Images. We are also grateful to Mr Akio Morishima 
for the design and production of this volume; the indexer Ms Liza Furnival; 
Mrs Sarah Beanland and Ms Fiona Plowman for proofreading; Mrs Debra Gee 
for transcribing the seminar; Ms Caroline Overy for assisting with running 
the seminar and Mr Adam Wilkinson who assisted in the organization and 
running of the meeting. Finally, we thank the Wellcome Trust for supporting 
the Witness Seminar programme. 
Tilli Tansey
Emma Jones 




Figure A Professor Peter Goodfellow; provided with 
permission xv
 
Figure 1 Witness Seminar participants 2
Figure 2 Professors Veronica van Heyningen, Bert Bakker 
and Tilli Tansey 3
Figure 3 Professor Peter Harper 4
Figure 4 Professor Sue Povey 8
Figure 5 Professor Sir Walter Bodmer 11
Figure 6 Professor Ellen Solomon, Professor Malcolm 
Ferguson-Smith 15
Figure 7 Professor Ian Craig, Professor Malcolm  
Ferguson-Smith 16
Figure 8 Professor Veronica van Heyningen 20
Figure 9 Professors Veronica van Heyningen and Sue Povey 
with 1973 EMBO conference photograph: see 
Appendix 2 for original with key 22
Figure 10 Professor Bert Bakker 30
Figure 11 Professor Ellen Solomon 31
Figure 12 Professor Maj Hultén 35
Figure 13 Professor Sue Malcolm 43
Figure 14 Professor Tim Bishop 47
Figure 15 Professor Chris Rawlings 58
Figure 16 Professor Michael Morgan 63
* Unless otherwise stated, all photographs were taken by Thomas Farnetti, Wellcome Trust, and 
reproduced courtesy of the Wellcome Library, London.
Figure 17 Dr Susan Wallace 86
 
Table 1 List of HGMW with dates of meetings, convenors, 
and editors of publications 6
Table 2 Outline programme for Witness Seminar 7
Appendix 1
Photographs of participants at HGM1, Yale; 
‘New Haven Conference 1973: First International 
Workshop on Human Gene Mapping’, reproduced 
from Ruddle et al. (eds) (1974a); pages 206–
11. The editors of the present volume have 
made every effort to obtain permission for all 
copyright-protected material. Any omissions are 
entirely unintentional. 90, 92, 94
Appendix 2 Photograph of participants in the European 
Molecular Biology Organisation (EMBO) 
workshop on ‘Cell Hybridisation and Somatic 
Cell Genetics’, Oxford, 12–14 July 1973; 
provided by Professor Sir Walter Bodmer with 
permission. 97
xi
CEPH Centre d’Étude du Polymorphisme Humain 
cDNA Complementary DNA
EMBO European Molecular Biology Organization
EU European Union 
GDB  Genome Database
HAT Histone acetyltransferase
HGM/W Human Gene Mapping/Workshops
HLA  Human leukocyte antigen*
HUGO Human Genome Organization
ICRF Imperial Cancer Research Fund 
LOD Log of the odds on linkage
MRC  Medical Research Council
NIH  National Institutes of Health
RFLP Restriction fragment length polymorphisms
UCL  University College London
OMIM (Online Mendelian Inheritance in Man) is a reliable information source 
for human genes and phenotypes: http://www.ncbi.nlm.nih.gov/omim
 HUGO Gene Nomenclature Committee has a search facility for internationally-
approved gene nomenclature; http://www.genenames.org/ 
(Websites visited 21 April 2015).
 
* See note 68 in main transcript about HLA nomenclature.




Scientific events that become part of everyday culture are rare but I can quote two 
from my lifetime: the determination of the structure of DNA and sequencing 
the human genome. Human gene mapping is one of the links between these two.
The famous double helix was first described in 1953 – two years after I was born, 
although I suspect that coincidence is linked only in my mind. And now a trick 
question – when was the correct number of human chromosomes determined? 
The answer to this question is 1956, three years after Watson and Crick’s famous 
paper.1 There are many technical and social reasons for the failure to accurately 
count what could be seen down a microscope. The technical reasons were to 
do with culturing cells, capturing them in metaphase and spreading the fixed 
chromosomes. There were two social reasons. The first was the knowledge that 
the correct number was 48; everyone ‘knew’ this because Painter had concluded 
that 48 ‘was’ the number in the early 1920s.2 The second reason is that human 
genetics was not regarded as that important by many scientists so why worry 
about chromosome numbers? Obviously, the biochemistry of inherited diseases 
was a field of active study but there was nothing that could be done about the 
genetic component. People inherited what they inherited and that was that. This 
view was still strong in the late 1970s when I was asked to teach immunology on 
a course for genetic counsellors at UC Berkeley. I was surprised to discover that 
50% of the students were nuns. When I asked them how they worked out risks 
for the repeated inheritance of syndromes, they showed me empirically derived 
tables. It was ironic that they did not apply the rules of the monk Mendel.
In 1972, I joined Walter Bodmer’s lab in Oxford to do a PhD. Walter and the 
others in the Genetics Laboratory in Oxford created an environment where as 
a student I could dream and thrive. It was the perfect start to my journey as a 
scientist. In the world I joined, human genetics was mostly a part-time, arcane 
pursuit of slightly eccentric people. The descendants of Haldane, Fisher and 
Wright talked to each other about population structures that did not exist, using 
equations that most of us could not understand (see Sue Povey’s comments about 
Newton Morton, page 9). The descendants of Galton and Garrod were studying 
enzymes, and Race and Sanger were looking at blood groups. Unknown to me, 
two techniques were poised to change the world of human genetics – somatic 
cell genetics and chromosome banding. I had joined Walter’s lab to study the 
1  Watson and Crick (1953); Tjio and Levan (1956). 
2  Painter (1922).
xiv
biochemistry of HLA but the somatic cell genetics stuff seemed both easy and 
fun. I wanted to play this game, so in secret from Walter, with help from my 
friends and mentors, I mapped the gene for beta 2 microglobulin to chromosome 
15. I was hooked; I was part of the small group of scientists mapping the human 
genome. 
As I read the comments and recollections of my friends at this Witness Seminar, 
I realised the obvious truth that history is very context dependent. Their 
history is not precisely mine but, at one level higher, we shared a vision that 
one day a map of the human genome would be useful. This vision was also 
shared internationally. I would particularly mention the contribution of Victor 
McKusick who relentlessly championed the importance of gene mapping. He 
collected and collated any and all data and he photographed all of us – all the 
time. He was a wise and gentle man.
Somatic cell genetics put hundreds of genes onto the human gene map. While 
this was happening, DNA cloning and DNA sequencing were beginning 
to be developed. Another revolution was going to happen – within a decade 
molecular biology was to be combined with human genetics. Direct access to 
DNA sequences provided an unlimited number of genetic markers. The maps 
of the human genome became useful; if you could map a gene you could clone 
it. Mapping and cloning genes provided tools for beginning to help patients and 
families afflicted with genetic disease. Five years later, in 1994, Jean Weissenbach 
produced the first complete recombination maps of the human genome and 
soon after the Human Genome Project introduced big science to biology.
Mapping genes and constructing maps connected the determination of the 
structure of DNA and sequencing the human genome. Without gene mapping 
it would not have been possible to sequence the genome – despite the rhetoric of 
some, ‘shot-gun’ sequencing of the whole human genome was impossible. The 
sequencers needed maps to tell them where they were. 
The mapping of the human genome was a collaborative activity that was co-
ordinated by the Human Gene Mapping Workshops. The meetings allowed 
practitioners to learn best practice, share rumours, steal ideas and do all the 
things that humans do when put together in a group. Sequencing the genome 
superseded the need for gene mapping – it was inherent in the sequence. Like 
many waystations in science, time and progress made gene mapping largely 
irrelevant. But capturing the spirit of the meetings and tracing the lineage of 
xv
ideas adds something important to the process and progression of science. I 
congratulate my friends who attended the workshop and greatly enjoyed reading 
their thoughts and anecdotes.
Scientists go through several stages of evolution. First, the apprentice is driven 
by love for new knowledge. Secondly, the journeyman is looking to produce 
the masterpiece to guarantee a career in research. Thirdly, the professional is 
fund-raising to feed a laboratory of apprentices and journeymen. And at last, 
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Professor Tilli Tansey: Good afternoon and welcome to this Witness Seminar on 
the history of Human Gene Mapping Workshops. I’m Tilli Tansey and I’m the 
Head of the History of Modern Biomedicine Research Group at Queen Mary, 
University of London. This format of Witness Seminars was set up some years 
ago, when we were part of the Wellcome Trust, to record living, recent history. 
Basically, what we want to hear is what really happened, the stories behind the 
published literature: who did what; who were the main drivers; who were the 
main resisters? What really went on? To that purpose, everything that is said 
today is recorded and will be transcribed, then published. This topic is part of a 
focus we have on genetics as part of a Strategic Award from the Wellcome Trust. 
We’re focusing on five main areas in modern biomedicine, clinical genetics being 
one of them.1 Peter Harper has been our expert consultant adviser for nearly two 
years, on devising workshops and Witness Seminars on modern genetics. This 
is the fifth meeting we’ve held on this topic,2 so we’re already building up quite 
a corpus of related information and knowledge, and I know there are many 
people here who have already contributed to a previous meeting. We’ve also had 
1  For further details about the History of Modern Biomedicine’s Strategic Award from the Wellcome 
Trust for ‘Makers of Modern Biomedicine: Testimony and Legacy’, see http://histmodbiomed.org (visited 1 
October 2014).
2  Witness Seminars have previously been held on the histories of genetic testing, clinical genetics, cancer 
genetics, and molecular genetics. See Christie and Tansey (eds) (2003); Harper, Reynolds and Tansey (eds) 
(2010); Jones and Tansey (eds) (2013); Jones and Tansey (eds) (2014). A Witness Seminar was also held in 
2014 on ‘Medical Genetics: Development of the Ethical Dimension in Clinical Practice and Research’.
Figure 2: Professors Veronica van Heyningen, Bert Bakker and Tilli Tansey
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a lot of help from Sue Povey and from Ian Craig in setting up this meeting. It 
seemed absolutely ideal that Peter should chair this meeting, to which he readily 
agreed and therefore, without further ado, I’m going to hand over to Peter.
Professor Peter Harper: Well, thank you, Tilli, and it’s good to see everybody. 
Yes indeed, I’d like to thank Sue Povey and Ian Craig because they’ve given a lot 
of input to this. I’m not entirely sure why they proposed me as Chair except that I 
think it’s the principle that a Chair should know a little bit about a subject but not 
too much, and perhaps I fulfil that.3 I’m really glad though that we are having this 
Witness Seminar on human gene mapping and specifically on the Human Gene 
Mapping Workshops (HGMW). That’s for several reasons. I suppose the first 
is that gene mapping has always been at the centre of genetics, not just human 
genetics but genetics overall, and that really goes back to the very beginning of 
genetics. We’ve just passed the centenary of the first gene map, which was the one 
made by Alfred Sturtevant in 1913 on Drosophila.4 I’m not sure whether there was 
an anniversary meeting of any kind held in connection with that?
Professor Malcolm Ferguson-Smith: The European Cytogeneticists Association 
had a special session on this at their Dublin meeting in June 2013. I talked 
about Alfred Sturtevant and his paper in the Journal of Experimental Zoology, 
and so did Evan Eichler and Pat Harrison.5
3  See Harper (2008), in particular Chapter 7, ‘The human gene map’, pages 194–212. 
4  Sturtevant (1913). 
5  For the programme of the ‘9th European Cytogenetics Conference’, 29 June to 2 July 2013, see http://
www.eca2013.org/en/scientific-information-programme.html (visited 1 October 2014). 
Figure 3: Professor Peter Harper
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Harper: Good. I hope that has been or will be published or made available in 
some form?
Ferguson-Smith: Well, there’s an account of it in the Association newsletter.6
Harper: That’s good to know. A second reason that I’m very glad we’re having this 
meeting is that it’s quite urgent in terms of documenting people’s memories of the 
field, because just to look through the participants’ lists from the various workshops 
shows that there are already a number of the main people involved who are no 
longer with us. So it’s good that we’ve got a core at least of those from the UK, and 
representation from the Netherlands too. You can see from the programme that 
our remit today is the series of Human Gene Mapping Workshops that were held 
between the early 1970s and the early 1990s. But I hope we won’t interpret that 
too strictly and I’m quite sure people will cover, or go over the area of human gene 
mapping more generally. But there’s no way that we can possibly hope to cover the 
entire field of human gene mapping in a single afternoon. One particularly difficult 
decision was whether to include the later workshops on individual chromosomes, 
and to what extent, which then led into the Human Genome Project. Really, this 
was a question of logistics because, if one had tried to cover that as fully as the early 
workshops, then it would have meant involving a lot more people, many of them 
from America whom we can’t afford to bring over for just one afternoon’s meeting. 
And so we’ve compromised, in the sense of including the X Chromosome Workshop, 
which I believe was the first of the specific Single Chromosome Workshops.7
Ferguson-Smith: May I just add another thing here?
Harper: You can, Malcolm.
Ferguson-Smith: It’s not necessary perhaps to go over all the Single Chromosome 
Workshops. I was coordinator and Bronwen Loder did most of the work 
of organizing them.8 But about 24 were done in the 3 years after the 11th 
Human Gene Mapping Workshop and another 22 were done up until 1998. 
There might even have been one or two in 1999; I forget. But anyway, these 
are recorded in various publications and also in the reports from the human 
genome analysis book from the European Commission.9
6  ECA Newsletter, No. 32, July 2013. 
7  Cook-Deegan et al. (1990). See pages 78–90.
8  See note 257. 
9  See Ferguson-Smith (1998), which contains a list of all Single Chromosome Workshops from 1993 to 
1997, and lists the journals in which they were published; see pages 342–5.
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Meeting  Date Location Organiser/Convenor Editor/s
HGM1 1973 New Haven Frank H Ruddle Frank H Ruddle, Dirk Bootsma, 
    Victor A McKusick, Harold P Klinger 
HGM2 1974 Rotterdam Dirk Bootsma Dirk Bootsma, Daniel Bergsma
    Frank Ruddle, Victor McKusick,
    Harold P Klinger
HGM3 1975 Baltimore  Victor A McKusick Daniel Bergsma, Victor A McKusick,
    Harold P Klinger, Dirk Bootsma,
    Frank H Ruddle 
HGM4 1977 Winnipeg  John L Hamerton Daniel Bergsma, John L Hamerton,
    Harold P. Klinger, Victor A McKusick,  
    H John Evans
HGM5 1979 Edinburgh H John Evans H John Evans, John L. Hamerton,
    Harold P Klinger, Victor A. McKusick
HGM6 1981 Oslo Kåre Berg Kåre Berg, H. John Evans,
    John L. Hamerton, Harold P Klinger
HGM7 1983 Los Angeles Robert S Sparkes Robert S Sparkes, Kåre Berg,
    H John Evans, Harold P Klinger
HGM8 1985 Helsinki Albert de la Chapelle Albert de la Chapelle,
    Harold P Klinger 
HGM9 1987 Paris Jean Frézal Jean Frézal, Harold P Klinger
HGM9.5 1988 New Haven  Frank H Ruddle Frank H Ruddle, Kenneth K Kidd,
    Harold P Klinger 
HGM10 1989 New Haven  Frank H Ruddle, Kenneth K Kidd, Harold P Klinger,
   Kenneth K. Kidd Frank H Ruddle
HGM10.5 1990 Oxford Ian Craig,  Ian Craig, Chris Rawlings,
   Walter Bodmer,  Harold P Klinger
   Ellen Solomon10
HGM11 1991 London Walter Bodmer, Ellen Solomon, Chris Rawlings,
   Ellen Solomon,  
   Harold P Klinger
Table 1: List of HGMW with dates of meetings, convenors, and editors of publications11
10 The published version of HGM10.5 credits Bodmer and Solomon as convenors, but correspondence 
from this Witness Seminar indicates the correct attribution should be Craig, Bodmer and Solomon. This 
change has the agreement of all relevant parties; see various items of e-mail correspondence, March 2015, 
in the archives of this meeting held at the Wellcome Library, London, Archives and Manuscripts, GC/253.
11  All details taken from the journal Cytogenetics and Cell Genetics published by Karger. 
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Harper: This is something we can come back to because you will see from the 
programme that that’s our last item and hopefully we’ll have time for you to 
say a bit more about that then. On the topic of publication, you can see that 
on the table we’ve actually got a complete series of the Human Gene Mapping 
Workshops volumes. I find it a little confusing, firstly that they were duplicate 
publications, which is probably a good thing, but also that in many cases the 
publication was a year after the workshop. 12 Anyway, that’s enough from me. 
To set the scene we’ve asked Sue Povey to give a general introduction to the 
workshop. I can’t think of anybody better than Sue, not just because of her 
own contributions but because she’s been based all these years at the Galton 
Laboratory, London, which has really been one of the key centres for human 
gene mapping from the very beginning.13
Table 2: Outline programme for Witness Seminar14
12  They were published as books by the National Foundation March of Dimes/Karger, and in the journal 
Cytogenetics and Cell Genetics (Karger). 
13  For a summary of the Galton Laboratory’s history at University College London, see http://www.ucl.
ac.uk/museums/galton/about/history (visited 1 October 2014). See also Jones (1993); Harper (2008), pages 
235–40. 
14  The outline programme was circulated to the seminar participants for their input a month in advance of 
the Witness Seminar.
Part 1
• Beginnings of human gene mapping
• Founding and organization of the Human Gene Mapping Workshops
• The first workshops (Yale 1973, Rotterdam 1974)
• Protein polymorphisms and other early genetic markers
• Somatic cell hybrids and cytogenetic markers
• DNA polymorphisms and the workshops
Part 2
• Linkage analysis and informatics
• Nomenclature
• Comparative gene mapping
• Evolution of the workshop series
• The final Human Gene Mapping Workshop (London 1991)
• The first chromosome-specific workshop (X and Y); beginnings of HUGO and 
Human Genome Project
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Professor Sue Povey: Thank you Peter. I’m sure I’m not standing here because 
I really witnessed the early human gene mapping but, as Peter said, I was in 
the Galton Lab where there had been very early involvement in human gene 
mapping and, of course, there had been an interest in the Galton Lab and in 
other places, but very largely in the Galton Lab in the first half of the twentieth 
century. And the first actual linkage found was, of course, as you would expect 
on the X chromosome, which was in 1937: Julia Bell and Haldane finding the 
linkage between haemophilia and colour blindness.15 And even at that time, they 
actually thought about the way this might be used for prediction of disease and, 
actually, what you now call eugenics.16 There had been a tremendous amount 
of theoretical work conducted in the Galton Lab by Fisher and Haldane and 
Hogben on how we would possibly ever compete with the Drosophila map, 
which was already very good in 1936.17 And the tiny bits of information you can 
15  Bell and Haldane (1937). Julia Bell FRCP (1879–1979) was at the Galton Laboratory from 1920 to 
1965. See for example, Bell (1922) and Bell (1935). J B S Haldane (1892–1964) was Professor of Genetics 
at UCL, and also Weldon Professor of Biometry (1937–1957), and Head of the Biometry, Genetics and 
Eugenics Department, of which the Galton Laboratory was a part. See, for example, Clark (1968). 
16  See Hall (2002). 
17  Ronald Aymer (R A) Fisher was Chair of the Galton Laboratory, University College London from 
1934 to 1943, where he set up a blood grouping unit; see UCL Archives, Galton Laboratory Records 
(1825–1998); http://tinyurl.com/o4tpowg (visited 17 November 2014). Lancelot Hogben (1895–1975) 
was Professor of Social Biology at University College London from 1930 to 1937. 
Figure 4: Professor Sue Povey
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get out from human families compared with what you can get from Drosophila. 
And so a tremendous amount of mathematical effort went into, for example, 
the next paper that I found interesting, which was by C A B Smith and Haldane 
about a refinement of this linkage between haemophilia and colour blindness, 
and by rather complex mathematics they managed to reduce, just by a small 
amount, the risk that was given to a mother of whether she would have a child 
with haemophilia. And the interesting thing to me about this paper was at the 
end of it they said, ‘It may appear a rather trivial advance but it may be in some 
centuries hence that a similar map may be available for humans as is available 
for Drosophila and the prediction of inherited disease and the prevention of 
congenital abnormalities will be routine.’ 18 I think to some extent in the next 
20 years it looked like that estimate might be right because the actual number 
of autosomal linkages found before the Human Gene Mapping Workshops was 
only about four. And most of those, I have to say, were something to do with 
the Galton Lab. The linkage between Lutheran and Secretor by Mohr was not 
done at the Galton Lab, but I believe he had been in the Galton.19
Then, of course, there was ABO and nail patella syndrome and ABO and AK 
a bit later.20 And then there was one interesting one, which I think was nothing 
to do with the Galton; it was Newton Morton finding that some forms of 
elliptocytosis were linked to rhesus.21 I think that one of the things that really 
carried forward to the Human Gene Mapping meetings was a paper of Newton 
Morton’s in 1955, which people, learned people, tell me says that if you get a 
lod score of three, honestly without cheating, without throwing anything out, if 
you ever get a lod score of three you can probably publish.22 If you read that paper 
you might not take home that message but I believe that’s what it’s meant to be, 
and that really persisted throughout the Human Gene Mapping Workshops, 
didn’t it? The only other two autosomal things really known before 1970 were 
the assignment of the Duffy blood group to chromosome 1 by Donahue in 
18  Haldane and Smith (1947); for quotation see page 30.
19  Mohr (1963). 
20  Renwick and Lawler (1955) and Rapley et al. (1968). 
21  Morton (1956). 
22  Newton Morton’s paper introduced the lod score from sequential analysis into genetic linkage analysis; 
see Morton (1955). See also page 55. Where a polymorphic gene and a gene related to a genetic disease are 
located in close proximity, on the same chromosome, lod (log of the odds on linkage) scores are a statistical 
measure of: a) the chance that a disease is linked to the locus of the polymorphic gene; b) the most likely 
recombination frequency between them. 
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the States, and of haptoglobin to chromosome 16 in the UK, both of them by 
going with a visible chromosome polymorphism. 23 So that was the scene really, 
just a very short time before the first Human Gene Mapping Workshops. But 
in those intervening years, a great revolution had occurred in the possible ways 
of mapping. So that was about all I was going to say.
Ferguson-Smith: Sue, was the haptoglobin one Bette Robson?
Povey: The haptoglobin was Bette Robson, yes.24 That was a Galtonian thing, of 
course. Lionel Penrose had become Galton Professor by then and he encouraged 
people to maintain an interest in mapping.25 He was very mathematically 
orientated and he hired people like C A B Smith, who was also very productive 
in many things that were afterwards applied.26
Harper: On the topic of that linkage of Jan Mohr, I was able to interview him 
before he died and I was really interested that, when I asked him, as I’ve asked 
other people, ‘Who would you consider the main influence on your work?’, he 
was definite that it was Penrose.27 That’s the case for so many people. So the field 
of human gene mapping has got a pretty distinguished background before the 
workshops began. Is there anyone who wants to say anything about those early 
years before we move on to the founding of the workshops themselves?
Professor Sir Walter Bodmer: We should remember that there was a lot of 
mapping of the sort that contributed to the workshops for several years before 
the first workshop. Maybe that’s something I could comment on?
Harper: Yes, I think that would be good to develop, because you’re referring 
specifically to the cell hybridization work? Before throwing things open on the 
founding of the workshops, I’d just like to quote a piece from Victor McKusick’s 
autobiographical article, which he published a couple of years before he died, and 
23  Donahue et al. (1968); Robson et al. (1969). 
24  Professor Elizabeth (Bette) Robson (b. 1928) was a founder member of the MRC Human Biochemical 
Genetics Unit at UCL (1962), and she was Galton Professor of Human Genetics at UCL from 1978 to 1993. 
25  Lionel Sharples Penrose (1898–1972) was Galton Professor of Eugenics (1945–1962) and Professor of 
Human Genetics at University College London (1962–1965). 
26  Cedric Austen Bardell Smith (1917–2002) was Weldon Professor of Biometry at the Galton Laboratory, 
UCL, from 1964 until the end of his career, where he developed several statistical methodologies. 
27  Professor Peter Harper’s interview with Professor Jan Mohr is freely available to download from the 
Genetics and Medicine Historical Network’s website: http://www.genmedhist.info/interviews/Mohr 
(visited 1 October 2014). 
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then ask whether people here think that actually is correct, or whether there are 
other things that need to be brought in. What he says is: ‘The annual or biannual 
Human Gene Mapping Workshops initiated in 1973 were Frank Ruddle’s idea. 
A regular member of the faculty of the Bar Harbor Short Course in Clinical 
Genetics, Ruddle solicited my collaboration in the organization of the HGM 
Workshops. He trusted that I would be able to arrange funding from the March 
of Dimes, which funded the Bar Harbor course and the Clinical Delineation of 
Birth Defects conferences and on whose medical advisory committee I’d served 
since 1959. The idea of the HGM Workshops was enthusiastically received 
by the March of Dimes and was implemented by Dr Daniel Bergsma, vice 
president for professional education.’ 28 I’ve always felt that, regardless of the role 
of the Galton and places elsewhere in human gene mapping, the actual idea and 
initiation of the workshops came from the American side as Victor McKusick 
states there. I’d be interested to know from those people who were around at 
that time whether you think that is indeed correct?
28  McKusick (2006); see pages 12–13. Victor McKusick (1921–2008) founded Johns Hopkins University’s 
division of medical genetics in 1957, becoming Professor of Medical Genetics there in 1985. For an overview 
of the scientific context in the 1960s and 1970s leading up to the Human Gene Mapping Workshops, see 
Ruddle (1984). See also biographies for McKusick and Ruddle on pages 104–5, 107. 
Figure 5: Professor Sir Walter Bodmer
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Bodmer: I think you’ve really got to go into the background, and early history 
of the tremendous contribution that came from somatic cell genetics to gene 
mapping because it’s that that actually initiated the idea of the workshops 
through Frank Ruddle, although he wasn’t the first person to do linkage in 
somatic cell hybrids.
Harper: Maybe that’s a good time, Walter, for you to say a bit more about that 
early hybridization work?
Bodmer: Well, I think it’s important to be aware of the history because, as I see it 
really, it was the opportunity to do genetics with somatic cells that was the next 
major leap forward. One can have the other sort of main leaps, well obviously the 
use of restriction mapping, which Ellen (Solomon) and I emphasized in 1979, 
and then, of course, the whole sequencing work.29 Just to give a bit of history, 
and it’s personal history, I actually spent the summer of 1959 in Pontecorvo’s lab, 
late summer, and Pontecorvo and Lederberg were the two people who’d actually 
suggested the idea that one might do somatic cell genetics.30 Pontecorvo, by the 
analogy of what he’d done in Aspergillus and chromosome segregation there, and 
Lederberg had the idea that one might actually do it by crossing cells.31 When 
I went to be a postdoc with Josh Lederberg at Stanford, which was in 1961, I 
actually had the ideas in the back of my mind as something that one might get 
into. One of the reasons I went there was because some very early work with 
tissue culture had been done by Len Hertzenberg when he was still, I think, 
at the NIH (National Institutes of Health) before he came to Stanford,32 and 
I thought that it would be a good place to start this. But in fact, it wasn’t till 
five years later that I was able to get started in my own lab and we did the first 
hybrids between lymphocytes and an 8-azaguanine resistant mouse cell line. The 
precursor to that, as I’m sure many people know, is that 8-azaguanine resistance 
29  Solomon and Bodmer (1979). 
30  Guido Pontecorvo (1907–1999) established a genetics research department at the University of Glasgow 
in 1945, of which he became Professor of Genetics in 1955. He worked there until 1968 when he moved to 
the Imperial Cancer Research Fund laboratories in London until his retirement. For an obituary see Anon 
(1999). His papers are held at the library of the University of Glasgow Archive Services, reference GB 0248 
UGC 198. Joshua Lederberg (1925–2008) was a bacteriologist and geneticist, and a Nobel Laureate in 
1958. 
31  Pontecorvo and Käfer (1956); Lederberg (1956).
32  Leonard Hertzenberg (1931–2013) was based at the National Institutes of Health from 1957 to 1959, 
where he worked in the laboratory of Harry Eagles on mammalian somatic cell genetics. See Hertzenberg 
and Hertzenberg (2013). 
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had been actually used by Szybalski to select using something like the HAT 
regime.33 Then it was Littlefield in a paper published in Cold Spring Harbor in 
1964, possibly there was earlier work, who made the first hybrid selectively using 
thymidine kinase minus cells and 8-azaguanine resistant cells so that you could 
do the HAT (histone acetyltransferase) selection, so the only things that would 
survive would be the hybrid.34 We had the idea that you could simplify that by 
taking human lymphocytes, which couldn’t divide anyway and then having a 
mouse cell line that was 8-azaguanine resistant, so you could then select hybrids 
only having the selection on the one side of the mouse because the non-dividing 
cells could provide the compensation that you needed. This would be a way of 
wide-scale sampling of different humans. About that time, I think the initial, 
the first real, experiment that showed linkage mapping in hybrids was Weiss 
and Green, who used the hybrid technique but not with lymphocytes, and 
they investigated the chromosomal localization of the thymidine kinase marker 
that was ultimately shown to be on chromosome 17.35 That was really the first 
case that you could associate a marker with something that you’d selected for, 
and interestingly enough, although Mary Weiss did further work, they never 
really followed that up.36 So actually, the first somatic cell hybrids that really 
showed linkage beyond that were in a paper that we published in Nature in 
1969, and had talked about in a meeting in 1968.37 This first of all showed, 
the most obvious thing it showed, was that in tissue culture the 8-azaguanine, 
the HPRT mutation, was on the X chromosome – which of course was already 
known because the Lesch–Nyhan syndrome was a mutation in that.38 We’d been 
made aware of that by Howard Green actually. I think in that paper we also 
showed, certainly, that we did something with LDH – we suggested that the 
genes for LDHA and LDHB were not linked – and then that was really the first 
paper beyond Weiss and Green that did any mapping. The next paper, there 
were two papers, one from my lab and one from Frank Ruddle in which we 
33  Szybalski and Smith (1959).  
34  Littlefield (1964). 
35  Weiss and Green (1967); Miller et al. (1971). 
36  Mary Weiss worked in Boris Ephrussi’s laboratory at the New York University School of Medicine, 
Department of Pathology, and also led the Institut Pasteur’s Genetics of Differentiation Unit in Paris. 
37  The meeting was ‘Heterospecific Genome Interaction’ at the Wistar Institute of Anatomy and Biology, 
22–23 October 1968. See Nabholz, Miggiano and Bodmer (1969) and Miggiano, Nabholz and Bodmer 
(1969). 
38  See Felix and DeMars (1969). 
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extended that, and we were using electrophoresis to distinguish human and 
mouse enzymes. Then we could show that we could use a random assortment 
of the chromosomes because what Weiss and Green had importantly shown was 
that you lost human chromosomes more or less randomly in the hybrids, so you 
got a range of cell lines that had different combinations of human chromosomes 
in the presence of a mouse background that allowed you to associate human 
markers with each other and then eventually with the identification of the 
chromosomes. In the same issue of Nature in 1970, we published at the same 
time as Frank Ruddle that, for instance, LDH A and B were definitely not 
linked and that LDH was linked with peptidase B.39 Actually, at that time Frank 
Ruddle and my lab were the only labs that were doing this sort of hybridization 
in the very early days. I used to have to referee all Frank Ruddle’s grants and no 
doubt he did mine. So, without going into a lot more detail I think it was that 
stimulus that immediately made one realise you could enormously extend the 
range of mapping using those techniques. That was the stimulus for the idea 
that one had to get the data together to do this and I think it’s correct that Frank 
Ruddle had that idea and got Victor McKusick involved, of course, the first 
HGM Workshop was in 1973. Of the people here, I know that Ian Craig went.
Ferguson-Smith: Ruddle also went to Pontecorvo in Glasgow in the 1960s.40 He 
went there specifically because he was influenced by the parasexual cycle that 
Pontecorvo had proposed first in Aspergillus.41
Bodmer: Well, he was only a year or two after me on that.
Ferguson-Smith: Yes, he was probably a year or two after you. He went also 
at the same time to John Paul to work on cell culture.42 Some of the earlier 
work that Pontecorvo had done is beautifully summarized in his book Trends in 
Genetic Analysis.43
Bodmer: Ponte’s work was extremely elegant. I had the honour of bringing 
Aspergillus to the Cambridge genetics department from Glasgow. His ideas were 
39  Santachiara et al. (1970); Ruddle et al. (1970). 
40  See biography on page 107. 
41  Pontecorvo, Roper and Forbes (1953); see also Pontevorvo et al. (1953).
42  Dr John Paul (1922–1994) was Founding Director of the Beatson Institute for Cancer Research, 
Glasgow. For an obituary, see Freshney (1994). 
43  Pontecorvo (1958). 
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very influential but they were not actually the way that somatic cell genetics 
eventually developed; it developed more along the lines that Lederberg had 
suggested through crosses.44 By the time of the first Gene Mapping Workshop, 
certain people here have got their names on papers, they’d actually extended 
the mapping quite a lot. With Victor McKusick’s enormous contributions 
in Mendelian Inheritance in Man, it became a sensible idea to try and gather 
together what was known and keep track of it from time to time.45 That’s the 
way I see the origin of those workshops.
Harper: Can I ask one thing to anyone here? Am I right in that, although Henry 
Harris with John Watkins was the initiator of the actual hybrid techniques, and 
Pontecorvo was very much involved also, I don’t think either of them were 
involved in applying this to human gene mapping.46
44  See note 31.
45  McKusick (1966). See also note 172. 
46  Sir Henry Harris (1925–2014) was Professor of Pathology at the University of Oxford (1963–1979) and 
Head of Department in the Sir William Dunn School of Pathology, Oxford (1963–1994). John Frederick 
Watkins (1927–2003) was based at the School from 1959 to 1966; see Morgan and Westmoreland (2003). 
For Pontecorvo, see note 30. 
Figure 6: Professor Ellen Solomon, Professor Malcolm Ferguson-Smith
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Bodmer: I can say. I was in Oxford at about the time when Henry Harris 
was doing that. Neither of those are quite true: Pontecorvo never actually did 
anything himself with somatic cells. He had a guy there you may know, Eugene 
Bell, who was a visitor in his lab at the time, who tried to implement some of 
the ideas. I don’t know whether that was before you went there, Malcolm?
Ferguson-Smith: It wasn’t for want of trying. I mean right up to 1968 he was 
still trying to work with human somatic cells, and then he came with Michael 
Stoker to ICRF (Imperial Cancer Research Fund).47
Bodmer: Could I just comment on the Henry Harris thing? The first hybrids 
that were made were long before Henry Harris, they were Littlefield’s.48 Those 
were the first somatic cell hybrids that were made. Then there were others, Boris 
Ephrussi and others.49 Henry Harris, his introduction was the use of Sendai 
virus that came from John Watkins, who was a reader at the Sir William Dunn 
School of Pathology, and he knew about viruses that stimulated the formation 
47  Michael Stoker (1918–2013) was the Director of the Imperial Cancer Research Fund laboratories from 
1968 to 1979. 
48  For Littlefield, see note 34. 
49  See Weiss (1992). 
Figure 7: Professor Ian Craig, Professor Malcolm Ferguson-Smith
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of hybrids.50 Harris never really did any genetics as such with that. Pontecorvo 
came to the ICRF; it was in 1968 he must have gone with Michael Stoker and 
it was a few years after that he introduced the polyethylene glycol fusion by 
analogy with work in plants, as an alternative to somatic cell fusion by Sendai 
virus.51
Professor Ian Craig: That was a really important breakthrough because Sendai 
virus was a real pain to use and Pontecorvo definitely helped in pushing forward 
the polyethylene glycol approach.
Bodmer: Oh yes he did, and he commented on the fact that it was surprising 
that we, being in Oxford, actually took that up because he thought that no one 
in Oxford listened to what he did. That was true but all the early work that 
we did led to a lot of the hybrids that you guys (Ian Craig and Veronica van 
Heyningen) worked on was done with Sendai virus.
Harper: Coming now back a bit to the workshops themselves, their founding 
and organization, and we’ll come on specifically to the Yale 1973 workshop in 
just a moment: the character of the workshops – coming in a good deal later 
myself – always seemed to me to be very hands-on and, am I right, that that was 
the case from the beginning? Who was around at the time of the first workshop 
by the way?
Craig: I was actually at the first workshop. I represented Walter Bodmer’s lab, 
reporting work done with Veronica van Heyningen and Walter.52 Well, you, 
(Walter) didn’t go but some of the work that you’d been doing went. The 
workshop was very much hands-on, it evolved on the spot as it were, in Yale, 
as a system of committees and reports. That persisted all the way through for 
the next 20 years and you could even argue that the later, Single Chromosome 
Workshops worked on the same principle. I have a strong recollection of 
arriving very nervously late at night in Yale and being introduced to a cocktail 
party. I think it was already quite late English time, and this very impressive, tall 
character, Frank Ruddle, came and said, ‘You have to talk first thing tomorrow 
morning’, which was not the best news. But over the next three or four days it 
did evolve; the system worked. There were committees – I can say a little bit 
50  See, for example, Harris and Watkins (1965). This paper states that the Sendai virus was ‘supplied by Dr 
H G Pereira of the National Institute for Medical Research, Mill Hill’, quoted from page 640. 
51  Pontecorvo (1975). 
52  Craig et al. (1974). 
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more about what they were – and the actual reports, but the point is that the 
workshop actually was self-regulating and it was with fairly easy, hands-on from 
the top as I remember.
Harper: Tell us a little bit about the structure of the workshops as you saw it, 
that first workshop.
Craig: Well, you have to imagine arriving on the scene not knowing how it 
was going to work and whether or not you were going to talk, or precisely how 
it was going to happen. But we started off essentially with individual reports, 
which gave everybody an opportunity to present on their own little pet topic, 
specific hybrid or whatever, gene assignment, etc.53 Then, as time went by, the 
assignments were collected together and you also introduced your information 
at a working group session, which was, I remember, held in the Kline Biology 
Tower in goldfish bowl-like lecture rooms. I think I was in one of the committees 
called ‘Autosomes other than One’.
Harper: Yes, you were. You were with Dirk Bootsma, who sadly can’t be here.54
Craig: Exactly. And John Edwards used to go around, working from committee 
to committee, introducing relevant information on lod scores and such like.55 
But in this glass sort of cubicle, it was a little bit confusing and in fact John got 
up from the table in the workshop I was at, and tried to exit via the glass wall 
and bounced off, but he didn’t seem to be at all perturbed by the process. There 
were 65 people at the first workshop and, with Adam Wilkinson’s help, we’ve 
got some photographs of the people who were there and their names; a lot of 
those then went on to be major figures in the field.56 And, as I said, the pattern 
of the committees in the workshops basically persisted. In the introduction to 
the HGM1 book, talking about the contribution of somatic cell genetics as Sir 
53  For all the published papers from HGM1, see Ruddle et al. (eds) (1974a). 
54 Professor Dirk Bootsma represented Erasmus University, Netherlands, at HGM1, and was a participant/
Conference Scientific Editor of subsequent workshops; see Cytogenetics and Cell Genetics for further details 
of his contributions. His career as a geneticist is discussed by Hans Galjaard in an interview with Professor 
Peter Harper, http://www.genmedhist.info/interviews/hans-galjaard-interview (visited 23 January 2015). 
55  Victor McKusick noted in his obituary of Edwards: ‘John was a regular and important participant in the 
international Human Gene Mapping Workshops held between 1973 and 1991. His input was in relation to 
linkage analysis and reporting, and to the comparative mapping, particularly of mouse and man.’ McKusick 
(2007). See also a biography on page 101.
56  See Appendix 1 for reproductions of these photographs. Mr Adam Wilkinson is the Project Manager for 
the History of Modern Biomedicine Research Group, and coordinator of the Witness Seminar events. 
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Walter has been talking about, it said, ‘Moreover these new data – i.e. the data 
coming in from somatic cell genetics – have proven exceptionally useful to those 
investigators who have employed kindred analysis for the purpose of genetic 
mapping. The combination of the two has been particularly productive.’57 And 
I think that’s exactly where the two worlds met. There were lots of committee 
reports, there was ‘Chromosome 1’, ‘Autosomes Other than One’, ‘the X 
Chromosome’, and, interesting to note, the Y chromosome wasn’t mentioned 
and didn’t have anything on it apparently.58 There was also a committee on in situ 
hybridization, markers, and also on nomenclature, which I’ll come back to in a 
moment. But just to give you an idea of the overall pattern at the workshop, there 
were four presentations of classical linkage analysis, there was one on meiotic 
frequency organization, then there was an appendix provided by John Edwards 
comprising 12 pages of lod scores for various populations, a feature that did 
not persist in the later workshop reports, although a lot of people felt like they 
should: so there were about four or five papers from linkage in that case; there 
were six from somatic cell hybrid assignments by markers and synteny; there were 
18 on chromosome analysis and regional assignment; there was one on dosage; 
and there were a few on biochemical techniques and such like in cytogenetics. 
It was interesting to see that in situ hybridization was already operating at that 
time, although obviously having to work with multiple gene copies. 5S RNA 
was assigned to chromosome 1. But there was a very memorable statement in 
the report from the hybridization committee: ‘Possible localizations included 
haemoglobin, to 2q and Bq59 by ‘hot’ mRNA and cDNA, but this occurred 
despite theoretical objections to its feasibility’, which proved very true.60
57  Ruddle et al. (eds) (1974b).
58  Hamerton and Cook (1974); Bootsma and Giblett (1974); Gerald and Brown (1974).
59  Several contributors noted ‘Bq’ as somewhat unusual terminology; however, in email correspondence 
Professor Ian Craig clarified: ‘The original report for HGM1 clearly states Bq as one of the localizations. I 
think they had problems in identifying individual chromosomes because of the hybridization conditions 
messing up banding and therefore assigned signals to one of a group A, B, C, etc.’ Email to Ms Emma 
Jones, 20 March 2015. Professor Bert Bakker further elucidated, ‘The chromosomes were sorted by size and 
centromere position, Bq then refers to the long arm of either chr 4 or chr 5 (these are B-group chromosomes). 
At that time there was no chromosome banding yet. The D group contains the chromosomes 13, 14 and 
15.’ Email to Ms Emma Jones, 25 March 2015. 
60  Hirschhorn and Boyer (1974), quotation on page 56. Professor Ian Craig wrote, ‘This observation 
which was memorable for the succinct coverage of a heated debate and the eventual localizations of alpha 
haemoglobin to chromosome 16 and of beta haemoglobin to chromosome 11.’ Note on draft transcript, 3 
March 2015. 
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There was a committee on ‘terminology’, which produced the categories of 
confirmed, provisional, and contradictory assignments, which persisted as 
far as I know pretty well all the way through. In that report it was also very 
presciently mentioned that a new distance unit should be introduced, which 
was for physical mapping, and the committee suggested what was called the 
‘mega nucleotide’ as a mapping unit – that was a very interesting introduction 
for that time.61 So that was where things more or less were then. Apparently 
people said there were 100 markers defined at the time. In fact, I only counted 
84 that were actually on Frank Ruddle’s data sheet.62
Harper: There are a couple of things that interested me when I was going 
through the workshop volumes a little while ago, and the first in relation to that 
first workshop – there was no actual map drawn of the autosomes. There were 
some lists but there wasn’t actually a map in that volume; that didn’t appear 
until I think the following workshop.
Professor Veronica van Heyningen: I went to the second workshop in 
Rotterdam with Walter. That was one of the first meetings I went to following 
my PhD, and I had to report disproving one of Frank Ruddle’s chromosome 
assignments. He’d assigned MPI, mannose phosphate isomerase, to chromosome 
7, but we had assigned very firmly the mitochondrial malate dehydrogenase to 
61  McKusick and Frézal (1974). 
62  Ruddle (1974). 
Figure 8: Professor Veronica van Heyningen
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chromosome 7 and it didn’t co-segregate with MPI.63 Then, later on, we put 
MPI on a different chromosome, on 15.64 So I remember being very nervous 
about having to disprove Frank Ruddle’s assignment but he said, ‘Oh yes, I 
think we can find evidence for that and publish it back to back with you.’65
Craig: I think there was a general enthusiasm for producing information, 
even if it was only provisional. The way that somatic cell hybrids work, the 
chromosomes do funny things as everybody knows, and it very often led to mis-
assignments of one sort or another. Hence evolved the idea of provisional and 
then confirmed assignments based upon that kind of thing.
van Heyningen: Exactly, yes. Going back to 1973, I just remembered sitting 
here, and that I happen to have on my iPad a photograph of an EMBO 
(European Molecular Biology Organization) conference on somatic cell genetics 
that Walter organized in Oxford.66 It’s a lovely photograph with lots of very well-
known faces on it.
Bodmer: I’ve got an anecdote for that. Ephrussi and Henry Harris completely 
disagreed on the question of whether transformation, if you could call it that in 
culture, was dominant or recessive. Ephrussi had written a book, and I was very 
friendly with him you see, I’d met him in Lederberg’s lab, and he said, ‘Do you 
think Henry Harris has read my book?’ And Henry Harris told me, ‘Why on 
earth should I read Ephrussi’s book?’, because they really didn’t get on terribly 
well, and that appeared at that EMBO meeting too.
van Heyningen: They’re quite close together in the photograph. Mary Weiss was 
there, Gordon Tomkins, who died not very long afterwards; John Minna; loads 
and loads of people: Meera Khan, Harry Harris, Hoppy – David Hopkinson.67
63  Craig et al. (1974). 
64  van Heyningen et al. (1975a).
65  Kucherlapati et al. (1975). See also Ruddle and McMorris (1975).
66  See Appendix 2 for photograph with key, pages 96–7. Archives relating to Professor Sir Walter Bodmer’s 
organization of the 1973 EMBO conference are available in the Bodleian Library, University of Oxford, 
Archives and Manuscripts, reference MS. Bodmer 1–2216. 
67  For Mary Weiss, see pages 14–15 and note 35; for Gordon Tomkins, see the University of San Francisco’s 
‘A History of UCSF, People: Gordon M Tomkins (1926–1975)’, http://history.library.ucsf.edu/tomkins.
html; for John Minna, see the University of Texas, Southwestern Medical Center’s website for details of his 
career in the 1970s, http://profiles.utsouthwestern.edu/profile/14991/john-minna.html (websites visited 16 
December 2014); for Meera Khan, see page 30; for Harry Harris, see biography on page 103, and for David 
Hopkinson, see note 76. See also Appendix 2. 
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Bodmer: When was that? What year was that?
van Heyningen: 1973.
Bodmer: It was really quite early. Could I just make a very brief comment on 
the nature of the workshops? You may recall the HLA field?68
Harper: Yes, I was going to ask you about the links.
Bodmer: The HLA field developed through workshops that were in many ways 
analogous to the HGMW and, certainly as I became more involved, I saw clear 
parallels between the way that they worked, although they were in a different 
area, with different issues, they had similar problems of reproducibility. They 
were very much workshops from the ground up, from the people who wanted 
to work together with no formal organization, no major committees, no 
society. We just got on and compared notes and eventually did collaborative 
experiments on seeing how things matched up with each other. Of course, that 
totally disappeared with the development of the Human Genome Project.
van Heyningen: You exchanged theory a lot, didn’t you?
68  Professor Sir Walter Bodmer noted: ‘I was responsible for that nomenclature and the ‘A’ was for the first 
locus, it’s not for antigen as is always assumed.’ Note on draft transcript, 24 March 2015. 
Figure 9: Professors Veronica van Heyningen and Sue Povey with 1973 EMBO conference 
photograph: see Appendix 2 for original with key
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Bodmer: We exchanged theory and cells and did combined analysis, all those 
things. That had been happening since 1964.
van Heyningen: I have a very minor, tiny little anecdote of Peter Goodfellow 
coming to the lab and he came to work on the HLA system.69 He did do some 
mapping as well. Neither Walter nor he really liked being bled, but, of course, 
one of the things if you worked in this lab was that you got bled and you 
donated whatever was necessary, sometimes after going on an exercise bike. We 
had a little bleeding room and Peter said, ‘Well, I’ll get better at it, I’ll watch 
Walter being bled.’ And Peter fainted across him while Walter was being bled.
Bodmer: No, it was a little worse than that. There was a little room, which was 
next to Julia’s [Bodmer’s] office and he actually banged the back of his head on 
the bench as he fell down; it was not a very good thing to do actually.70 I didn’t 
like being bled but I’ve often been bled. I didn’t suffer the way that Peter did 
– the reason they did exercise at that time is because it increased the proportion 
of circulating B cells.
Harper: But you should have known always to bleed people lying flat because 
it’s impossible to faint when you’re lying flat.
Bodmer: Usually sitting down is alright.
Harper: Usually but not always.
Bodmer: That’s what we’d done quite a lot for many years.
van Heyningen: But Peter wasn’t being bled, he was just watching.
Harper: Any other comments about the first workshop in Yale? Because that 
did set the tone in a way for a number of years after?
Ferguson-Smith: I think, whereas some people were invited, it was also an 
open meeting, which was nice because everything was shared. I remember 
being very proud to put in the first localization using chromosomal deletions: 
that was red cell acid phosphatase to chromosome 2 short arm.71 There were 
other chromosomal translocations and rearrangements and, of course, in situ 
69  See introduction and biography on pages xiii–xv, 102.
70  For Julia Bodmer, see note 165.
71  Ferguson-Smith et al. (1973). 
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mapping started off with radioactive tritiated thymidine and autoradiography. 
Fluorescent probes came in in the late 1980s.72
Harper: One other thing that I’ve noted looking through the New Haven 
workshop and the list of committees: at the bottom after ‘terminology’ there 
was one headed ‘Organization of Future Meetings’, which was represented by 
John Edwards and Daniel Bergsma.73 But it obviously worked very well, so 
perhaps John going around everybody else’s was part of the organization?
Craig: Just to add to that, the scientific editors, were Frank Ruddle, Dirk 
Bootsma, Victor McKusick, and Harold Klinger. And what they wrote in that 
final report was that the purpose of these annual meetings was to publish reports: 
‘It is our aim to review progress on human gene mapping on a yearly basis. 
… The meetings should provide a standard terminology and nomenclature, 
which will facilitate future developments’, and I think that’s a really important 
thing to note.74 Of course, informatics was really interesting. You could see John 
Edwards and Bette Robson going around and calculating lod scores on the 
backs of envelopes and telling people whether their linkage was significant or 
not, or whatever, but that was basically how it worked.
Harper: I think at this point it would be a good idea to get back to the 
actual markers involved. Sue, we’re working you very hard today but I think 
appropriately so. So the theme of protein polymorphisms and other early 
genetic markers, again you being at the Galton gives you a good vantage point 
for talking about this part of the field.
Povey: Before I start on that, you may laugh at John Edwards organizing 
things, but actually he used to organize very good meetings in Oxford, and in 
Birmingham.
Harper: Yes, you’re absolutely right and I think we laughed in a sympathetic 
way because John made such huge contributions, but he just wasn’t quite like 
anybody else in the way he did things.
72  Professor Malcolm Ferguson-Smith wrote, ‘Mary Lou Pardue and Joe Gall were the first to use in situ 
techniques. In 1970 they showed that mouse satellite DNA was located at centromeres. Angie Henderson 
next used the same technique in 1972 to map human ribosomal genes to the short arms of the acrocentric 
chromosomes.’ Note on draft transcript, 3 January 2014. Pardue and Gall (1970); Henderson, Warburton 
and Atwood (1972). 
73  Bergsma and Edwards (1974). 
74  Ruddle et al. (1974b). 
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Povey: Protein polymorphisms, there were many there before I was involved. 
The blood groups were, of course, protein polymorphisms and the HLA field 
and that was well established really.
Bodmer: Not applied to hybrids.
Povey: No, they were not applied to hybrids. The main interest in protein 
polymorphisms in our lab under Harry Harris, and anyone that came to the lab 
was in biodiversity. That was very much helped by Oliver Smithies’ discovery 
of starch gel electrophoresis,75 and then Harry, and particularly Hoppy,76 were 
very, very expert in working out a good system for visualizing each enzyme 
and making quite sure that it was actually the enzyme you thought it was. A 
lot of them had a final common pathway of PMS (phenazine methosulphate) 
and MTT (methyl thiazolyl tetrazolium) and so you got a particular colour 
and you did really need to make sure that every ingredient was essential for 
getting this band, otherwise it might be something completely different. In fact, 
Harry was more interested in the biodiversity than he was in gene mapping, but 
there were a lot of people around, such as Bette Robson and Peter Cook, who 
were interested in gene mapping even in the Galton Lab.77 The contribution 
originally, I think, to the somatic cell hybrids was the discovery of the ways of 
looking at the separation of proteins in this way, in starch gel electrophoresis. 
In the lab, any new person in the lab was given a new system to look at and you 
had to look at 500 people before you were allowed to say it wasn’t polymorphic. 
[Laughter] That represented a considerable change later on when, in the 
construction of a comprehensive human genetic map with microsatellites by the 
group of Jean Weissenbach, the only loci used were those that showed at least 
three different alleles in the four individuals tested.78 The starch gels, of course, 
75  Smithies (1955). In 2007 Oliver Smithies became a Nobel Laureate for his contributions to stem cell 
research; see http://www.nobelprize.org/nobel_prizes/medicine/laureates/2007/smithies-facts.html (visited 
16 December 2014). 
76  Professor David Hopkinson (b. 1935) was Director of the Medical Research Council Human Biochemical 
Genetics Unit from 1976 to 2000, now Emeritus Professor of Human Biochemical Genetics, University 
College London. 
77  Professor Sue Povey wrote, ‘Peter Cook was the main analyst of linkage in the Galton Lab during the 
workshops up to about HGM6 and was almost entirely responsible for the overall maps of chromosome 1.’ 
Email to Ms Emma Jones, 12 June 2014. For Elizabeth (Bette) Robson, see note 24. 
78  Gyapay et al. (1994). Jean Weissenbach was Director of the Généthon gene mapping project in France 
from 1990 to 1996. For its history, see http://www.genethon.fr/en/about-us/history/ (visited 5 March 
2015).
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the major thing about them was you didn’t need biodiversity within the species, 
you only needed to be able to separate the mouse and the human. Those protein 
polymorphisms as Walter said they did, or somebody said, they did interact 
with the linkage because, although it was a fantastic amount of work to use the 
protein polymorphisms for linkage analysis in families, it did tie in with using 
them in somatic cell hybrids. The protein polymorphisms were useful for a long 
time and even quite late in finding, for example, Batten’s disease, which was 
found in 1989 to be linked to chromosome 16 by Eiberg with haptoglobin, but, 
of course, had been put on 16 a long time before.79 I think all the major somatic 
cell groups looked at enzymes in their somatic cells for mapping, and eventually 
people at the Galton Lab did that as well, but we were a bit slow to get into 
actually making hybrids. We were busy looking at other people’s hybrids.
Harper: Can I ask you, Sue, about the links between the folk working on 
enzymes at the Galton and the blood groupers, Ruth Sanger and Robert Race,80 
because my impression was always this was incredibly close and if one sent a 
sample it got passed around in a circle so that everybody could use it for both 
blood groups and enzymes.
Povey: Yes, that’s actually correct. We collected enormous numbers of placentas 
from Edgware General Hospital, I think probably with no permission from 
anybody.81 We had at least 3,000 and then we looked and we had blood samples 
from the families of anything where we found variants, we pursued them. Then 
those samples, and many other samples sent to us by clinicians, were subject to 
being blood grouped by Race and Sanger, and anything that was going that was 
polymorphic was done.82 And there was a central system of logging everything 
79  Eiberg, Gardiner and Mohr (1989). See also Magenis, Hecht and Lovrien (1970). 
80  Dr Ruth Sanger (1918–2001) was on the Scientific Staff of the Medical Research Council’s Blood 
Group Unit from 1946 to 1983, and Dr Robert Race (1907–1984) was the Unit’s Director from 1946 to 
1973. See Race and Sanger (1950). See, for example, an overview of their work in the introductory text to 
archives held at the Wellcome Library, London, as part of the ‘Codebreakers: Makers of Modern Genetics’ 
collection, ‘The Robert Race and Ruth Sanger papers’; http://wellcomelibrary.org/collections/digital-
collections/makers-of-modern-genetics/digitised-archives/robert-race-ruth-sanger/ (visited 16 December 
2014). See also Christie and Tansey (eds) (2003). 
81  For another discussion of acquiring placentas for blood samples, see Overy, Reynolds and Tansey (eds) 
(2012); pages 42–5. 
82  Professor Sue Povey wrote, ‘In the search for useful heterozygosity most families were tested for about 
25 loci. There were a mixture of blood groups and enzymes and other proteins which could be detected by 
starch gel electrophoresis or iso-electric focussing.’ Note on draft transcript, 26 February 2015. 
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found. And so linkages were found but it was an awful lot of work to find a 
linkage, most of it analysed by Peter Cook, who sadly died suddenly in 1982, 
at the age of 42.83
Ferguson-Smith: I just want to mention Jim Renwick here because, with Marian 
Izatt in Glasgow, he set up a linkage lab there.84 Twenty-three polymorphisms 
were looked at and this included all the blood groups as well as serum markers 
and red cell enzymes, and we used all these in collaboration with him for many 
years until he left for London in 1968. I continued the marker lab when he left, 
and later added DNA markers to our armamentarium.
Povey: Yes, I think we had about 23. I think that was about the number we had 
that was routinely done. But of course many of them were not informative in 
every case.
Bodmer: I’d just like to comment on that and enlarge on what Sue said. The 
polymorphisms, of course, were important for the family studies. They didn’t 
really play a dramatic role in the somatic cell hybrids. As Sue said, the main 
thing there which made it so easy to start with, you would expect to find, to 
a large extent, starch gel electrophoresic differences between the species and 
that helped enormously because all you needed to have was a way of deciding 
whether you had the human version of the enzyme. But there were other 
techniques that came into play fairly early – Veronica might like to comment. 
One idea we had was to immunize mice with the human enzymes and then to 
use Ouchterlony plates and analyse enzyme activity.85 Actually, the blood groups 
never, as such, played a major role because it was very hard to establish blood 
group determinants on the hybrids and it was not really until the HLA work, 
when we began to have monoclonal antibodies in the late 1970s, which enabled 
the use of surface antigens as markers began. We made some specifically, so we 
looked for some antigens that were chromosome-specific and things that Puck’s 
group had developed.
83  For a tribute to Peter Cook’s work on gene mapping, with biographical details, see Robson (1982). 
84  Professor James Renwick (1926–1994) worked at the Department of Genetics, University of Glasgow 
in the 1960s. He was responsible for some of the earliest human genetic linkage studies, as well as for 
developing computerized approaches to genetic linkage analyses. Further details of his career are available 
on the ‘Codebreakers: Makers of Modern Genetics’ website; http://wellcomelibrary.org/using-the-library/
subject-guides/genetics/makers-of-modern-genetics/digitised-archives/james-renwick/ (visited 8 October 
2014). 
85  For the ‘Ouchterlony double diffusion in agar’ technique, see van Heyningen, Craig and Bodmer (1973). 
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Ted Puck, who has not been mentioned so far, had a completely different 
approach, and an important one to somatic cell genetics.86 He was looking for 
mutations in CHO (Chinese hamster ovary) cells that seemed to be mainly 
haploid.87 So there were these other techniques that one could begin to use 
and, of course, that all completely changed when DNA studies came in. It’s an 
interesting point, the differences in techniques: one of the early papers from 
Frank Ruddle’s group was solution hybridization to try and identify whether 
you had a human or a mouse gene.88 Then there was the in situ hybridization 
but then what really changed it was Southern blotting.89 And the first paper on 
the mapping, I think, Ian, your name’s on it with Alec Jeffreys, was a pioneering 
paper that actually mapped the haemoglobin genes using Southern blotting.90 I 
looked it up the other day and it’s only been referenced 58 times, yet I think it 
was actually the pioneer of really being able to use DNA-based techniques for 
doing gene mapping before you got sequencing.
Harper: We’ll come on to that, Walter, if we may when we deal with the DNA 
polymorphisms in detail.
van Heyningen: My PhD was to look at the mitochondrial enzymes that are 
encoded by the nucleus and look at their segregation.91 Human mitochondrial 
DNA is lost in somatic cell hybrids and so you only have the nuclear DNA 
contributing, therefore we could only look at the nuclear components. But 
many of them could not be distinguished readily on electrophoresis, they had 
the same specific charge. First of all, I think mitochondrial enzymes migrated to 
the negative electrode and also we couldn’t separate the mouse from the human, 
and that’s why we started having to make the antibodies to distinguish them. 
So we had to prepare more semi-purified enzymes to inject into rabbits and 
make the anti-sera. We also found it quite difficult to be as skillful as the Galton 
labs in running starch gels and we switched to cellulose acetate, which was very 
86  For an obituary of Ted Puck (1916–2005) see Rowley (2006).
87  See Puck, Cieciura and Robinson (1958). 
88  Deisseroth et al. (1978).
89  Southern blotting was a technique developed by Professor Sir Edwin Southern (b. 1938) for DNA 
analysis; see Southern (1975). 
90  Jeffreys, Craig and Francke (1979). 
91  van Heyningen (1973). 
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good. It was much quicker and we didn’t have to pour the gels, but, of course, 
you couldn’t slice the cellulose acetate and you couldn’t therefore compare one 
enzyme with another.
Craig: I always felt we were slightly inferior beings when we went to visit the 
Galton labs and Harry said, ‘You’ve done that on cellulose acetate?’ The starch 
gels were much better at the Galton, I think.
Bodmer: We did actually collaborate. You were co-authors on many of our 
papers because of your starch gel electrophoresis skills.92 Just a couple of 
things on the points that Veronica made: by doing the enzyme activity on the 
Ouchterlony plates, you got a measure of specificity so even if your anti-serum 
had a mixture of different things, you could see whether or not you got a band 
that was human.
van Heyningen: Yes, in the Ouchterlony plates I also got spurs from the 
mouse because there was cross reaction so it was a polyclonal serum and it 
had components, which were specific to the human and components that were 
shared with mouse.
Bodmer: Another point, if I might make it, on the question of mitochondrial 
DNA and the hybrids, was actually work that we had done earlier with David 
Clayton at Stanford, which he wanted to publish on his own and we managed to 
stop him.93 And that was an interesting story because what happened was you lost 
the human mitochondrial DNA if you didn’t have enough human chromosomes 
in there. So, in other words, there was a human/mouse incompatibility in the 
maintenance of the mitochondria if you only had a predominantly mouse 
protein component for the mitochondria.
Craig: This is what we followed up in Oxford. It was actually extremely difficult 
to find any human mitochondria in any normal type hybrid; you had to have a 
hybrid that reverse-segregated. In other words, it had a complete set of human 
chromosomes, which is an interesting thing to do with retention of mitochondria 
and the interactions between the mitochondria and human genome.94
92  The last three authors of van Heyningen et al. (1975b) were from the Galton Lab: Sue Povey, S E 
Gardiner and David (Hoppy) Hopkinson. 
93  Clayton et al. (1971). 
94  Professor Ian Craig wrote, ‘This work eventually led to our isolation of mitochondrially encoded 
chloramphenicol resistant cell lines with Lawrence Siegel.’ Note on draft transcript, 14 August 2014.
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Professor Bert Bakker: I entered the lab of Peter Pearson in 1974, so that’s around 
the time of the meeting in Rotterdam.95 I didn’t go to the Rotterdam meeting 
because I was just a junior technician in the lab. But at that time Meera Khan in 
the lab was running all these starch gels and later also the cellulose acetate for the 
somatic cell hybrids that were made together with the people in Rotterdam – Dirk 
Bootsma and Andries Westerveld and all these people there.96 They used patients 
carrying chromosomal translocations to prepare somatic cell hybrids, to map 
different pieces of a chromosome, parts of chromosome 1, parts of chromosome 
17; just to segregate it out. One other thing that has not been mentioned yet, 
is the analysis of the chromosomes – staining techniques for chromosomes to 
distinguish between the mouse and the human chromosomes. For example, G11 
staining, all very new, and heterochromatin staining, the latter described by Martin 
95  Dr Peter Pearson was Head of the Human Genetics Department at Leiden University (1972–1989). He 
is now Co-director of the National Institute for Stem Cell Research in Genetic Diseases, São Paulo, Brazil. 
96  At the time of the HGM2 workshop, Professor Meera Khan (d. 1998) worked at the Sylvius laboratory 
in the Department of Human Genetics, University of Leiden; Dirk Bootsma worked at the Department 
of Cell Biology and Genetics, Erasmus University, Rotterdam, as did Andries Westerveld. Bootsma was a 
Conference Scientific Editor, Khan and Westerveld were Assistant Editors of the Human Gene Mapping 2 
publication; see Bergsma et al. (1975). For Andries Westerveld see also Appendix 2. 
Figure 10: Professor Bert Bakker
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Bobrow et al. in a Nature paper.97 These techniques were very important at that 
time because they helped a lot. I tried to do the staining, of course, I got the paper, 
and Peter said, ‘Do the staining.’ I looked through the microscope and I couldn’t 
see a difference. Then Peter came and he looked through the microscope and he 
said, ‘Oh, beautiful! Oh look!’ I couldn’t see it. It appeared I was colour blind. 
[Laughter] So at that he said, ‘Okay’ and he took a kind of spectrum filter, he put 
on the light source and shifted a little bit and then I saw it. The difference between 
the human and the mouse chromosomes was very clear. And at that time we could 
just use all the different hybrids. There were many hybrids selected against TK 
(thymidine kinase) and we used them to segregate out all these chromosomes.
Professor Ellen Solomon: I was just saying, I think we used the selection of 
the X chromosome, the HPRT, which from a patient was fused to chromosome 
15 and it was the first X autosomal mapping because we could select the X and 
then mapped a whole number of genes to 15 including beta 2 microglobulin, 
which was on chromosome 15 and not in the HLA region on chromosome 6.98
97  See Friend, Chen and Ruddle (1976); Bobrow, Madan and Pearson (1972). Professor Sir Walter Bodmer 
commented: ‘[Heterochromatin staining] was actually done in the Bodmer laboratory in Oxford.’ Note on 
draft transcript, 26 May 2014.
98  Solomon et al. (1976) and Goodfellow et al. (1975). 
Figure 11: Professor Ellen Solomon
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Bodmer: Yes, and just to add, that was the reason we started doing hybrids with 
lymphocytes, with peripheral blood lymphocytes so you could take lymphocytes 
from anyone who had such changes and put them into a hybrid and you didn’t 
have to have a cell line.99 That was, I think, an important part of why the somatic 
cell genetics became so useful.
Bakker: I want to go back a little bit to the family studies. When I came in the 
lab, my blood was taken and chromosomes were made and these were lying on 
Peter’s [Pearson’s] desk. Then Kamlesh Madan, a cytogeneticist from the Free 
University of Amsterdam came in, and she looked at the chromosomes, and 
said, ‘Hey, there’s a polymorphism on chromosome 6 centromere’. It turned 
out that I seemed to have two different centromeres of chromosome 6. Kamlesh 
wanted to confirm segregation of these variants in a pedigree. So not only was 
I bled again but also the whole family. So at a birthday party, someone came 
and blood was taken. The polymorphisms segregated nicely in the family as 
was expected. GLO was typed, HLA was typed, and PGM3 was typed. Within 
my family we could order those loci in the region and the orientation of the 
HLA locus relative to the centromere of chromosome 6, place GLO between 
the centromere and HLA, and put PGM3 outside this linkage unit, probably 
on the q arm, where it later turned out to be. That was one of the first papers 
where you needed information from the somatic cell hybrid data, such as some 
gene locations, a chromosome polymorphism, and segregation from the family 
analysis to put it all in place.100 I think that was a nice, early mapping effort.
Harper: We’re coming on right now to cytogenetic markers, but before we leave 
the early protein marker area, I’d just like to again emphasize the role of the 
Copenhagen lab, which I really do think was very great indeed. I interviewed both 
Jan Mohr and Hans Eiberg, and Hans was Jan’s right-hand person absolutely, 
one of these people with green fingers who could essentially get any technique 
to work.101 But I am amazed how much, as Sue was saying, they managed to do 
with protein markers, which many of the DNA folk rather forgot later on. For 
instance, cystic fibrosis was first mapped using paraoxonase.102 It’s important not 
to forget this very considerable role. The other thing to bear in mind all the time 
99  See note 37. 
100  Bakker et al. (1979). 
101  See notes 19 and 27 for Jan Mohr. For the Hans Eiberg interview, see http://www.genmedhist.info/
interviews/eiberg-interview (visited 8 October 2014). 
102  Eiberg et al. (1985); Schmiegelow et al. (1986). See also Christie and Tansey (eds) (2004).
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is the role that diseases played as markers, Mendelian diseases. Because really, 
in the early years, they were some of the chief markers and large segregating 
families could give a lot of information.103 Again, this is something that I think 
gets downplayed, that if one looks at the evolution of the human gene map, it’s 
very patchy and there tend to be islands focused around important diseases like 
cystic fibrosis, Huntington’s disease, or myotonic dystrophy or a lot of others, 
quite largely because that was what the work was funded for.104 There were 
quite extensive areas that were mapped first with early markers and then later 
on very intensively with DNA. And all along this whole area of work carried 
a big clinical contribution. If you got that wrong, and people’s statuses were 
misassigned or they were misdiagnosed, as happened with some key individuals 
supposed to have Huntington’s disease, that could really screw up the work 
completely and send people off in the wrong direction.
Now, cytogenetic markers: Malcolm, anything you want to put in at this point, 
thinking in terms of the early workshop years?
Ferguson-Smith: Yes, of course, the first one was the Duffy blood group locus 
on chromosome 1, centromeric polymorphism, and a lot of us were excited 
about this because many of us had seen polymorphisms on other chromosomes, 
mostly on the heterochromatic regions of chromosome 16, chromosome 9, 
and the acrocentric chromosomes.105 I was encouraged immediately after the 
Donahue paper to get a grant application off because we had collected loads of 
these families with chromosome polymorphisms. This project turned out to be 
a complete waste of time, because we had only these few markers, the 23 blood 
group and serum protein markers and red cell enzyme, and after typing these 
over a period of three years in many large families, we didn’t get a really decent 
lod score with any of them. This was because none of these happened to be 
close to any of the chromosome markers that we were using, as was confirmed 
later on. I don’t know whether other people had similar bad luck at the time 
but, anyway, that was a very big lesson for us. Fortunately, we switched to using 
families that we had identified with chromosomal deletions and duplications, 
103  For a related discussion of familial genetic studies, specifically in hereditary non-polyposis colorectal 
cancer (HNPCC), see Jones and Tansey (eds) (2013), pages 33–8. 
104  For the mapping of cystic fibrosis to chromosome 7 see Tsui et al. (1985), and for the identification of 
the CFTR gene and the delta F508 mutation in 1989 see Tsui et al. (1989); for the mapping of Huntington’s 
disease to chromosome 4 see Huntington’s Disease Collaborative Research Group (1993), and for myotonic 
dystrophy’s mapping to chromosome 19 see Shaw et al. (1985). 
105  Donahue et al. (1968); Robson et al. (1969). 
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together with our 23 markers, particularly the red cell enzyme polymorphisms 
in which we could also measure enzyme dosage. Our first assignment in 1973 
was red cell acid phosphatase (ACP), in which gene dosage was halved in our 
patient heterozygous for a 2p deletion, who had failed to inherit an ACP allele 
from one of the parents.
Working with Jean de Grouchy, we assembled a group of families with 
chromosome 9 duplications and deletions, some due to translocation. This led 
to mapping a number of genes in 1976 at the end of the long arm of chromosome 
9, including the ABO blood group Npa-1, and AK1.106 We followed this with 
deletion mapping of GOTs, NP, ABL, HP, GALT, and ADA.107 So this approach 
proved really useful. By using the same system and these few polymorphisms 
and chromosome aberrations, it was possible to exclude from a lot of the genome 
regions which could not contain these loci. John Edwards was helpful to us in 
trying to work the best way of presenting these data in a joint publication at 
the Rotterdam Conference.108 For a number of the human genome workshops, 
David Aitken and I put in our exclusion map based on these deleted regions 
of the chromosome, which proved helpful in narrowing down the MNS blood 
group locus, for example.109 I think that was quite useful, although pretty low 
key and didn’t require very much imagination.
Povey: I was just going to say that Peter Cook also was very interested in what 
he called ‘desperation mapping’ [laughter], which was excluding things.110 One 
of the things that was quite funny was, when we were finding that ABO must 
be on chromosome 9 – because AK1 was clearly on chromosome 9, which was a 
bit controversial – some of these reports have ironed out the differences between 
the workers at the meeting and what turned out to be in the report. Anyway, at 
106  Ferguson-Smith et al. (1976). 
107  For GOT
s
, see Aitken and Ferguson-Smith (1978a); for NP, see Ferguson-Smith and Aitken (1978b); for 
HP, see Ferguson-Smith and Aitken (1978); for GALT, see Aitken and Ferguson-Smith (1979); for ADA, 
see Aitken and Ferguson-Smith (1978c). 
108  Ferguson-Smith et al. (1975).
109  See, for example, Aitken and Ferguson-Smith (1978d). David Aitken was Senior Scientist responsible 
for biochemical genetics in the Department of Medical Genetics (Malcolm Ferguson-Smith’s department), 
Royal Hospital for Sick Children in Glasgow. 
110  Professor Sue Povey explained to Professor Peter Harper in an interview, ‘… Peter Cook had very much 
developed what he called desperation mapping from the families, which was that although it was almost 
hopeless to try and put things anywhere, you could exclude them from large bits of the chromosome …’; 
http://www.genmedhist.info/interviews/Povey%20Sue (3 February 2015). 
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the time when we said from hybrids that ABO was on chromosome 9, Peter said, 
‘I’ve excluded it absolutely from everywhere except the real tip of chromosome 
9. Most of chromosome 9 has a lod score of -50 and it can’t be there.’ But it was, 
right on the tip. He did say that he did not get a positive lod score anywhere but 
you can’t actually exclude it from the tip. So some was done by linkage analysis 
but in this case the hybrids and chromosome deletions were conclusive.
Ferguson-Smith: There is a great deal of recombination at the end of 
chromosomes!
Harper: Maj, I wonder if you’d like to say a bit about meiotic work because I 
think it’s part of the gene mapping story and links with the physical map?
Professor Maj Hultén: When we did the meiotic work we didn’t have a clue 
about the mapping situation and it’s only other people who have alluded to the 
type of work that we did. I was interested in the recombination patterns per se.
Ferguson-Smith: You do not do justice to your contribution. You did almost 
all the work at the time [in the late 1970s] on the location and frequency of 
chiasmata.111
Harper: Yes, I think you underestimate what you did, Maj, honestly because 
most of the molecular folk didn’t really register what meiosis was, or things like 
111  See, for example, Morton et al. (1977) and a paper presented at HGM4, Hultén et al. (1978). 
Figure 12: Professor Maj Hultén
Human Gene Mapping Workshops c.1973–c.1991
36
the sex differences in recombination, or the distances along the chromosome. 
I think the fact that your, and similar, work was going along at the same time, 
well it helped the later work retain a physical map alongside the linkage and 
then later the sequencing data.
Hultén: Well I’m glad to hear that, but from my own point of view it was pure 
curiosity.
Ferguson-Smith: Yes, but, come on Maj, your lab and my lab were the only 
labs that were actually counting the number of chiasmata in humans and where 
they were.112
Hultén: Did you not do it from curiosity then?
Ferguson-Smith: Of course. We stopped this work after Brenda Page departed. 
Brenda Page, who was much engaged in this, was tragically killed before much 
of the work was published.113
Hultén: Yes.
Ferguson-Smith: So after that our meiotic work stopped, but you carried 
on using all the new immunofluorescence technologies for more precisely 
identifying recombination sites, etc.
Hultén: But still it didn’t map a single polymorphism [laughs].114 
112  See, for example, Ferguson-Smith and Page (1973). 
113  The cytogeneticist Brenda Page was murdered in her home on 14 July 1978, in Aberdeen. Her killer was not 
identified nor brought to justice, ironically it seems because of the limitations of DNA analysis at that time. 
For an article about her case, see http://www.scotsman.com/news/getting-away-with-murder-1-509980 
(visited 13 October 2014). Professor Malcolm Ferguson-Smith wrote: ‘Brenda was my PhD student in 
Glasgow working with me on human meiosis from patients with chromosome rearrangements. She wrote 
an excellent thesis and became an outstanding scientist.’ Note on draft transcript, 8 February 2015. See, for 
example, Page (1973). 
114  Professor Maj Hultén wrote, ‘I am sorry not to have explained why we have not been able to map any 
genes per se, but our research has only provided the framework for the gene mapping. One of my main 
research interests has concerned the behaviour of meiotic chromosomes, as seen by microscopy of human 
fetal ovarian biopsies and testicular biopsies from adult men. At first meiotic prophase the homologous 
chromosomes pair and crossing over/recombination takes place between parental chromatids, eventually as 
the homologues contract and separate, only held together at the points of crossing-over/recombination, now 
identifiable as chiasmata. The chiasmata delineate the borders of the loops, which I have called linkage loops, 
that can be readily identified and measured. This research has thus not been able to identify the positions 
of any genes per se, but it has provided a framework for the gene mapping, i.e. by giving information on the 
areas of linkage along the individual chromosomes.’ Email to Ms Emma Jones, 1 October 2014. 
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Harper: We’ve reached a point on the programme where we get to DNA, and 
DNA polymorphisms, but before we go on to that, anything more on other 
kinds of early markers involved in the workshops?
van Heyningen: There were also quite a lot of cell surface markers, you know, 
when people started making monoclonal antibodies. I suppose it was a bit later, 
yes, 1980.
Bodmer: Well I guess we did the first work really with monoclonal antibodies 
and hybrids. They didn’t come along until the end of the 1970s.
van Heyningen: Yes, you did. 1980.
Bodmer: No, late 1970s. The first paper we did on W6/32, this was the first 
pan HLA-ABC monoclonal antibody published with César Milstein and Alan 
Williams in 1978.115 Then I also remember Francis Brodsky’s whole PhD thesis 
and the detailed thesis was on monoclonal antibodies to HLA: that was in the 
late 1970s.116 So that came then, but it coincided with the discovery of restriction 
fragment length polymorphisms and using restriction fragment differences to 
assign sequences and with Southern blotting.117
Solomon: Just to add to that conversation, in addition to membrane proteins, 
the structural proteins with non-enzymatic proteins were devilishly difficult 
largely because they were highly interspecies conservations, very hard. We made 
possibly the first structural gene mapping of collagen, which is very highly 
conserved, and we had to make antibodies too; I think we did chicken and 
sheep and goat and rabbit and mice, and whatever, until we got something that 
would distinguish them, so moving on to DNA was a huge relief.118
Povey: If I can just say a final word on an avenue that was probably not a very 
good one to pursue that we did with Mary Weiss.119 We made hybrids with rat 
hepatoma cells to try and activate the liver-specific enzymes and we only ever 
mapped one enzyme successfully; that was GPT which did map to chromosome 
8. Of course, that was entirely overtaken by DNA cloning of these genes.
115  Barnstable et al. (1978). 
116  Brodsky (1979). 
117  For Southern blotting see note 89. 
118  See Weiss et al. (1982). 
119  Jeremiah et al. (1984). See also note 36. 
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Bodmer: Maybe one should mention the phenomenon of extinction here. It 
was a strange phenomenon that was absolutely key, of course, to the discovery 
of monoclonal antibodies because the phenomenon of extinction was that 
you genuinely didn’t make some of the cell-specific products in hybrids, so 
when we first made some hybrids with Mel Cohn, between trying to look for 
immunoglobulin in hybrids with mouse cells, you found you didn’t see the 
immunoglobulin.120 One could already predict at that time that the only way 
you’d get the tissue-specific products was actually to use a B cell and that’s what, 
eventually, (Georges) Köhler and César Milstein did.121 It was actually quite an 
obvious idea at the time but that phenomenon of extinction is still not explained. 
It’s a very interesting phenomenon: what happens, what are the mechanisms 
that prevent you from being able to express a tissue-specific product in a hybrid 
between cells of different tissue types?
Craig: Just one more thing on structural proteins, since structural proteins 
are kind of a minority topic in this area. A lot of work went into solubilizing 
mitochondrial proteins, which were under the control of mitochondrial 
DNA and looking at how they were different in various different organisms, 
particularly humans and mice, and Alec Jeffreys did a lot of work on that which 
was interesting at the time.122
Harper: I’m going to suggest that for DNA polymorphisms, where it perhaps 
started, I think I’m right in saying that in terms of the workshops that it was 
the Oslo workshop where they first came in, or at least when people in the gene 
mapping community rather suddenly became aware that this was something 
rather new but it was going to be a major avalanche. The thing that I remember 
that it brought in, quite apart from the new techniques and the new information, 
was a completely different community of people, most of whom had never been 
involved in gene mapping before, and some of them had never really heard of it 
very much. I think it’s little short of amazing that some kind of, not merger, but 
a sort of integration occurred and that the two areas didn’t just stay totally apart 
because they were really very different indeed. It’s actually to the credit of the 
original gene mapping community that they were pretty tolerant of these brash 
120  This research was unpublished. Note on draft transcript from Professor Sir Walter Bodmer, 8 February 
2015. 
121  Georges Köhler (1946–1995) and César Milstein (1927–2002) shared the Nobel Prize in Physiology 
or Medicine in1984 with Niels K Jerne; see Köhler and Milstein (1975). See also Tansey and Catterall 
(eds) (1997). 
122  Jeffreys and Craig (1976). 
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incomers who really didn’t know anything much about genetics, but I think 
it’s also to the credit of the molecular folk that they soon realised what they 
didn’t know and sat down and learnt. Now Bert, in Leiden you saw and were 
responsible for some of the first X chromosome DNA polymorphisms coming 
in, and again I wish Peter Pearson was here too.123 Peter is very elusive, quite 
apart from being in Brazil, but it would have been nice to have him as well.
Bakker: He should have been here.
Harper: You’ll have to deputize for him. Tell us a little bit about this.
Bakker: I think it was in 1978 when the paper of Kan and Dozy came out with 
a polymorphism in the beta globin gene.124 At that time Peter said, ‘We should 
have more of these types of restriction site length polymorphisms on the map’, 
and he came across another paper from 1956, which gave him a prophecy on 
using markers on the genome that were highly polymorphic, and which could 
be used like the ABO blood group to follow genes on the genome.125
Bodmer: That idea was older than the 1950s.
Bakker: Earlier? Anyway, it was the thing that Peter showed me at that time, 
and he said, ‘We should use these RFLPs, these restriction fragment length 
polymorphisms, to put them on the map.’ But there were no probes, there 
was nothing. So I said, ‘I can try to make some.’ So I got from the hospital a 
placenta, isolated DNA from that, digested some DNA with EcoRI, a restriction 
enzyme, ran the digested DNA through the sucrose gradient, took fractions of 
1kb, and 2kb, ligated these fragments into plasmid – we used a vector called 
pAT153, transfected the plasmids into bacteria, had some plates with bacteria, 
and each of these bacteria colonies had one plasmid carrying a probe, a specific 
piece of human DNA. I selected then the unique ones by hybridizing with total 
human DNA and some probes turned out not to be hybridizing so we used 
these bacterial clones to grow them up, isolated the plasmid, and put them on 
Southern blots to see if they were single, unique EcoRI fragments. In a single 
experiment, which I could not do in Leiden, I had to go to the MRC's National 
123  See note 95. 
124  Kan and Dozy (1978).
125  Professor Bert Bakker selected this quotation from Edwards (1956): ‘It should eventually be possible 
for most prospective parents with inherited disorders transmitted by single genes to obtain a fairly precise 
estimate of the likelihood of their coming child being affected in the twelfth week of pregnancy…’ Note on 
draft transcript, 4 March 2015. 
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Institute for Medical Research in Mill Hill, London, to the lab of Dick Flavell 
because there we could put the plasmids in bacteria and grow them.126 I went 
back to characterize them in Leiden, and a few weeks later again I went back 
to London to grow a larger batch of these clones. In total, I had 216 of these 
probes, of which 23 turned out to be unique, and I hybridized them to different 
DNA samples digested with different restriction enzymes, ran Southern blots, 
and found out that many of these were polymorphic. This was published at the 
Oslo [HGM6] meeting. We had 23 probes showing polymorphisms throughout 
the human genome.127 Thirty per cent of all DNA polymorphic markers were 
known at that time, and these were called, because the nomenclature was then 
started, D1S2, D2S1; these probes were the early type of polymorphic probes. 
One of these probes on the X chromosome was L1.28, or DXS7, for Duchenne 
muscular dystrophy, and in the group in London at that time, where Kay Davies 
worked in Bob Williamson’s lab, and, together with Rob Elles, had cloned the 
RC8, or DXS9, and that was located also on the X chromosome.128 These two 
were flanking the Duchenne locus and therefore we could use them for carrier 
detection. From that time on, many more probes had to be cloned to fill the 
gap, to gain informativity, so Maarten Hofker in our lab started phage lambda 
cloning of X chromosome fragments to clone more probes and the number of 
probes expanded.129
Harper: How about the autosomal probes that you generated?
Bakker: Yes, there were some autosomal probes. There was one located on 
chromosome 2. Peter (Pearson) asked me to use in situ hybridization for fine 
mapping, because in 1977/1978 I also went to the lab of Ken Jones in Edinburgh 
to learn in situ hybridization techniques.130 I used mouse satellite DNA isolated 
from a band from a caesium gradient and hybridized that back to mouse 
126  At an earlier meeting on clinical molecular genetics, Professor Bakker explained that regulations over 
DNA cloning in the Netherlands prevented certain aspects of his research, hence the need to use MRC 
facilities; see Jones and Tansey (eds) (2014), page 10, note 20. 
127  Pearson, Bakker and Flavell (1982). 
128  Davies et al. (1983). At St Mary’s Hospital Medical School, University of London, Kay Davies was 
Cystic Fibrosis Research Fellow (1980–1982), and Bob Williamson was Professor of Molecular Genetics 
and Biochemistry (1976–1995); see full biographies and further details of this research in Jones and Tansey 
(eds) (2014), pages 33–5, 101–2, and 111–12.
129  See, for example, Hofker et al. (1985).
130  See, for example, Jones (1970).
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chromosomes and only saw the centromeres and these types of things.131 So the 
technique worked, but for unique probes it did not work so well. So in 1981 
we tried it with the chromosome 2 probe we had. I labelled that L2.30 probe 
with tritium, hybridized it to human chromosomes. I knew its chromosome 
assignment from the somatic cell hybrids because we localized all these probes by 
Southern blotting on DNA of somatic cell hybrids available in the lab of Meera 
Khan next door to us.132 So I looked at in situ hybridization slides. They had to 
have a three-week exposure of this tritium hybridized cells, and after three weeks 
I developed them, there was a lot of background, and started counting. I knew 
it was on chromosome 2 so I counted a lot of silver grains on the chromosome 
2s in different cells, only the chromosome 2s, and it came out that there were 
significantly more grains on the tip of the p-arm of chromosome 2. So I said to 
Peter, ‘It’s on the tip of chromosome 2’, and he ran to the microscope, looked 
in the microscope and started counting. Scrolling and scrolling and he said, 
‘I don’t know, I don’t know’. So it was put aside and in situ hybridization was 
not used; we used the somatic cell hybrids’ DNA, with Southern blotting and 
also translocation hybrids to localize our probes, until, from the lab of Tobias 
Gedde-Dahl, a request came. At one of the HGM meetings Peter met him and 
was told that red cell acid phosphatase was on chromosome 2 and Tobias now 
had evidence that it was on the tip of chromosome 2.133 Then Peter said, ‘Okay, 
maybe we can look at linkage with this marker of ours.’ Our L2.30 marker on 
chromosome 2 seemed closely linked and, by in situ hybridization we knew that 
it was localized also on the very tip of the p-arm of X, so at that time we could 
localize both of them on the tip of chromosome 2p and my in situ data was also 
published in the same article of Lothe and Tobias Gedde-Dahl.134 That was in 
1986, so five years after I did the experiment.
Ferguson-Smith: It was mapped first by us in 1973 at exactly the same spot.135
Bakker: Oh sorry, but this was linkage and in situ hybridization, localizing both 
ACP1 and D2S1 more precisely to the tip of 2p.
131  Singh, Purdom and Jones (1977). 
132  For Meera Khan, see note 96. 
133  HGM3, Baltimore, 1975. Bergsma (ed.) (1976). 
134  Lothe et al. (1986). 
135  Ferguson-Smith et al. (1973).
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Bodmer: Some of the radiation hybrids, that was one thing that Henry Harris 
did. He had a student called Steven Goss who, using X-rays, produced the broken 
chromosomes and we did one little paper with him in one of the workshops that 
showed you could use those for regional mapping.136 Then Peter Goodfellow did 
a lot of mapping. That must have been in the late 1970s because it was while we 
were still in Oxford. So 1978/1979, something like that probably. Then Peter 
made a lot of radiation hybrids. That was much later; that would have been in 
the 1980s.137
Bakker: The sorting of chromosomes was also important to make sorted libraries 
and have a library of the X chromosome or a library of chromosome 21.
Harper: I should say, it’s a shame that Kay Davies can’t be here because of 
the combination of the sorting with the chromosome-specific libraries.138 The 
sorting was done in Glasgow, by Bryan Young’s lab.139
Ferguson-Smith: Bryan Young, and Rob Krumlauf, who was with him at the 
time, did the early work. Their first venture used an MRC cell line that had 
several copies of the X chromosome.140 Kay Davies used this X library to isolate 
X markers for Duchenne muscular dystrophy.141
Professor Sue Malcolm: That was because Bryan Young had been taken on at 
the Beatson Institute as a physicist to help with all problems around physics and 
he then very naturally got into chromosome sorting.
Harper: Sue, nobody here apart from yourself has been in Bob Williamson’s 
lab – I think I’m right? In that case, tell us a bit about this beginning of DNA 
polymorphisms as seen from the perspective of that lab.
136  Buck, Goss and Bodmer (1976). 
137  For a useful review, see Walter and Goodfellow (1993). 
138  Professor Dame Kay Davies (b. 1951), now Director of the MRC Functional Genomics Unit, Oxford 
and Deputy Chairman of the Wellcome Trust, was at St Mary’s Hospital Medical School, London (1980–
1982), Senior Research Fellow at the MRC from 1982, joining Oxford’s Institute of Molecular Medicine in 
1989. See also note 128.
139  Bryan Young was a Research Fellow at the Beatson Institute, Glasgow, from 1972 to 1984. 
140  Young et al. (1983).
141  Davies et al. (1981).
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Malcolm: My role was in 1975, I was the postdoc go-between between Bob 
Williamson and Malcolm Ferguson-Smith’s labs with a project to set up in situ 
hybridization for gene mapping, which I hadn’t quite appreciated at that time 
was probably a little bit more challenging than I’d realised. So, to begin with, 
we were doing repetitive DNA 5S ribosomal gene locus and we were all in 
Glasgow, and then half of us moved and I shuttled between the two. The little 
breakthrough then was we were looking for ribosomal probes and Don Brown 
from the Carnegie in Baltimore came through one day and we had a tea break, 
and he said, ‘Why aren’t you using recombinant DNA?’ There was a kind of 
shocked silence because you know all this stuff had happened in the States about 
recombinant DNA, and we thought it was so terribly daring so we diverted into 
setting up the right sort of committee to do it and getting the permissions and 
everything.142And from then on we used plasmids.
As it turned out, when we got it to work, the signal from the plasmid vector 
was what gave us enough signal to be able to do the experiments. So we then 
did that along with translocations, which Malcolm had and he always stressed 
to Bob, and to a lesser extent myself, that we didn’t really appreciate just the 
sheer importance of gene mapping – we were always trying to look for medical 
connotations and so on. Then we tried to use cloned genomic probes and we 
realised straight away there were Alu repeats all over the genome and that was 
142  See, for example, Berg et al. (1974). See also Berg and Singer (1995). 
Figure 13: Professor Sue Malcolm
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a little paper.143 Then, as an aside, because it was inevitable to do, we cloned 
globin in order to have the probes to do this, but obviously other people were 
interested as well. I went to Zurich to Charles Weissmann’s lab but all the RNA 
that got sent was in a little tube that got smashed in the post by somebody 
obviously pushing it through to try and frank it. So that didn’t happen until we 
got back to London. Then my role was to carry on with the in situ bit, for which 
the real breakthrough was the immunoglobulin heavy chain on chromosome 2 
because it was the first gene where you didn’t already know more or less where 
it was.144 Of course, we hit gold dust because it was next to c-myc and then we 
showed that you could have translocations on either side of c-myc, all by the 
same techniques.145 That was tremendous. But then we all went – I know this 
has been mentioned already in one of the other Witness Seminars – to this 
very influential workshop in Crete where we all heard Y W Kan give a talk.146 
That was the first time we’d heard it anyway. It was a thalassaemia workshop 
and from then on, from that day on, we were just saying, ‘Well, we need these 
probes for polymorphisms’. But Bob was very, I’m sure he still is, focused on 
the medical side and not the gene mapping for its own sake.147 He was really 
looking, always, for a practical application.
Ferguson-Smith: But the first ones that you mapped in situ were the globin 
genes because we knew which chromosomes the globin genes were on from the 
solution mapping that has already been mentioned. However, their location 
on the chromosomes was not known. But you were able to show, doing those 
wretched silver grain counts, that beta globin mapped to the short arm of 
chromosome 11 and alpha globin to the short arm of chromosome 16.148
143  Malcolm, Barton and Ferguson-Smith (1981). 
144  Malcolm et al. (1982). 
145  Professor Veronica van Heyningen commented, ‘The IgH heavy chains map to chromosome 14; 
kappa light chains to 2 and lambda light chains to chromosome 22. c-MYC (or MYC) is on chromosome 
8. Translocations in Burkitt Lymphoma move MYC to one or other Ig chain vicinity which then drive 
expression of the oncogene in these lymphoma cells. The chromosome 8 breakpoint can be either side of 
MYC.’ Note on draft transcript, 1 September 2014. 
146  For a discussion of the Crete workshop, see Jones and Tansey (eds) (2014), pages 20–1, and a photograph 
of ‘The Molecular Biology of Thalassaemia’ conference delegates, with key, on pages 88–9.
147  See note 128. 
148  Malcolm, Barton and Ferguson-Smith (1981); Barton et al. (1982). 
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Bakker: And was that before the paper of Harper and Saunders where they put 
insulin on 11p?149
Ferguson-Smith: That’s correct. Exactly. The beta globin result was published 
the same year.
Bakker: Harper and Saunders showed for me that in situ hybridization for a 
single copy probe was possible; that’s why I pursued it that year but it took 
longer.150 [Laughs]
Harper: Sue, were you in Bob’s lab at the time of his transition from working 
on haemoglobin to other diseases?
Malcolm: Yes, moving from Glasgow to London.
Harper: This was something I saw from the outside, or semi-outside, with our 
involvement with the diseases but how did that transition seem from the point 
of view of you as part of the lab?
Malcolm: Well, perfectly logical I think. I mean, Bob had no medical background 
at all but he’d got into the thalassaemias because he had a very good working 
relationship with David Weatherall.151 I mean extremely close, and the groups 
met and John Old would travel backwards and forwards.152 And so then, that 
was the way he realised the medical potential of what he was doing and then 
started to apply it to other things and cystic fibrosis was the main one and, 
of course, he did not find the genes but his contribution was to explain to 
patients, GPs, and respiratory physicians why they needed to collect samples 
and families. He really got people involved in it. From then on he saw how to 
conduct such a study in terms of engaging with families, and that became very 
influential.
Harper: Veronica, do you want to say something about cystic fibrosis?
149  Harper, Ullrich and Saunders (1981).
150  See note 134.
151  Professor Sir David Weatherall (b. 1933) was Nuffield Professor of Clinical Medicine at the University 
of Oxford (1974–1992), where he founded the Institute of Molecular Medicine. For his contributions to 
thalassaemia research, see, for example, Christie and Tansey (eds) (2003), pages 11–14, 32, and a biography 
in Jones and Tansey (eds) (2014), page 111. 
152  Dr John Old was a postdoctoral research scientist in Professor Sir David Weatherall’s laboratory in 
Oxford from 1974 to 1981. 
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van Heyningen: I went to a meeting in New York in 1982, which was called by 
the Cystic Fibrosis Foundation; you know they supported it. Bob was definitely 
there, and I remember encouraging everybody to make lymphoblastoid cell lines 
from the patients because then they would have a permanent source of DNA, 
and all sorts of other possibilities, through having the cells. I think that started 
being much more routine around that time, especially for disease samples where 
you might not be able to go back to the same family. We were in New York 
when the Falklands War broke out.153
Malcolm: I don’t think Bob ever cared which chromosome cystic fibrosis was 
on; he just wanted a linkage to a disorder. His research was really focused in that 
respect whereas Malcolm (Ferguson-Smith) would keep saying, ‘We’re interested 
in the map’.
Ferguson-Smith: But I’m a medic and we were also interested in translating 
what we’d learnt into patient care and this is what we did.
Bodmer: But the idea that you could actually find the gene from its position, 
it was certainly something I suggested in 1980 and was a strong stimulus for 
the mapping and one of the major rationales for it as Victor McKusick always 
said as well.154 And I remember trying to tell Bob Williamson, explain linkage 
disequilibrium to him to say how he might be able to use that to get a bit closer 
to the gene. And in the end, in fact, it was that approach, but not by him, that 
led Lap-Chee Tsui to find the gene.155
Povey: In the 1970s, people, I anyway, didn’t think we’d ever find a gene by 
where it was. I think that you (Walter) introduced that in 1980, the reality of it. 
But I remember Peter Cook saying to me, ‘Well, the challenge is, it’s like a great 
big crossword puzzle to which there’s only one solution’, and it kept him up all 
night, definitely, with enthusiasm. That was what drove him.
Bodmer: Just a historical comment there because I got very involved as a 
graduate student, or just after, in studying the interaction between linkage and 
selection and the whole phenomenon of linkage disequilibrium. And I remember 
153  The Falklands War between Britain and Argentina, concerning the disputed territory of the Falklands 
Islands broke out in April 1982. See, for example, Commons (1982). 
154  See Bodmer (1981), in particular page 675. 
155  See Tsui et al. (1985); Tsui et al. (1989).
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discussing this with (R A) Fisher who was my supervisor and, basically, his view, 
which was interesting at the time, was that there would never be a high enough 
density of polymorphic genes for linkage disequilibrium to matter. He realised 
it would matter if you had enough polymorphisms but at that time researchers 
only had the blood groups and they thought that polymorphisms would be far 
and few between.
Professor Tim Bishop: I went to the University of Utah, Salt Lake City, in 1977 
as a young postdoc. In 1978, within the biology department, we would take our 
PhD students and early postdocs up to Snowbird for a two-day meeting.156 The 
idea was that then they had the opportunity to both present work themselves 
but also to bring in others. They brought in some great names to speak to them. 
They were forced to stay up in the mountains for two days; it’s tough, you 
know, but someone’s got to do it. Anyway, I went to Utah to use the Mormon 
genealogy to try and work out ways to identify genes predisposing to cancer. 
So at this meeting, there was Mark Skolnick based in Utah, Ron Davis, Ray 
156  Snowbird is a ski resort near Alta, Utah; http://www.snowbird.com/about/history/ (visited 13 November 
2014). 
Figure 14: Professor Tim Bishop
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White, and David Botstein all came that evening.157 One of our students, I 
can’t remember who it was, gave a talk about hereditary breast cancer because 
we were actually trying to get funding at that stage to do linkage mapping for 
breast cancer. In fact, we got our first award in 1979 to do that. Ray White 
spoke about recombinant DNA technology work, and so the question was: 
How could you use this new technology to try and find genes for breast cancer? 
The next day we discussed it further and subsequently described approaches 
to construct a linkage map following Kan and Dozy’s initial observation for 
human beta globin.158
Bodmer: We said it in one paragraph a little before in the Lancet and they 
reproduced Mendelian genetics in a long paper in the American Journal of 
Human Genetics in 1980.159
Bishop: Yes, but we looked at the issues about actually constructing the map, 
and using that map. Actually, the estimates we came up with at that stage, that 
you’d require something like 400 markers to map the genome actually turned 
out to be reasonably close.
Bodmer: I think we’d said 300 in our note in the Lancet and we had a good 
idea of how to do linkage; you didn’t have to tell people how to do it again. I 
remember at the 1986 Cold Spring Harbor symposium, I’ve forgotten who it 
was, started the symposium by explaining Mendelian genetics to people.160
Bakker: There was this group in Utah: Mark Skolnick; Ray White; and the 
students probably at that time, David Barker, Web Cavanee, Mireille Schäfer, 
they were starting to make clones.161 They also found some polymorphic markers 
157  Mark Skolnick was based at the University of Utah’s biophysics department from 1973 (later called the 
Department of Medical Informatics), where he developed familial genetics databases; Raymond White 
was based at the Massachusetts Institute of Technology in 1978, and, from 1980, at the Department of 
Human Genetics in the University of Utah, of which he became Professor and Co-chair; see http://content.
lib.utah.edu:81/cgi-bin/showfile.exe?CISOROOT=/uupahsc&CISOPTR=2928&filename=2892.pdf; 
Ronald Davis was Assistant Professor in Stanford University’s Department of Biochemistry from 1972, 
later becoming Professor, http://gruber.yale.edu/genetics/ronald-davis; David Botstein was based at the 
Massachusetts Institute of Technology; see his remarks on the 1978 Alta meeting in Gitschier (2006) (all 
websites visited 28 January 2015). See also Gesteland and Leppert (1992). 
158  See note 124. 
159  See Solomon and Bodmer (1979), final paragraph, and Botstein et al. (1980). 
160  Lander and Botstein (1986). 
161  White et al. (1982). 
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and they were publishing that at a human genetics meeting in Jerusalem 
where Peter Pearson also went with the result of our probes in 1981, which 
was published from the Oslo meeting but he also presented an abstract in 
Jerusalem.162 He discussed with these people from Utah and said, ‘We should 
start to make a course for preparing these RFLPs and training people in clinical 
genetics to use RFLPs for linkage and show how to put them on the map.’ So 
we had this course in 1982 in our lab in Leiden, organized by Peter Pearson and 
myself, and we had as other teachers Ray White, Web Cavanee, David Barker, 
Mark Skolnick, and Mireille Schäfer.163 There were 20 participants from all over 
Europe: Jan Mohr, Tobias Gedde-Dahl, Marianne Schwartz, and many others. 
They all were in this course and learnt how to prepare and use these probes. 
We also gave out the probes that we already made before for people to use 
and to start doing linkage for genetic mapping. So that was a very interesting 
collaboration between Utah and Leiden at that time.
Harper: Can I bring people back for a minute or two to the workshops 
because the character of the workshops was pretty radically changed by the 
advent of DNA polymorphisms, and the numbers of polymorphisms built up 
astronomically. I know this caused huge changes for the people involved in 
informatics and statistical analysis. Have people who were involved got any 
impressions in terms of the kind of general, not just the structure, but the 
atmosphere of those workshops, from the time of the Oslo meeting, in 1981, 
over the succeeding 10 years?
Solomon: They were always exciting and always fun. I think for the people who 
were very much hands-on with producing the next map, the workload became 
overwhelming. Possibly that’s one reason why they stopped, you just could not 
manage it all in 24 hours a day, so it was very, very intensive.
Bodmer: The big change was the amount of data and therefore the systematic 
introduction of computing, and I know Chris Rawlings would have comments 
on that, which really started just about after that time. Although, initially, it 
was mainly just to use them as word processors; it was the development of the 
need to have your proper databases in an organized way that was pushed by the 
amount of data being produced at that time. That was before the sequencing.
162  Cavalli-Sforza et al. (1982); Berg (ed.) (1982). 
163  Details of the postgraduate course ‘Restriction Fragment Length Polymorphisms and Human Genetics’ 
at Leiden, July 1982, including a photograph of laboratory work, and a sample of the laboratory manual, 
are available in Jones and Tansey (eds) (2014); pages 11–13, 91–4.
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Harper: This whole question of databases, at the beginning there really wasn’t 
that much data in the first and second workshop but how did the beginning of 
the databases relate to the workshops? How did that come about?
Craig: To start off with, there were rather haphazard data collections on diskettes 
that were sent through the post, which you updated and sent back. I think 
the turning point was the introduction of ‘Edit 9.5’ at the interim meeting in 
Yale, in 1988. This was the first attempt to have a coordinated database, which 
was a progenitor basically of GDB (Genome Database), but this was at the 
interim meeting 9.5 before HGM10, which, again, was at Yale.164 I think that 
was probably the main turning point from my recollection. That was 1989, it 
was quite late.
Bodmer: The HLA workshop in 1977, in Oxford, made a huge use of computers. 
Some of us were really quite used to the need for large-scale computing. That’s 
what we introduced, Julia Bodmer and I, when we went to the ICRF in 1979.165
Craig: But I think GDB was the first really useful relational database as far as I 
can recollect and I think that we’re touching on that afterwards.
Bakker: At that time you needed to have some very good computer people in 
the lab who understood linkage and who understood computers, and one of 
these guys was a clinical geneticist from Rotterdam, Lodewijk Sandkuijl, who 
did massive linkage work for the whole of the Netherlands.166 He came to all the 
different groups and did all the linkage work and that was very handy.
Ferguson-Smith: One measure of the activity and place of RFLPs comes by 
looking at the number of assignments made at the various workshops. Suddenly, 
from 633 autosomal gene assignments in Helsinki (1985), you go up to 1,146 
in New Haven four years later. At the time of New Haven, I’ve got a note here 
that 5,100 additional DNA markers had been assigned, so that’s an incredible 
amount of data that can be used to build maps of every chromosome.
Bakker: Yes, all the VNTRs (variable number tandem repeats) came in and later 
all the STRs (short tandem repeats), yes.
164  See Ruddle and Kidd (1988). 
165  Lady Julia Bodmer (1934–2001) was a geneticist who collaborated with her husband Professor Sir 
Walter Bodmer in HLA research. Their archives are available at Oxford’s Bodleian Library; http://blogs.
bodleian.ox.ac.uk/savingoxfordmedicine/2014/05/12/the-bodmer-archive/ (visited 14 November 2014). 
166  See, for example, Freimer, Heutink and Wijmenga (2003). 
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van Heyningen: A very brief interjection: in 1979 we had a gene mapping 
meeting in Edinburgh and I very much remember Frank Ruddle, I think he 
was giving one of the plenary lectures, and he said, ‘By the time I retire – and 
that was due to be in 2003 – all the genes will be known and mapped.’167 And I 
thought he was being incredibly optimistic but, of course, he was right.
Craig: Just to recap on Edit 9.5, which was at the interim Yale meeting, it 
was largely Ken Kidd who was certainly behind setting the whole thing up in 
informatics.168 It was not wonderful but it was the first real attempt to do that, 
and that was 1988.
Bodmer: If you look at this, I think it was in one of the workshop summaries 
by McKusick; I don’t know if people can see that?169 It’s an exponential curve in 
assignments that starts taking off between 1982 and 1984. I think it was that 
that stimulated the real need to have a more systematic way of dealing with the 
data. The gene mappers were well behind a lot of other people who were using 
computing extensively, including the HLA community.
Solomon: Another way of relating this huge increase in data to the workshops 
was that, as somebody so nicely described – Ian I think – at the first one there 
was ‘chromosome 1’ and then ‘all other autosomes’, and I can’t give you dates 
and times but it certainly came down to, there were committees for 1 to 3, and 
4 to 6, and then there was a committee for each chromosome, and then larger 
and larger numbers of people on each chromosome, and ultimately it became 
a piece of DNA.
Harper: From the individual workshops, the number of committees, the list gets 
longer and longer, as seen in the reports. By the London workshop in 1991, 
there was indeed one for every chromosome, quite apart from mitochondrial, 
comparative neoplasia, and several other things too. Perhaps because I’m a 
clinician, one of the things that I think was quite a challenge was keeping the 
disease side linked with what you might call the more basic marker-related side, 
because it had soon reached a point where you didn’t actually need the diseases 
any more to make the map but a large point of the whole exercise was in relation 
167  Frank Ruddle’s plenary lecture was not published in the HGM5 publication, as explained by Evans 
(1979); see page 2. 
168  See note 164. 
169  See Figure 1, ‘Growth of information on chromosome assignments’ in McKusick (1991), which 
illustrates the steep rise in gene loci mapped between the early 1980s and 1990, page 13. 
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to the main diseases. I can well remember, I was on the clinical committee with 
Victor McKusick and Jean Frézal – and actually Jean is someone whom I think 
we shouldn’t forget.170 His GENATLAS was very good indeed apart from the fact 
that originally it was only in French.171 Then he got it translated into English, but 
it was always rather overshadowed by Victor’s OMIM.172 GENATLAS was a big 
contribution, and I was very pleased that the clinical side always stayed in the 
map, and actually it was helpful for everyone that it did so because the diseases 
themselves turned up so many unusual molecular phenomena that without them 
it would have been a bit of a sterile thing if it hadn’t had any diseases at all involved.
Bodmer: I’m just surprised you say that, Peter, since the emphasis was so much, 
as Ellen and I pointed out, and others did, on using the linkage to find genes 
for diseases.173 At least there were a few people around who straddled that quite 
strongly who weren’t even clinicians.
Harper: No, I don’t think I did say that, Walter. What I was saying was the diseases 
were no longer necessary. Once we’d got abundant DNA polymorphisms, you 
didn’t actually need the diseases.
Bodmer: You didn’t need the diseases for mapping, you needed the mapping 
for the diseases.
Harper: Exactly. Absolutely.
Bakker: That was very important at the HGM9 workshop in Paris, in 1987, 
that all these different chromosome groups had to produce a map at the end of 
the workshop. So the leaders of these groups had a number of people assigned, 
mainly PhD students, and I was one of them, to collect information from all 
170  Jean Frézal (1922–2007) was a French geneticist based at the Hôpital Necker, Paris, where he developed 
medical genetics research and clinical services. He also developed the GENATLAS database; see, for 
example, Professor Peter Harper’s interview with him, freely available at http://www.genmedhist.info/
interviews/Frezal (visited 17 December 2014). He participated in HGM1; see McKusick and Frézal (1974).
171  GENATLAS was a database created for compiling the data from the chromosome committees’ reports 
for HGM9 in 1987; see Frézal (1987). 
172  Online Mendelian Inheritance in Man (OMIM) is a database that was founded by Victor McKusick, at 
Johns Hopkins University, as a catalogue of Mendelian-inherited traits and disorders, first published in print 
as McKusick (1966). The database is now available as an online resource; see http://omim.org/about (visited 
17 November 2014). 
173  See comments from Professors Sue Malcolm, Veronica van Heyningen, and Malcolm Ferguson-Smith 
on pages 42–6. 
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the posters. We were sent around to note the locations and the distances, and at 
the end we produced a map on paper. All these pieces were glued to each other. 
It was not so much really in the computer but it was all on stretches of paper 
and I know that we had for the X chromosome a very dense map at that time.
Ferguson-Smith: Single Chromosome Workshops were taking over in the 
1990s, within two or three years. As I said before, there were 24 different single 
chromosome mapping workshops that had been established and had met in the 
period of three years.174
Craig: 1989 was the first one, X chromosome, December 1989.
Harper: We’ll come back to the Single Chromosome Workshops.
van Heyningen: I’ve got in front of me this little perspective from Trends in 
Genetics, June 1986. David Porteous and myself writing ‘Cystic fibrosis: from 
linked markers to the gene’.175 I see one of the methodologies that we are already 
talking about there is pulsed field gel electrophoresis and that, of course, is one 
of the things, and yeast artificial chromosomes, which helped us to bridge the 
gap in terms of size.
Harper: The evolution of the technology is hugely important and, in fact, Tilli 
Tansey suggested it might merit having a workshop, or a Witness Seminar, 
specifically on technologies in genetics because in a way they did determine to 
a huge extent what was feasible.
van Heyningen: Yes. You must get Ed Southern.176 He invented pulsed field gel 
electrophoresis as well, I think.
Bodmer: No, that was invented by Charles Cantor.177
van Heyningen: Oh, Ed Southern developed one cheap machine then, the 
Waltzer.178 
174  The proceedings from the Single Chromosome Workshops are published mostly in the journal 
Cytogenetics and Cell Genetics, but also one in Genomics and two in the Annals of Human Genetics; for a 
breakdown see Ferguson-Smith (1998). 
175  van Heyningen and Porteous (1986).
176  See note 89. 
177  Schwartz and Cantor (1984). 
178  Southern et al. (1987). Professor Sir Edwin Southern discusses the informal title of the electrophoresis 
apparatus he devised with his colleagues as the ‘Waltzer’ in Southern (2005). 
Human Gene Mapping Workshops c.1973–c.1991
54
Craig: Just to go back to the beginning really and the somatic cell hybrids, and 
Frank Ruddle who died last year.179 So in memory of him, it’s worth mentioning 
that, in fact, he had a whole factory. He had 40 to 50 people working in the 
Kline Biology Tower [in Yale] by about the middle of the 1970s or late 1970s 
doing somatic cell genetics. It’s no wonder that the field has a lot of papers by 
him and his group.180
Harper: Did Frank Ruddle ever write a historical or autobiographical account 
of the gene mapping work? We’ve got Victor McKusick’s account but I’m not 
aware of one that Frank Ruddle wrote.181 It’s a pity if he didn’t because he would 
have given a very valuable and rather different perspective on things. Anyone 
got any idea on that?
Craig: He moved on to study HOX genes in his latter career.
Harper: Yes, but he didn’t as far as you know write a kind of retrospective paper 
on his gene mapping work?
Craig: I’m not aware.
Malcolm: No, but it might be relevant here. I don’t know where the McKusick 
archive is but, of course, he took photographs of everybody and everything. So 
that could be very valuable.
Harper: Yes, indeed it is. I can tell you that. So could Malcolm. But, yes indeed, 
all his records are at Hopkins and they are properly archived and most of them 
have already been sorted.182
We now get onto the area of linkage analysis, informatics, computing, which 
many of us either on the clinical or the lab end tended to regard as a sort 
of necessary evil. I think there’s a real danger in documenting the history of 
this that it gets made more subsidiary than it deserves to be. So Tim Bishop 
and Chris Rawlings are going to try and cover this area and anybody else can 
contribute.
179  See biography on page 107. 
180  Ruddle (1998); Ruddle and Kidd (1989). 
181  McKusick (1988). For Ruddle, see note 28 for a brief historical account that he presented on gene 
mapping.
182  ‘The Victor Almon McKusick Collection’ of personal papers is available at the Alan Mason Chesney 
Medical Archives of the Johns Hopkins Medical Institutions; http://www.medicalarchives.jhmi.edu/papers/
mckusick.html (visited 17 November 2014). 
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Bishop: Let’s start with the linkage analysis. As Sue and Walter have already 
said, much of the basis for linkage analysis was formulated either through 
the work of Fisher or Haldane,183 while made feasible through the work of 
Newton Morton. His 1955 paper was the paper that defined the kind of 
statistical approach to conducting linkage mapping, in particular to assert the 
finding that a linkage had been found.184 It was the first approach that took 
into account the fact that you would have a map or a large number of markers, 
that you’d be doing multiple testing and there would be an issue about the 
correlation, linkage disequilibrium, between markers. A lot of that was defined 
in advance of the consideration of these workshops, as was the method of 
actually defining the lod score if you like. So the procedures were in place. For 
implementation they required better statistical probabilistic software, and so 
software was produced – I think Jurg Ott’s LIPED programme, or the Elston–
Stewart algorithm, or the PAP (Pedigree Analysis Package) programme a 
little later.185 There was a series of algorithms like that which were produced 
and which worked on the kind of computers that were available in the early 
1980s, and were really quite successful in terms of taking these approaches 
forward. We spent a lot of time discussing the robustness of linkage analysis, 
while we were very concerned as to whether linkage analysis would work in 
the presence of significant heterogeneity, for example if there were multiple 
genes. In fact, it turned out that none of those things were so important at 
these early stages. Recognizing traits with a clear Mendelian inheritance gave 
enough power to make the methods actually quite robust. We spent a lot of 
time worrying about this, as statisticians do, but the approach really worked 
very well with the benefit of the fact that heterogeneity was not actually as 
great as we had worried about. It meant that there was a steady increase in 
linkage power and approaches, etc., and it really was, statistically, impressively 
successful.
It’s interesting going back and looking through the papers, that the kind of 
issues that were a concern were probably opposite to the way that Maj was 
suggesting. For instance, a lot of the early work was motivated by how to 
include chiasma mapping into the approaches, to optimize the approach to 
183  See notes 15 and 17. 
184  For Newton Morton see note 22, and for the background to the development of the statistical technique 
of sequential analysis during covert war operations in Britain, see Peter Harper’s 2005 interview with 
Newton Morton; http://www.genmedhist.info/interviews/Morton (visited 18 November 2014); page 8.
185  Ott (1976); Elston and Stewart (1971); Hasstedt and Cartwright (1979).
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linkage. Actually we were very worried that the approaches would not be 
powerful enough, and you had to invoke other information to make the most 
of the co-inheritance. In fact, the modelling was not so critical, it turns out. 
But it was certainly the focus of much of the earlier considerations, as was the 
development of mapping functions. So, statistically, the issues were not that 
great, certainly not as great as we thought they were going to be. Although, as 
Peter says about many people taking linkage analysis to be a ‘necessary evil’ for 
these workshops, there were groups of us that met together regularly. The main 
leader of this was Bronya Keats, who was originally in Hawaii and then moved 
to LSU (Louisiana State University).186 Bronya was very much the person who 
encouraged the sharing of information by geneticists to promote cooperation 
and collaboration, and to bring linkage analysis to the level that it did. I often 
see discussions about extensive meta-analyses and the comments about how 
well these had been developed. But, in fact, I think it’s the geneticists that did 
this first of all, when, by agreeing that you would share information in the 
form of a standard lod table, this was the basis for putting all that information 
into the public arena. So you could combine with other studies, take your data 
to the Gene Mapping Workshops and combine information from multiple 
studies, and come up with statements about linkage and linkage groups.
Towards the late 1980s/early 1990s, the discussion was changed in terms of 
not being a matter of how to identify linkage groups, it was how to identify 
marker order and gene order, and the fine-scale mapping approaches that were 
rather different and had quite subtle problems of their own. Overall then, 
the linkage analysis probably wasn’t as much of a ‘necessary evil’ as expected 
but, of course, that changed when you change from major gene inheritance 
through to polygenic inheritance, and multifactorial diseases where in fact the 
complications become much more serious. It’s clear that we probably still don’t 
have a very good handle on those.
Moving on to informatics. Actually, as I wasn’t really involved in the informatics 
until the late 1980s, I think 1987 was the first time I was involved, I can’t say 
anything about it before that. I was in the States at that time and was involved 
with the Utah group, which was the group that in the States was largely driving 
the creation of genetic information and databases. They had a very enthusiastic 
colleague, Peter Cartwright, who worked with Ray White, who was developing 
186  Bronya Keats was Assistant Professor at the Department of Biometry and Genetics at Louisiana State 
University (1982–1986) and Associate Professor (1986–1991); see http://www.medschool.lsuhsc.edu/
genetics/faculty_detail.aspx?name=keats_bronya (visited 18 November 2014). 
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databases in Sybase for storing genetic information, including information on 
different types of markers: their locations, their polymorphisms, their mapping 
status, etc. Peter and Fran Lewitter and, of course, then led by Peter Pearson in 
Baltimore, together with Ken Kidd, were the ones who really developed GDB 
that we got to know and love.187 Bert will be able to fill in more on this,188 but 
also Ken Kidd had a system, which was based on Lotus Notes, that was available 
for sharing information that worked well with the system that Bronya Keats 
had put in place.189 She simply stored the information in a home location, put 
together all these linkage results and then produced summary statements for 
each of the chromosome committees. I think Chris can comment on how that 
was translated into the UK version at HGM9.5 and 10.
Professor Chris Rawlings: I got involved towards late 1988/1989, when 
it had been agreed, or certain members of the people in this room had 
volunteered, to run the next pair of workshops, 10.5 and 11 in the UK.190 
And this happened at an interesting time, as we’ve already mentioned, when 
the need for the computing support had become clear and I think there was 
a general concern that the tools that had been built for the Yale meeting 
weren’t going to scale up to the way that was going to be needed for the 
London meetings. At that time, as Tim has said, there was already this move 
to initiate a bigger development of a relational database using professional 
software engineering techniques, which was being driven by the people in 
Baltimore at Johns Hopkins University. But there was also, at the time, 
a degree of uncertainty as to how that database was going to support the 
workshops because it clearly needed a lot of developmental work, and it wasn’t 
going to be ready. There was a need for an intermediate solution that would 
187  Frances Lewitter contributed to HGM9.5, in 1988, as a representative of BBN Laboratories, Cambridge, 
Massachusetts, reporting on the Informatics Committee; Cartwright and Lewitter (1988). See, for example, 
Pearson (1991). For Peter Pearson, see also note 95, and, for Ken Kidd, note 164. 
188  Professor Bert Bakker wrote, ‘This was later: Peter Pearson moved from Leiden to Baltimore to become 
Director of the GDB in 1989, so the first data in GDB were entered and curated manually by the editors.’ 
Note on draft transcript, 4 March 2015. A copy of the 1990 ‘User Guide to GDB and OMIM. Version 1.0’, 
which was part of the package that the official GDB editors and curators received, published by the Howard 
Hughes Medical Institute/Johns Hopkins University, was provided by Bert Bakker and it will be deposited 
in the archives of this meeting at the Wellcome Library, London, Archives and Manuscripts, GC/253.
189  Lotus Notes was software developed by IBM in the mid-1980s; see http://www.ibm.com/developerworks/
lotus/library/ls-NDHistory/ (visited 18 December 2014). 
190  HGM10.5 was convened in Oxford, and HGM11 in London. For the Informatics Committee report, 
see Rawlings and Lucier (1990). 
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support the intermediate workshop that was going to be held in Oxford that 
Ian (Craig) was leading. So the team that I led took on the responsibility 
for providing the intermediate solution, which still capitalized on the Lotus 
Notes application that Ken Kidd had pioneered, but we made sure that it was 
coordinated with the chromosome committees, and the data were gathered 
and presented to the then early version of the Genome Database that was 
in Oxford. There were quite a lot of political tussles in the background as to 
who was going to build this database, what it was going to be implemented in 
and all the technical complexities, and who was controlling the whole thing – 
that’s perhaps more for a conversation over a beer later.
The outcome was, or the desire was, that for the meeting in Oxford in St John’s 
College to have the first version of the Genome Database populated with the 
preliminary data from the chromosome committees, for them to work on in 
study bedrooms in one of the accommodation blocks, and so we set about 
making sure that that could happen. The UK team provided a lot of the 
infrastructure, both the network and the computing power. We were hunting 
around the whole of the UK trying to find where we could get suitable work 
stations for everybody because each chromosome committee required two PCs 
and we needed a server, and we needed to get all this stuff ready and in place in 
Figure 15: Professor Chris Rawlings
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St John’s College, which had no internet or ethernet connections [laughter]. It 
was quite early days to do some of this, and I often describe it a bit like running 
a rock concert, as you had to bring a team of roadies in to get all this stuff in 
place. We benefitted from Hewlett Packard, which I had some links with, and 
contacts there who were able to loan us all the PCs for nothing, but this was 
no small logistical exercise to get this in and out in the required time, and there 
was a fair amount of blood, sweat, and tears involved in this operation, as Ian 
will remember.
Then we had to repeat the whole exercise again for HGM11, which was held 
in the New Connaught Rooms in London, not far from Lincoln’s Inn Fields 
where ICRF was based and where my department was.191 As well as having the 
infrastructure development, that year was when we needed to make sure that 
the final printed version was automatically generated from the database and 
so the work was much more oriented towards writing the software that would 
produce hard copy, camera ready copy for Karger to print the proceedings 
of the meeting.192 I think the meeting finished in somewhere around July or 
August time and we wanted to get the proceedings out early the following year, 
and so there was a lot of optimizing the database queries, writing the software 
that would generate the mark-up language version of the book, producing the 
camera ready copy, checking it with the chromosome committees, editing the 
whole thing as an editorial team and then delivering to Karger in time to get the 
thing out of the door quickly. In the end it was a scrabble but we got it out in a 
timely fashion with very few problems in the end.
For the rest of the informatics development we had a very different sort of 
architecture then – the Genome Database went back to its home fully populated 
with the best available maps that were curated at the London meeting and then 
the whole infrastructure changed when we moved to more single chromosome 
committees and then to an extent my involvement drifted off and I went on to 
other things. By then the whole concept of community databases and sharing 
of information was moving into the whole genome sequencing era, and we see a 
huge change in culture within the research community about the importance of 
data and the importance of sharing it in support of research for the public good.
191  The New Connaught Rooms is a Central London venue, now the Grand Connaught Rooms; 
http://www.connaughtrooms.co.uk/ (visited 20 November 2014). 
192  See Probert and Rawlings (1991), and Rawlings (1991). 
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Solomon: I’d just like to say that the Connaught Rooms were not networked 
at that time either [laughter], and getting that infrastructure in place was an 
absolutely gargantuan task, a real nightmare. I think that also made us reconsider 
how this sort of thing could possibly go forward.
Bodmer: Just a question to Chris: was the GDB actually used for workshop 11?
Rawlings: Yes.
Bodmer: So it was the database that was developed over on the other side? But 
it was an adequate version? I’d just like to add a few general comments that 
are not so much on the science of it but what went on behind the scenes.193 
The informatics operation was really, for its time, a huge enterprise and I’m 
not sure whether it was you (Chris) who said, ‘Oh what a pity they didn’t 
get the volume up by December 31.194 I think it was a miracle that those two 
1,000-page volumes were produced with all that huge amount of information 
by April 1992 after a meeting that had been in August. It was an amazing task 
for its time. I think it’s hard to imagine and I just have a few things I note here: 
a computer server had 2 GB on its disk. [Laughter] I bought a memory stick 
the other day with 128 GB on it, and I’m getting a computer today that has a 
terabyte. The resources that one had for working at this scale, at that time, were 
incredibly less than they are now. So it’s hard to imagine just how difficult it 
was to get these things going. The other thing, though, is that there was a huge 
amount of politics – one argument I remember a lot about was Sybase versus 
193  Professor Sir Walter Bodmer was Chair of HGM11, Professor Ellen Solomon was Co-chair. Other 
members of the UK Executive Committee for organizing the workshop who contributed to this Witness 
Seminar were: Tim Bishop, Ian Craig, Malcolm Ferguson-Smith, Peter Harper, Sue Povey, Chris Rawlings, 
and Veronica van Heyningen. The other HGM11 UK Executive Committee members were Martin Bobrow, 
Kay Davies, John Edwards, Peter Goodfellow, John Johnson, Michael Probert, Bette Robson, Nigel Spurr, 
and Bob Williamson. See Solomon and Rawlings (eds) (1991), page v. 
194  Professor Chris Rawlings wrote, ‘I don’t think it was me who made this comment at the time, but in 
our meeting Walter may have been seeking my acknowledgement that the comment had been made. My 
recollection was that one of the HGM committee chairs had made the comment that it would have been 
nice to have had the proceedings of HGM11 published by the end of the year. This may have been the 
original plan. It would indeed have been nice but the technical and organizational challenges needed to 
produce this huge two-volume report as camera ready copy were significant.’ Note on draft transcript, 4 
March 2015. 
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Oracle; it was a huge argument.195 It was politically motivated according to who 
was using Sybase and who was using Oracle and there were also enormous 
problems getting the funding. I mean at that time you’ll notice that it says that 
ICRF sponsored that meeting, and it jolly well did. I think it cost nearly three 
quarters of a million pounds, it was a huge enterprise. It’s interesting that the 
grants don’t mention the MRC and the Wellcome Trust.196 They did provide 
some money but neither of them had really got going. Well, by that time maybe 
the MRC had got going a bit.
I’ll have to remind you of earlier times: I remember going to a meeting organized 
by Victor McKusick and Charles Scriver at the headquarters of the Howard 
Hughes Medical Institute, a beautiful villa on the coast in Florida. At that time, 
Don Fredrickson was the director. That was a very early, specific discussion 
about the idea of doing the Human Genome Project. This was in early 1986 
at the latest. Then there was the Cold Spring Harbor meeting that Jim Watson 
organized, and I gave the opening talk where there were lots of discussions 
about doing it.197 Later that year, there was a meeting at the NIH so actually 
the impetus for starting to think seriously about doing the Human Genome 
195  Professor Chris Rawlings wrote, ‘When the planning for HGM11 started at ICRF, the expectation 
was that the database that would support the workshops and associated work of the HGM committees 
would be built using the Oracle relational database platform. This reflected the expertise and long-standing 
commitment to Oracle by the ICRF clinical research database team. When the Genome Database (GDB) 
Project, funded by the Howard Hughes Medical Institute at the Johns Hopkins University, undertook 
to develop a reference database for the human genome map to complement the OMIM® catalogue of 
Human Genes and Genetic Disorders, they chose the Sybase database system. At that time Sybase had been 
identified as the database system of choice for human genome projects. Furthermore, competitive software 
licensing deals were available to US researchers from Sybase as a result of an agreement brokered by the 
National Science Foundation. As the GDB and ICRF teams began working together, it took a while for 
the mutual benefits to become apparent of adopting a common database platform to deliver both the data 
content needed for GDB from HGM11 and the data curation interfaces needed for the workshops. After 
much discussion, the ICRF team conceded that the available resourcing and rate of progress already made 
on the GDB database design made it more sensible to adopt Sybase for this project. For the informatics at 
HGM11, see Rawlings et al. (1991). 
196  In the Introduction to the published volume for HGM11, Professor Sir Walter Bodmer acknowledged 
funding from the Imperial Cancer Research Fund, Medical Research Council, and the Wellcome Trust, 
although none of these organizations were included in the list of ‘granting agencies’; Solomon and Rawlings 
(eds) (1991), pages v and 1. 
197  The symposium was entitled ‘Molecular Biology of Homo Sapiens’; see a summary of the conference on 
Cold Spring Harbor Laboratory’s website at http://symposium.cshlp.org/site/misc/topic51.xhtml (visited 
18 November 2014). See also Watson (1986), and Bodmer (1986). 
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Project, as it came to be called, had started five years before the 1991 meeting, 
and I remember Sydney Brenner and I having to go to Dai Rees, the then head 
of the MRC, to persuade him that this was something they should be thinking 
about.198 At that time, the Wellcome Trust had hardly got involved at all. So, 
in fact, we’d appointed Hans Lehrach at the ICRF, in 1987, to deal with this 
sort of thing. One has to remember, it was a project that was being criticized 
for being ‘big science’, taking money away from everyone else, that it wasn’t 
going to be useful. Somehow that didn’t quite include the gene mapping but it 
certainly included the Human Genome Project. So it was extremely political, 
and and there were questions of whether we would continue to get money 
from Howard Hughes, and the Wellcome Trust didn’t want to support HUGO 
(Human Genome Organization),199 and I think it was actually very difficult but, 
in the end, that meeting in 1991 was really a watershed. It was a major meeting 
but it was also the transition between the old style of getting together in nice 
cosy groups and what became a highly politicized Human Genome Project.
Harper: Walter, I’m going to shift, we’re going to come back to that in a little 
bit.
Bodmer: I think it’s highly relevant to the whole discussion of the issue of the 
significance of that meeting and the difficulties at that time of really getting 
something like this adequately supported.
Craig: I’ve got a couple of comments about both the interim meetings 9.5 and 
10.5, and what a miracle it was to get everything up and running in Oxford 
with Chris and his team. But I should just mention the fact that at St John’s 
College, the bursar there, Dr Tony Boyce, was so enthusiastic about the whole 
thing that I think they paid for the networking of the different rooms, which 
was a huge contribution, so that every committee could have its own access 
198  See Friedberg (2010) for Sydney Brenner and Walter Bodmer’s collaboration on lobbying for the 
UK’s participation in the Human Genome Project in the mid-to-late 1980s, pages 236–9. Sydney 
Brenner (b. 1927) was a Nobel Laureate in 2002; see http://www.nobelprize.org/nobel_prizes/medicine/
laureates/2002/brenner-facts.html (visited 4 February 2015). 
199  The Human Genome Organization (HUGO) was founded in 1988 as the international coordinating 
body for research and collaboration between scientists on the human genome, a so-called ‘UN[United 
Nations] for the human genome’; see, for example, McKusick (1989), quotation from page 386. Of this 
seminar’s participants, Professor Sir Walter Bodmer and Professor Malcolm Ferguson-Smith were members 
of HUGO’s first Executive Committee, see page 385, and Bodmer (1990a). See also HUGO’s website for 
further details of its previous and current work, http://www.hugo-international.org/index.php (visited 25 
November 2014). 
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to the database. So it worked in both ways, absolutely. Just one point, in 9.5 
where the Edit system was tried for the first time, so much time was spent 
worrying about the computing and everything else, they forgot about the rooms 
for the people who were actually going to the meeting, and the first thing that 
happened at the first session was a handout of light bulbs because there were no 
light bulbs, and, as far as I can remember, there was no furniture in the rooms 
apart from a bed.
Professor Michael Morgan: I just want to make one brief comment at this 
stage, on the fog surrounding decision-making at the Wellcome Trust with 
respect to genomics and funding this particular workshop. I don’t think there 
was anybody, or very few people, on the Board of Trustees then, apart from 
David Weatherall, who really had any idea what this was all about, and the fact 
that Walter actually squeezed, I remember, a quite significant sum of money ...200
Bodmer: £250,000. [Laughter]
Morgan: [laughs] Not bad, Walter. That’s all for the moment.
Harper: Okay, while we’re still on the subject of computing and linkage analysis. 
Bert?
200  For Professor Sir David Weatherall, see note 151. 
Figure 16: Professor Michael Morgan
Human Gene Mapping Workshops c.1973–c.1991
64
Bakker: Around 1988, when all this computing business was a problem, there 
was a group of people who started to work on a project and on a grant from 
the EU, and Sue Povey was involved in that with a lot of people. Nigel Spurr 
was the guy who started that project, EUROGEM (European Gene Mapping 
Project).201 Because there was the plan to make a 5 centimorgan-spaced map 
of all human chromosomes, they asked for funding from the European Union 
(EU) and in 1991 this project started and they got money from the EU to 
buy huge UNIX machines, actually ULTRIX it was, a type of UNIX, so that 
every centre could do their own linkage map for chromosomes.202 There were 
different groups involved and after a few years there was this paper with maps, 
5 centimorgan maps of all chromosomes.203 The same project went on and on 
and made meiotic breakpoint maps.204 The basis for this all was the CEPH 
(Centre d’Étude du Polymorphisme Humain) families on one side and the 
Utah families, of course, and on the other side the markers from the States and 
from Dausset and Weissenbach that were all put in these.205 And that was the 
basis for the sequencing project later.
Bodmer: Could I just add one thing to that because, although it was a little 
later, I think perhaps around about that time, Nigel Spurr was asked by me to 
set up a probe bank.206 The whole aim of the probe bank was to make nationally-
available probes that could be used for these mapping purposes, and I think 
that may have fed into the European project that you’re talking about. Nigel, 
in case people don’t remember him, sadly died a year or two back. He did his 
201  In 1988 and 1989, at the time of HGM9.5/10, Dr Nigel Spurr was based at the ICRF’s Clare Hall 
laboratories in Hertfordshire, England. See also Professor Sir Walter Bodmer’s comments on page 82. For 
EUROGEM, see Spurr et al. (1994). Ferguson-Smith (1991) describes the then forthcoming EUROGEM 
project as ‘consisting of two resource centers and a network of research laboratories from member states. 
These laboratories will undertake genetic mapping studies and contribute to a central database’, quoted 
from page 64. 
202  For UNIX, the IBM software programme, see, for example, Kernigham and Morgan (1982). 
203  Spurr et al. (1994). 
204  Cox et al. (1996). 
205  The Centre d’Étude du Polymorphisme Humain (since 1993 the Fondation Jean Dausset-CEPH) 
was founded in 1984 by Professor Jean Dausset (1916–2009), an immunohaematologist and a Nobel 
Laureate in 1980; http://www.cephb.fr/en/presentation_historique.php (visited 19 November 2014). See 
also pages 81–2. 
206  The ICRF-funded probe bank was tied to the launch of the UK’s Human Genome Project in 1989. See, 
for example, Ferguson-Smith (1991), page 62, and Alwen (1990).
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PhD with me and then got involved in a lot of the mapping work that was 
done at the ICRF; he was extremely productive. Then he went to Leeds for a 
while, I can’t quite remember when that was, but we sent him up and that was 
the first involvement really of the Medical Research Council in a serious way in 
supporting the whole mapping enterprise because we felt that making available 
those probes in an appropriate way was a key step towards getting good maps.
Bishop: Nigel came to Leeds in 1997, and then subsequently he moved to the 
pharmaceutical industry.
Ferguson-Smith: I just want to add that the EUROGEM was set up by the 
Human Genome Advisory Group of the EU Commission in which they took 
advantage of the probe resource centre that Nigel Spurr and Walter were involved 
in. And the other branch, of course, as you’ve just mentioned, was CEPH and 
their idea was that Nigel Spurr’s group would supply these probes to a series of 
22 collaborating centres. It was originally 23 in Europe to do Southern blots on 
filters produced by CEPH from 69 different families.
Bakker: We started this with Southern blots, yes.
Ferguson-Smith: This was the European project, which was built up to counter 
what was happening in North America. It was really established to provide an 
independent European initiative on the Human Genome Project that would 
work in collaboration with the USA on human genome research. It was thought 
that all the development and potential intellectual property shouldn’t be left to 
the United States.
Bakker: Well, it’s very good because each of these laboratories had their own 
chromosome and they were really responsible for that to make the map.
Ferguson-Smith: That’s correct, and they were also funded. Each of these labs 
was given a technician, funds to support their work, and computing equipment. 
Again, Bronwen Loder at the EU was involved in this and I happened to be 
responsible for her and for looking after the coordination. Out of that grew the 
Single Chromosome Workshops, something which I rather regret we don’t have 
time to talk about.
Harper: Well, we will have time, Malcolm, if we move on to other things.
Povey: Just on the EUROGEM, John Attwood in our group was very helpful 
on the computing for that.207 For example, he noticed that when you submitted 
207  See Povey et al. (1994) and note 201.
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results to the CEPH, it knocked out the results of the previous submission 
[laughter], and we had to ring the people in Paris and they said, ‘Oh we hear 
you’re having trouble with this’, and John explained and then immediately an 
email came to everybody saying, ‘Stop doing it, there’s a terrible bug in the 
system!’ But it was a good collaboration, a very good collaboration. It really 
spread the technology, and it spread the collaboration, which lasted a long time.
Bodmer: Just a very quick comment on the background to the European setting. 
The obvious centre that should have done a lot of the European coordination 
would have been the EMBO lab in Heidelberg. I remember at that time Hans 
Lehrach was there. The person who was in charge of the EMBO lab, Lennart 
Phillipson, had absolutely no interest in it. I knew Lennart well, and I liked 
him. I think it was actually a major mistake because if, in fact, he had taken it 
on and said, ‘Look, we will act as a coordinator to have a really decent genome 
project in Europe’, that would have been very hard to turn down. It was a 
mistake in my view. That’s why Hans Lehrach came to the ICRF and stayed 
there for a few years doing these things.208
Harper: I’m going to suggest we move on slightly now, and next on the 
programme we’ve got a rather different, but I think no less important, topic, 
which is nomenclature. This comes back to you again, Sue. Maybe you could 
tell us a bit about the background and progress, and your involvement?
Povey: Well, my involvement was really much later.
Harper: Okay, tell us about the early stage.
Povey: I hear now that even in that first conference there was some discussion 
of terminology. Indeed, in the second one, I think Harry Harris offered to draft 
some guidelines.209 They set up a committee to have a meeting between the main 
meetings in order to produce guidelines for a nomenclature of genes and alleles 
and of proteins and loci. And this was produced, and something I remember 
myself but I can’t remember exactly whether it was HGM3 or HGM4, but 
there was a presentation by Eloise (Giblett) where she produced the work of 
this group and established the principles really on which the naming of genes is 
still based.210 Somebody criticized something, and that there was some criticism 
208  See, for example, Francis et al. (1994). 
209  Professor Harry Harris was a member of the Committee on Nomenclature at HGM3, which recorded 
that he would prepare nomenclature guidelines for human genetic markers; see Giblett (1975). 
210  See Giblett (1976), page 65.
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is so characteristic of nomenclature, it’s always so controversial and people get 
so het up about it. Their gene is like their baby and everyone always agrees that 
one gene should only have one name but they are sure it should be theirs. In the 
end tears came into Eloise’s eyes on the stage, I remember, and she said, ‘Well, 
we thought we’d done something, perhaps we hadn’t done anything at all.’ The 
sight of her being about to cry made the whole conference vote unanimously 
to accept it. 
Harper: It was the third workshop, Sue, in Baltimore, and she was also deputed 
to be in charge of terminology at the second. In the first workshop, perhaps 
surprisingly, it was Victor McKusick and Jean Frézal but it moved on from that 
and then on to Phyllis McAlpine.211
Povey: So anyway, that was interesting as a successful strategy. Also, in the 
naming of the genes, and, of course, one of the principles that was held to was: 
‘if there’s a community out there with particular genes and they’ve already been 
named, we don’t interfere with that.’ So there was a specific statement that 
they wouldn’t interfere with the HLA genes, and they wouldn’t interfere with 
the blood group genes, they would concentrate at the moment on enzymes 
because that seemed to be the thing that most needed doing at the time. And 
the committee wanted people to have italics for the gene and non-italics for 
the protein. Because they were dealing with enzymes, they wanted the short 
form of the name, then called the symbol, to be not more than four letters, 
and to have some relationship to the name of the enzyme but not necessarily 
the EC (Enzyme Commission) name. And they would allow some flexibility 
in things that had already been named. Most of that has continued, although, 
of course, it became increasingly difficult to have the function and it became 
impossible to have only four letters in the symbol. Then, after that, Tom Shows, 
I think, really took over, after Elo (Eloise Giblett) and that group of people. It 
gradually moved to being Shows and McAlpine, and then it became McAlpine 
and Shows.212 And at every meeting I think there was a room where you had to 
go and you couldn’t go any further until you’d got the right name. [Laughter] 
You have to be quite fierce doing nomenclature.
Bodmer: I’d been involved in the HLA nomenclature for years, and the 
principles by which one had HLA nomenclature we felt were quite sound. As I 
recall, actually, a lot of those principles, not so much what the blood groupers 
211  McKusick and Frézal (1974). For Phyllis McAlpine, see Cox, Povey and Show (1999). 
212  See, for example, Shows and McAlpine (1982) and McAlpine et al. (1991). 
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did, were then incorporated into what eventually transpired. Of course, HLA 
nomenclature dealt particularly with a set of related genes and with the problem 
of how to deal with polymorphisms, but I think that the HGM nomenclature 
group which eventually evolved has done an extremely valuable job. It’s 
absolutely essential to have a common language. Even as a mathematician, one 
of the most important things is nomenclature – it’s actually the notation that 
you use. Without that, you get into a real mess. So the nomenclature committee 
turned out to be extremely valuable.
Malcolm: I also remember, Tom Shows or Phyllis McAlpine would sit towards 
the front, and it was like the Commission for the Doctrine of the Faith [laughter], 
and they would give their approval, they would give a nod, an imprimatur.
Povey: Naming genes is a really good way of making enemies. [Laughter] I’m 
sure Phyllis had some, and I think she worked herself into the ground. One of 
the things she said to me was that you have to have good people. If you have 
anyone helping you, it has to be someone with a PhD, and that was absolutely 
right, but, mostly, Phyllis actually made the decisions herself. We just discovered 
that the person has to have a PhD or else they are not capable of arguing with 
these people who quite reasonably say, ‘I’ve worked on this thing for 20 years 
and you only heard of it 15 minutes ago, how can you possibly tell me what to 
call it?’ My staff had to go on courses on how to deal with aggressive telephone 
calls when I got involved in nomenclature. But this is all years later, because we’re 
speaking of the years long before I took over, because Phyllis was 1990 to 1996 – 
I’d been helping her for a bit but she was very much in charge. She was definitely 
the last person who knew the name of every known human gene. And in those 
days we didn’t argue so much about what is a gene. I see there’s no argument 
about what a gene is in these workshops. I think that’s got more complex.
There’s obviously lots of other nomenclature, DNA nomenclature, all sorts of 
things but I only know about genes. The other thing we did, we never claimed, 
and Phyllis never claimed domination over proteins because you can sometimes 
get away with, really people that hate you as long as they’re allowed to call the 
protein what they like. [Laughter]
van Heyningen: There were also always problems about bringing genes over 
from other species, and there were discussions about whether it was ethical to 
call a gene ‘lunatic fringe’ if somebody then had a child with a disease who had a 
mutation. I found it quite difficult to make my colleagues understand that they 
couldn’t use hyphens and that they had to use the right format.
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Harper: Maybe that’s a good point to go on to comparative mapping. I think, 
Malcolm, you could say a bit about this, it’s something that shouldn’t be left 
out.
Ferguson-Smith: I’m just trying to remember when comparative mapping was 
first discussed at the workshops.213 I remember that Jenny Graves was involved 
with gene mapping in marsupials in 1985,214 and John Edwards too because 
he introduced his Oxford grid at the workshops, which was an important 
contribution to comparative maps between mouse and man.215 The important 
outcome was the realization after a while that genomes were highly conserved. 
I don’t remember really too much about the discussions at the workshops on 
comparative genomics because I was always at another session.
Harper: The first time comparative mapping had a committee, according to 
my notes, was the Los Angeles, 1983 meeting, where it’s down with Roderick, 
which would be Tom Roderick, as the chair.216
Ferguson-Smith: Yes, this was mostly mouse and human, I guess.
Harper: Then it appeared again at the Helsinki meeting in 1985, and indeed 
again at the Paris meeting.217 I think it stayed in after that.
Ferguson-Smith: Yes, it did.
Harper: Tell us a bit about it anyway.
Ferguson-Smith: Well, basically it was really looking at linkage groups between 
the different species and mouse and human figured prominently in this. I can’t 
think of other species that were as important. Bert, can you think of any?
213  Professor Malcolm Ferguson-Smith wrote: ‘Comparative mapping was first reported at Baltimore in 
1975 when several genes were localized to corresponding chromosomes in human, mouse, and several 
primates. Over the next ten years the chromosomal location of an increasing number of linkage groups were 
mapped between human and various primates, mouse, rat, Chinese hamster, cat, dog, rabbit, cattle, sheep, 
pig, etc.’ Note on draft transcript, 3 June 2014. 
214  Dobrovic and Graves (1985). 
215  Buckle et al. (1984). For a review of the ‘Oxford grid’, see Edwards (1991). For John Edwards, see also 
note 55. 
216  Roderick, Lalley and Davisson (1984). 
217  See Lalley and McKusick (1985). 
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Bakker: Also for some of the great apes, yes, the primates were also put next to 
it and there was a kind of map with linkage groups, what is conserved and what 
not.218
Ferguson-Smith: Yes, and I can recall that Jean de Grouchy had some early 
comparative gene maps between human and rabbit, and there were others that 
I can’t remember.219 Of course, chromosome painting did not appear until the 
1990s, and widespread homology maps until 1994. 220
Bakker: Yes, later, much later.
Ferguson-Smith: Much, much later. So that’s really when my lab became 
involved.
Harper: Can I ask, were the Harwell people directly involved with the workshops 
or was it via John Edwards mainly that they were represented?221 Were people like 
Mary Lyon and Tony Searle involved directly in the Gene Mapping Workshops?
Craig: Not that I can recall. I think John used to go over to Harwell; there 
were regular visits every month or so. He was the ambassador, basically, and the 
enthusiast, and the driving force of it, and it actually turned out to be extremely 
useful and informative, the ‘Oxford grid’.222
Povey: I meant to say on nomenclature, that now, and, in effect, for a long 
time, the human and mouse names for genes have been almost identical. And, 
indeed, there’s a sort of vertebrate genome now and mostly it’s the same names 
following the human ones. But I notice that the very first time it was mentioned 
at a Human Gene Mapping Workshop was in Winnipeg, it was clear that what 
we called PGM1 was in the mouse called PGM-2,223 and when I looked it up 
yesterday, I see mouse people are still calling it Pgm2. They’ve not given in yet.
Ferguson-Smith: But the mouse use lower case?
218  Professor Bert Bakker wrote: ‘In our group, the lab of Peter Pearson, Jim Garver and Anna Estop worked 
on this topic.’ Note on draft transcript, 22 August 2014. See, for example, Estop et al. (1983). 
219  Soulie and de Grouchy (1982).
220  For chromosome painting, see Cremer et al. (1988). Professor Malcolm Ferguson-Smith wrote, 
‘Homology maps produced by cross-species chromosome painting first appeared in the 1990s. Notable 
publications were: Scherthan et al. (1994) and Yang et al. (1995)’ Note on draft transcript, 3 June 2014.  
221  Harwell Medical Research Council laboratories, Oxfordshire, UK. 
222  See note 215. 
223  Pearson and Roderick (1978), page 158. 
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Povey: Well, yes, but I mean it is not the equivalent gene. The PGM1s are not 
the equivalent genes in the human and the mouse. They’re still not right to 
this day because neither side would give in, because they were both looking at 
phosphoglucomutase, and both of them found a common polymorphism but, 
actually, there are many protein bands in PGM1 and PGM2, and the ones that 
are actually orthologous are not the ones that were expected. I was interested 
that my successors in the HUGO Human Gene Nomenclature Committee had 
not managed to solve that one.
Harper: Perhaps now we should come to the final London meeting, and the 
transition and evolution into the single chromosome meetings, and then the 
links across with the Human Genome Project. So I don’t know who wants to 
start? Perhaps Ellen – I think I’m right in saying that you had a lot of hard work 
at the London meeting, didn’t you?
Solomon: Yes, I would say. I think we’ve covered it to a large extent. I agree 
with Walter: fraught with politics, fraught with technical difficulties. Chris will 
remember, we had to hire and call in an IT team to get involved in the wiring 
and the networking of the Connaught Rooms, who also benefitted from this. It 
was huge, and, you know, the workshop was massively successful but ‘not to be 
repeated’, I think, would be the message from it.
Povey: I think the computing, from the Committee-chair point of view, the 
computing was absolutely perfect; it never went down at all.
Solomon: Yes, but unless we were going to buy the Connaught Rooms, it wasn’t 
going to be there again, and, in retrospect, and nowadays, you would have a 
dedicated place where you could run a meeting like that, and we now do, but at 
that time we had to move into some sort of other mechanism.
Bodmer: First of all, I think what has been the successor in the practice of 
HGM11 are the HUGO meetings, which we’re not going to get into. In a 
way, my impression is that to some extent they have components that are 
different, they’re just straight scientific meetings. We did have a component, 
of certain plenary lectures, and, certainly, I remember that I asked Mary 
Warnock to give a lecture on bioethical aspects, so that there was a mixture of 
the workshop component and an element of scientific meeting.224 During the 
224  Baroness Warnock (b. 1924) is a philosopher who particularly influenced UK public policy on 
reproductive medicine through her report on human fertilization and embryology; see Warnock (1985). 
Wilson (2011) examines her role in the emergence of the field of bioethics in the 1980s. 
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time of the NIH meeting in July 1986 Craig Venter came up with his business 
of sequencing, I forget what it was called, the bits of cDNA (complementary 
DNA). It was a huge controversy.225 It was actually an idea that Sydney Brenner 
had put forward and Sydney Brenner was with us there,226 and he was incensed 
at that and we had quite a lot of discussions about that area, which started 
off the whole debate really of what are the rights and wrongs of trying to 
patent DNA sequences. That was a precursor of Craig Venter’s ostensibly 
independent venture to sequence the human genome, which to my mind never 
really was independent because he depended on all the mapping information 
that had been produced by others. That was actually a significant feature of 
that workshop, the discussion at that time.227 Maybe others have a memory of 
what went on as well?
van Heyningen: Was there a meeting, was it organized by the MRC? Because 
I remember going there and that’s where I remember hearing Sydney Brenner 
saying, ‘Why don’t we just sequence the coding bits of the DNA?’ Do you 
remember that? It was at the London Zoo.
Ferguson-Smith: This became MRC policy at an early stage in the UK Human 
Genome Project, is that right?
Bodmer: I think Sydney Brenner would have emphasized sequencing cDNAs, 
which, in a way, is what would now be called, more-or-less, exome sequencing. 
He, rightly, at the time – given the technology – focused on the value that 
would come from sequencing cDNAs. I don’t think he thought of that as an 
alternative to eventually doing the whole sequence. I remember a meeting at 
the NIH, which I think was some time in the late autumn of 1986,228 the whole 
question of how to do it, whether just to sequence it all, whether to do maps, 
whether to throw it into a big pot and not worry about where things were, all 
225  Craig Venter is well known for his role in the creation of synthetic DNA, or cDNA, ‘expressed sequence 
tags’: Adams et al. (1991). For the controversy over applications to patent these gene fragments, see, 
for example, Eisenberg (1992), and for the gene patenting and a subsequent biotechnology controversy 
involving ‘expressed sequence tags’, see Crowther (1999), pages 118–20. See also Venter (2013), pages 
83–95. 
226  At HGM10.5, Sydney Brenner was a representative of the Medical Research Council’s Molecular 
Genetics Unit; see participants’ list in Craig and Rawlings (eds) (1990). 
227  Brenner (1990).
228  See Cook-Deegan (1991). 
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these questions came up, and all the people who were later important in the 
major sequencing technologies each had their little bit of say, including Wally 
Gilbert.229
Solomon: I’d like to add an anecdote about HGM11. A plenary speaker pulled 
out with a day’s notice and I rang Richard Dawkins and asked would he consider 
stepping into a plenary talk at this meeting, and he said, ‘Ellen, are you kidding? 
Me, speaking to a conference full of geneticists? Never!’230 [Laughter]
Bodmer: Talking about Richard Dawkins, it was Glenys Thomson and I who 
actually taught him a little bit about linkage disequilibrium, which he even 
acknowledged in the preface to his first book.231
Craig: Just since we’re on anecdotes about HGM11, I can remember in the final 
sessions, I was chairing, and the news came through that Gorbachev had just 
been released by Yeltsin.232 It was quite an important announcement and highly 
significant news at the time.
Povey: It reduced the press coverage of the meeting.
Bodmer: You might remember the foundation of HUGO was actually in 1988 
and one shouldn’t forget the importance of HUGO in this whole story. Victor 
McKusick was the first President and I was the second, and that was basically 
why we offered, in a sense, to have that meeting in London. We were seeking 
representatives of the genome community in different parts of the country 
and people may remember the name Mirzabekov – he was actually a notable 
molecular biologist in Russia, in Moscow, who had very early ideas on the 
sorts of things that are done now.233 If I recall, he actually came to the London 
229  Walter Gilbert (b. 1932) was a Nobel Laureate in Chemistry in 1980 for his role in the development 
of DNA sequencing; http://www.nobelprize.org/nobel_prizes/chemistry/laureates/1980/gilbert-facts.html 
(visited 20 November 2014). See Gilbert (1987).
230  Richard Dawkins is an author, philosopher, and zoologist, renowned for discussing atheism as a popular 
philosopher and author in, for example, The God Delusion, Dawkins (2006); see also the author’s website at 
https://richarddawkins.net/richarddawkins/ (visited 20 November 2014). 
231  Dawkins (1989), see ‘Preface to 1976 edition’, page vii. 
232  In 1991, during an attempted coup, Mikhail Gorbachev, the head of the Soviet Union, was placed under 
house arrest at his holiday home in Crimea for three days, and was released on 22 August 1991. See, for 
example, Dejevsky and Clark (1991). 
233  Andrey Mirzabekov (1937–2003); see the Azerbaijan National Academy of Science’s website, http://
science.gov.az/forms/pochetnyie-chlenyi/160 (visited 5 January 2015). 
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meeting – I think he came to the London meeting.234 I certainly remember 
contacting him and saying, ‘How is everything with all the turmoil there?’ 
He said, ‘Oh it’s alright, there’ll be no problem.’ It was very soon after that 
that I went to, I think, a meeting in Russia at that time, and actually saw the 
White House from where Yeltsin had said his success had been. I think this 
international aspect was very important. I’m trying to remember the name of 
a very good Japanese molecular biologist from Kyoto University. I think it was 
Matsubara, he was one of the early Vice Presidents of HUGO.235 Yes, he was a 
very important figure because dealing with the Japanese was a delicate matter. 
You couldn’t tell them what to do, there had to be a consensus and Matsubara 
was actually extremely helpful in getting the Japanese to be involved and 
behind the Genome Project.
Morgan: There is a famous letter from Jim Watson to Matsubara.
Bodmer: I wouldn’t know, but if you look in the Jim Watson archive you might 
find it I suppose. What would it have said?
Morgan: It would have said something along the lines, ‘It’s about time that the 
Japanese put some money into human genome sequencing and join the Human 
Genome Project.’ 236
Bodmer: That probably would have been after, later. When did Jim Watson 
become head of the genome research project at NIH?237
Morgan: 1988.
Bodmer: Oh was it that early?
Harper: Before we leave the London meeting and go on to the specific 
chromosome meetings, can someone give an idea, at least for me, on the 
timescale: how did this link, around 1991, across with the French Généthon 
and the whole genome map? Had that started at all at that stage, or was it a 
234  Andrey Mirzabekov is not listed in the participants for Human Gene Mapping 11. 
235  Kenichi Matsubara was a member of the Founding Council of HUGO, 7 September 1988, and was 
elected an officer, see http://www.hugo-international.org/abt_history.php (visited 6 February 2015). 
236  See ‘Letter from James D. Watson to Kenichi Matsubara’, 12 July 1989, available in The Victor 
A. McKusick Papers, US National Library of Medicine, at http://profiles.nlm.nih.gov/ps/retrieve/
ResourceMetadata/JQBBKQ (visited 6 February 2015). 
237  For a biography of Dr James Watson, see the Cold Spring Harbor Laboratory website; http://www.cshl.
edu/Faculty/james-d-watson.html (visited 27 January 2015). 
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few years later?238 I’m trying to get a picture as to the state of mapping of the 
different chromosomes overall at this meeting, which was the last time before the 
Genome Project when they were all considered together at the same meeting.239
Malcolm: It’s only a partial answer to your question but at the London meeting 
the yeast artificial chromosomes (YACs) were the flavour of the month, and so 
on, and I remember somebody, and I’m pretty sure it was David Ledbetter, and 
I think it was chromosome 17 ... 240
Bodmer: In 1990, in my introduction to HGM10.5, in Oxford, I said that 
the development of molecular techniques should lead to a complete union of 
the aims of the Human Gene Mapping Workshops and the Genome Project.241 
That was the aim, and the thought was that, actually, the two would merge 
and that HUGO as an organization would somehow oversee in a cooperative 
manner what would happen with the Genome Project. And, of course, that 
never happened. It was too political, too much money was involved, and the 
scientists themselves were not allowed to keep control of it.242
Harper: Walter, tell us a bit more then about this transition. I mean the London 
HGM meeting was the last of the old style but it had already in a sense begun 
to change. How did the change happen?
Bodmer: As I just mentioned, someone may remember: when did the Wellcome 
Trust start getting involved, maybe Michael knows, in the Genome Project?
Morgan: How long have you got? [Laughter]
Bodmer: No, just give me a date.
238  See, for example, Weissenbach et al. (1992). 
239  At HGM11, in 1991, there were separate committees for each of the autosomes, and for the X and 
Y chromosomes. See Solomon and Rawlings (eds) (1991), pages vi–vii. The introduction stated that: ‘At 
HGM11, as well as at subsequent other meetings and discussions, it was agreed that the Human Gene 
Mapping Workshop community should work together with those involved in physical mapping, under the 
overall umbrella of the Human Genome Organisation, HUGO. In future, communication and discussion 
of chromosome-specific data will be organized through the Single Chromosome Workshops’; Solomon and 
Bodmer (1991).
240  Solomon and Ledbetter (1991). 
241  Bodmer (1990b). 
242  For a personal account of working on the Human Genome Project, see Sulston and Ferry (2002). See 
also Cookson (1994) for the politics of gene mapping, and conflicts between academic and commercial 
interests prior to the HGP, pages 31–45. 
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Morgan: Basically, it was following a conversation between David Weatherall 
and myself …
Bodmer: When?
Morgan: Well, I’m trying to give you a meeting and then you’re going to give 
me a date.
Harper: Take the microphone away from Walter and give it to Michael. 
[Laughter]
Morgan: International Congress of Human Genetics, Philadelphia or 
Washington, 1991?
Bodmer: It was in Washington in 1991.
Morgan: Yes, thereafter we set up the Genetics Interest Group.243
Bodmer: Well, let me just comment because that date is important, right, 
because that date reflects the time when a big bang first came into doing a lot 
of sequencing and when the project was lost from the hands of the involved 
community of the mappers, and that was the transition really from what the 
Gene Mapping Workshops were, to the Genome Project as such. So it was 
taken, in a way, out of the hands of the people who might have thought that 
they should be the ones to deal with this. And it was for a mixture of political, if 
you will, and financial reasons, and then it involved the Wellcome Trust and the 
NIH and it all became grand politics. That was what changed it. The difference 
was going from the bottom up, and then the top down.
Morgan: I couldn’t disagree more. In fact, Watson was appointed as Director of 
the Center for Human Genome Research at NIH in 1988 and resigned in 1992 
because of the EST (expressed sequence tags) fuss and the Director of the NIH 
wanting to patent ESTs.244 He certainly didn’t get on with a lot of people.
Bodmer: I don’t think that was his fault.
Morgan: I’m not suggesting it was. [Laughter] He funded, with the Medical 
Research Council in the UK, a major mapping project on the nematode, 
which in many respects was the precursor of the technology for sequencing 
243  Professor Michael Morgan wrote: ‘The GIG I was referring to is (was) an internal Wellcome Trust 
Advisory Body, not the lobbying group (external).’ Note on draft transcript, 5 February 2015. For the 
lobbying group, see http://www.geneticalliance.org.uk/history.htm (visited 25 November 2014). 
244  See Professor Sir Walter Bodmer’s comments on pages 71–2. 
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the human genome.245 And Watson approached the MRC at Christmas 1991 
because a Mr Bourke, who was an entrepreneur in the States, wanted to set up 
a private process to sequence the human genome and he was recruiting Bob 
Waterston and John Sulston who, at that stage, knew more about large-scale 
sequencing than anybody else.246 And he came and spoke with Dai Rees, the 
secretary of the Medical Research Council, Aaron Klug, who was the director of 
LMB (Laboratory of Molecular Biology) at that time, and eventually to Bridget 
Ogilvie, the Director of the Wellcome Trust, about the possibility of raising 
enough cash to keep John Sulston in the UK.247 I could go on for a lot longer 
but I’ll pause there. That’s how the Wellcome Trust got seriously involved. So 
in 1992, we invited John to make an approach for funding and by the end of 
1992 we were able to open the initial format of the Sanger Centre at Hinxton.248
Bodmer: That is top down.
Morgan: It was John Sulston and Bob Waterston.
Bodmer: Top down still involves scientists but it doesn’t involve a community. 
I’m not criticizing it, I think it was inevitable that it went that way, but it was 
a differently natured thing, it went through a smaller number of people, strong 
advocates that were needed, very strong influence from the funding agencies, 
without which nothing could be done. I think it was probably inevitable that it 
went that way. My comment wasn’t meant to be a criticism, it was a statement 
of fact of how things change and probably had to change.
Morgan: The way in which the Human Genome Project was run was a direct 
result of three bottom-up meetings held in Bermuda, where representatives of 
the scientific community got together and worked out the rules of the game. 
245  See, for example, Waterston, Sulston and Coulson (1997). 
246  From 1993 to 2003, Robert Waterston was Director of Washington University’s Genome Sequencing 
Centre, and Professor/Chairman of the Department of Genetics; see http://depts.washington.edu/givemed/
prof-chair/holders/robert-waterston/ (visited 6 January 2015). Waterston and John Sulston collaborated 
on the sequencing of the nematode genome and the human genome. Sulston was the Founding Director 
of the Wellcome Trust Sanger Institute, Hinxton, Cambridge (UK), leading the organization until 2000. 
An overview of his work at the Institute is available at http://www.sanger.ac.uk/about/people/biographies/
jsulston.html (visited 6 January 2015). Professor Sir John Sulston became a Nobel Laureate in 2002. 
247  ‘Cash’ refers to infrastructural support and personnel, not solely the cost of a salary. Correspondence 
with Professor Michael Morgan, 5 February 2015. 
248  For more on the history of the Wellcome Trust Sanger Institute’s foundation in Hinxton, Cambridge, in 
1992, see https://www.sanger.ac.uk/about/history/history.html (visited 26 November 2014). 
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That was definitely bottom up, not top down, which is what I’m talking about. 
It’s true that a lot of money was thrown at it by the NIH, the DOE and the 
Wellcome, and others, but the drivers were the main scientists who were 
involved.
Bodmer: That meant that the ‘top’ listened to good advice. [Laughter]
Harper: Right, I’m going to ask that we switch now to the Single Chromosome 
Workshops because that was also a transition of a sort. So how did that transition 
occur? And I think, Ian, am I not right that the X Chromosome Workshop was 
at least either the first, or one of the very first Single Chromosome Workshops, 
and how did that take on from the previous HGM meetings?
Craig: I wasn’t at the first X Chromosome Workshop.
Harper: You weren’t?
Craig: It was in Houston the year before the London meeting.249 I, with Kay 
Davies, organized the second X chromosome meeting but really that followed 
on, essentially, from the first.250 I’ve got a couple of comments, talking about 
the first X chromosome meeting in terms of developments, but the relationship 
to the normal HGM meetings is basically the team who looked after the X 
chromosome at the workshops ran the single chromosome meetings, including 
Caskey, Ballabio, people like that.
Harper: Yes, what year was that, may I ask?
Craig: 1989. Oh, hang on, yes, the first X chromosome meeting was 1989, 
December 14 to 16. And the Second X Chromosome Workshop was January 
1991; that was also before HGM11 as it turns out. But, certainly, by the time 
of the Second X Chromosome Workshop, we were talking about liaising with 
the GDB data and that was a complete mesh with what had already been 
established and information was transacted between the two.251 The Houston 
meeting was organized by David Nelson, Andrea Ballabio, and Tom Caskey.252 I 
think it was there that the first talk on sequencing came into the workshops.253 
249  Cook-Deegan et al. (1990). 
250  Davies and Craig (1991). 
251  For GDB, see page 50. 
252  Baylor College of Medicine, Houston, Texas. 
253  Cook-Deegan et al. (1990), page 652. 
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Tom Caskey was presenting about the experience of sequencing around the 
HPRT using the first commercially available machines, the LKB/Pharmacia 
machine. And, we’ve heard the name before, Craig Venter was there describing 
his bold plan to sequence the Xq terminal region in three years at an estimated 
cost of $3.5 per base, which is kind of interesting in retrospect.254 The new 
machines on the market were allowing this to be done by labs, generally, which 
had sufficient money to invest: Applied Biosystems, ABI370, and the LKB/
Pharmacia machines particularly.255 At the Oxford meeting, I remember we were 
talking about how the chromosomes should be divided up. Essentially, we had 
four subgroups dividing the chromosome into four pieces and so there were 
really four Single Chromosome Workshops within the Second X Chromosome 
Workshop. It set up a kind of networking system for YAC libraries and such 
like and for somatic cell hybrids with translocations.256 It was really interactive 
with the workshops. I don’t think there was a sudden, ‘let’s go separately’. Both 
of these happened before HGM11, and so what was done in the early single 
chromosome meetings went into HGM11.
Ferguson-Smith: In 1990, the European Union supported the idea of Single 
Chromosome Workshops. Then, because the first were successful, I think the 
advisory committee of the Human Genome Analysis Programme in the EU 
contracted the organization of Single Chromosome Workshops to HUGO, and 
that was to involve not only people in Europe but people further abroad, and 
they would provide basic funds for meetings, and also for travel to the meetings 
for those people who didn’t have a human genome project in their national 
programme. So the EU provided this core support and I think that’s how they 
took off. This was under the HUGO London coordination and the contract 
was made to HUGO London to organize them. That’s how Bronwen Loder 
254  See note 225. 
255  Professor Ian Craig confirmed that these machines were launched in 1987 and 1989, respectively. 
Note on draft transcript, 3 March 2015. Applied Biosystems was founded in 1981, gaining the rights to 
automated DNA sequencing in 1983; see http://www.lifetechnologies.com/uk/en/home/about-us/news-
gallery/company-fact-sheet/company-history.html (visited 6 January 2015). The Applied Biosystems 370A 
Prototye DNA Gene Sequencer, 1987, is exhibited at the Science Museum, and can also be viewed online 
at: http://www.sciencemuseum.org.uk/online_science/explore_our_collections/objects/index/smxg-61227 
(visited 4 March 2015). 
256  Davies and Craig (1991), page 843. 
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and I got involved. I think Bronwen initially was at the ICRF in 1990 and then 
she was funded later by the EU when she was based with me at Cambridge.257
Bodmer: She had been possibly still funded by the EU, and I think we employed 
her at the ICRF. There was always a problem with HUGO as to whether it 
could be an employment organization.
Ferguson-Smith: Ah, yes.
Bodmer: So I’m just guessing that, actually, what happened is that ICRF 
provided the employment framework for things that were funded for HUGO 
activities if you will.
Ferguson-Smith: Well, anyway, she was based in my department in Cambridge 
eventually.
Craig: Just a clarification: the funding for the first X Chromosome Workshop was 
from the NIH and US Department of Energy, and the second one was the MRC 
and also some money from NIH for travel and such like. Well, that’s what the 
published report of the meeting indicates. Peter Goodfellow is not here but he was 
at the first X Chromosome Workshop and I did make a note of one thing that he 
was reported to have said, which was that ‘the future mapping integration efforts 
hinge on the success of the new Genome DataBase at Johns Hopkins, and its 
technical objectives being met on time for HGM10.5 and 11’, which they were.258
Harper: Is anybody in a position to say anything about the whole genome map? 
We haven’t got anybody here from France but I feel that, in a lot of accounts, 
257  Professor Malcolm Ferguson-Smith wrote, ‘Bronwen Loder was seconded from the MRC around 1988 to 
assist with an ad hoc Working Party set up by the Coordinating Committee on Medical and Health Research 
of the European Commission. The Working Party was charged to formulate a European Programme of 
Research on the human genome entitled “Predictive Medicine”. After their first meeting it was changed to 
“Human Genome Analysis”. Funding of €15 million was approved by the European Parliament in 1990. This 
resulted in the European Human Genetic Mapping (EUROGEM) project, which ran from 1991 to 1993 
with an Advisory Committee (CAN-HUG) chaired for the first year by Peter Pearson and thereafter by me, 
with Bronwen’s assistance. Bronwen’s job was as an administrative assistant and much of her work involved 
the day-to-day organization of the Single Genome Workshops (SGWs), almost all of which she attended 
to monitor the arrangements (including funding aspects) and to advise on the CAN-HUG guidelines. The 
project was continued for the following five years under BIOMED 1 who contracted out the project to 
HUGO Outstation Cambridge via HUGO (London). Bronwen was based in the Cambridge University 
Department of Pathology that I was responsible for, funded by BIOMED 1. Bronwen’s involvement with the 
project lasted 10 years and she retired when it finished in 1998.’ Note on draft transcript, 8 February 2015. 
258  Cook-Deegan et al. (1990), pages 653–4. 
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their work gets, not left out but it gets slightly downplayed, and would anybody 
like to say something about the overall genome map as it evolved? I’m thinking 
of Généthon.259
Ferguson-Smith: That was funded wasn’t it by a television appeal initially and 
Jean Weissenbach, as I recall, was one of the key people in that. And Daniel 
Cohen perhaps?
Harper: Yes, indeed.
Bodmer: Wasn’t that to do with CEPH?
Ferguson-Smith: Oh yes, using CEPH families, absolutely.
Bodmer: So the whole basis, I mean do people know that CEPH is Centre 
d’Étude du Polymorphisme Humain, which was founded by Jean Dausset.260 
He used to run an art gallery and a woman who he knew very well who had 
an extremely valuable set of paintings auctioned them and it’s that money that 
actually set up CEPH and he had the idea of having this collaborative family 
study, which involved the Utah people as well. It was CEPH that provided a lot 
of the basic family data that led to conventional mapping using DNA markers to 
give you an actual map. I take it that’s what Généthon was largely about, was it?
Ferguson-Smith: Yes. Everybody was using the CEPH families, very much later 
too.
Povey: Really we need to remember the date of the Weissenbach map with the 
5,000 dinucleotide repeats. When were they available? I think it was 1994.
Bakker: There was a smaller one published in 1992, a smaller version.261
Povey: Yes, my impression was that it was really after the HGM meetings.
Bakker: Yes, so 1992 was a basic map with less markers, then in 1994 it was a 
Nature genetics paper with many markers, over 5,000 or so.262
259  ‘Généthon was founded in 1990 by the Association Française contre les Myopathies (AFM-Telethon) 
and the Centre d’Etude du Polymorphisme Humain (CEPH). Its mission was to develop the tools needed 
to understand genetically inherited disorders.’; quoted from the Généthon website, http://www.genethon.
fr/en/about-us/history/ (visited 5 March 2015).  
260  See note 205.
261  See note 238. 
262  Gyapay et al. (1994).
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Povey: So that was using CEPH for the same purpose but it was a different 
set of markers, which really hadn’t come in at the time we’re talking about, 
HGM11.
Bodmer: To what extent did that feed into the genome sequencing and making 
YAC maps that overlap and things like that?
Bakker: Yes, it did, because the Chromosome Workshops that ended up like 
the one in Palo Alto in Stanford University, led by Richard Myers, was the third 
workshop on chromosome 4 in 1993.263 There, they had the YACs mapped but 
on the YACs you had also the STR (short tandem repeat) markers mapped, so 
you knew what was there.
Bodmer: So you could align them up?
Bakker: Align the YAC maps and the cosmids. For chromosome 4, I had 31 A4 
pieces glued together for the long arm of chromosome 4, all the YACs, and the 
markers across. And it was based on the EUROGEM map.264
Bodmer: Were a lot of those markers actually assigned to their chromosome 
initially by somatic cell hybrids?
Bakker: No, these were all by linkage in the EUROGEM map. There were a few 
basic ones that were, of course, from the old data marker points.
Bodmer: But if you were using some of the marker probes that Nigel Spurr 
produced, a lot of those would have come from knowing where they were on 
the chromosome already.
Bakker: Those were the original probes, yes. And they were used as anchor 
points. They were a mixture of all things. Also, Utah markers were in there, and 
some older markers were relocated.
Bodmer: Of the somatic cell mapping, the YACs and the family data that created 
the statue on the basis of which then the public genome sequence was done.
Harper: I’d like now to pass things back to Michael Morgan in the first instance 
to look at, again, not just the transition between gene mapping and sequencing 
but also to ask the question: how much did the sequencing initiatives depend 
on the map, both physical and linkage? I’ve read different stories and in some 
263  Myers and van Ommen (1994). 
264  Bakker et al. (1994).
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the map hardly appears and the sequence seems to have been the beginning 
and the end of it.265 And there are others, it’s different. And it would be nice, 
particularly since Wellcome is undertaking a major history of the Human 
Genome Project in its historical documentation, it would be nice to hear first 
from Michael and then from others how the one either evolved into the other 
or what strength the links actually had.266 So Michael, if you’d like to say a bit 
about that.
Morgan: Before going on to the Human Genome Project, I wanted to speak 
of Généthon and Jean Weissenbach simply to say that there is an equivalent 
process going on in France in Généthon to set up an archive of the French 
history in genomics.267 As far as I’m concerned the maps were very important, 
physical maps and genetic maps, if for no other reason than wanting to tie the 
sequence into the appropriate material so to speak. So I think there was a lot 
of feed in and feed out. Obviously the clone maps were extremely important 
as the necessary tools for doing the sequencing. In terms of how did Wellcome 
get involved, as I say it was really as a result of the Medical Research Council 
not having sufficient resources to build up a major sequencing facility at LMB 
(Laboratory of Molecular Biology). I’m sure they had the foresight to see that 
that is what they wanted to do and they did have this model already of major 
collaboration with the NIH over mapping and eventually sequencing of the 
nematode.268
Well, the interesting thing from my perspective, as an administrator/manager, 
was the process by which the Wellcome Trust happened to be in a position to 
be involved, which was basically because a trustee of the Wellcome Trust had 
a father who allowed the Nuffield Foundation, he thought, to sink without a 
trace when the share price of Morris Motors disappeared and he was determined 
that that wouldn’t happen to Wellcome.269 So they’d engineered, they had to go 
to the High Court to do it, to get permission to sell off a chunk of Wellcome, 
265  Jordan (1993). 
266  Historical records for the Human Genome Project are deposited in the Wellcome Library, Archives and 
Manuscripts, reference PPSUL/B/2. 
267  See note 78. 
268  See notes 245–6.
269  Sir Roger Gibbs was the person in question, a trustee of the Wellcome Trust and Chairman of its Board 
of Governors from 1989 to 1999. His father was Sir Geoffrey Gibbs, a trustee and later Chairman of the 
Nuffield Foundation.
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the company. That gave them, for the first time, significant resources. And it 
was happenstance in a sense that the scene was set to enable them to come to 
a fairly rapid decision to spend the largest grant they’d ever made, £47 million, 
with a contribution from the MRC, in 1992. By early 1993 the first sequencing 
was going on at the Hinxton campus.270 John Sulston was a very persuasive, shall 
we say, advocate of large-scale human sequencing rather than the cDNA route 
that’s been talked about, as was Francis Collins, in particular, at the NIH.271 I 
remember John and I looking for ways and means to actually enable this very 
large enterprise to go ahead, and at the time John felt that all he needed was 
about 50,000 square feet to get the job done. Eventually, I mean I don’t know 
how big the genome campus at Hinxton now is, but it’s significantly larger, shall 
we say. I think the turning point for the Trust was, first of all, the setting up of 
the workshops that took place in Bermuda and set out the principles that as soon 
as two kilobases of human DNA sequence was accumulated it would be released 
immediately on the internet, the ‘no intellectual property’ position would be 
taken rather than a protective position to make sure that the data remained freely 
available. That’s had as much of an impact outside of genomics as probably the 
human genome has had within genomics. I take Walter’s point that this was 
not in a classic sense small laboratory science, there were a lot of participants to 
begin with, but it became clear that this was an instance where large scale did 
reduce costs. It was managed mainly by Francis Collins from the NIH; there 
were meetings every single week by telephone, so it was not micromanaged. It 
was driven by the scientists, it was driven by targets and of course at some stage 
Craig Venter came back on the scene but that’s another story.272
Bodmer: The Human Genome Project surely came from what the Human 
Gene Mapping Workshops and the HUGO community had done. That’s how 
they knew about it. So Bridget Ogilvie was still the Director of the Wellcome 
Trust at that time, at the time the main decision was made. Is that right?
Morgan: Yes, absolutely.
Bodmer: Yes, and, of course, we’re sitting in the Gibbs building and it was 
Roger Gibbs who you were talking about?
270  See note 246. 
271  Dr Francis Collins directed the National Human Genome Research Institute at the National Institutes 
for Health (NIH), USA, from 1993 to 2008. He has been the Director of the NIH since 2009; http://www.
hhs.gov/about/foa/opdivs/nih.html (visited 5 February 2015). 
272  See note 225.
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Morgan: No, it wasn’t actually, it was David Steel.
Bodmer: My understanding was it was Roger Gibbs who actually empowered 
the whole business of getting the money and doing the investment but I may 
have got that wrong.
Morgan: You may be right, Walter.
Bodmer: It’s a very important point because it’s the availability of that free 
money without government constraint that clearly made this possible and then 
probably forced the MRC to play some part in it because they had been quite 
reluctant to take any major initiative in this direction.
Morgan: What’s actually interesting, Walter, is that the decision to go ahead with 
Hinxton, not with Hinxton, with supporting a proposal for John (Sulston), was 
made before the share sale so it was a real trust, it was a real gamble. They must 
have known about it.
Bodmer: It sure was if they hadn’t got the money. [Laughter]
Morgan: They must have known about it but they didn’t have the money. They 
did by the time they made the decision but they didn’t have the money when 
they told John to put in a proposal.
Bodmer: The political climate was really quite difficult because at the time 
Sydney Brenner and I were talking a lot about it, and I wrote a letter to the 
then president of the Royal Society, George Porter, saying perhaps in order 
to get people together on this, because they were in a sense different factions, 
the Royal Society could play some sort of a coordinating role. And basically 
they wrote back and said, ‘We don’t do that sort of thing because we can’t get 
everybody to agree to it’, which I think was also a shame.273
Morgan: The other thing that is important are the other strands that eventually 
came together at Hinxton. The major one was Lennart Phillipson helping with 
the decision for the EMBL (European Molecular Biology Laboratory) to receive 
a proposal to house a European Bioinformatics Institute (EBI) other than 
alongside the EMBL. The UK got its act together, very quickly driven by the 
MRC, and put in a proposal that won the bid and the EBI came to Hinxton.
273  Some correspondence with Sir George Porter during this period is deposited in Professor Sir Walter 
Bodmer’s archives at the Bodleian Library, Oxford, reference MS. Bodmer. A.2.
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Bodmer: When was that? By that time he must have changed his tune about 
the Genome Project?
Morgan: Well, I think the main driver for that in the UK was Michael 
Ashburner, in 1992, and the decision was made in 1993, I think, and then the 
MRC decided to move the resource centre from Northwick Park to Hinxton.274
Dr Susan Wallace: I was the administrator for HUGO’s American office starting 
in 1993, so I apologize I’m a little late for your meeting time-wise but I just 
wanted to skip back to the link between the Single Chromosome Workshops 
and HUGO, and I believe there was a strong relationship and there’s a strong 
acknowledgement on the part of, certainly, members of the HUGO council 
that the Single Chromosome Workshops needed to be supported. I know for 
a fact, because I worked with Bronwen on the other side of the Atlantic on 
some of the Single Chromosome Workshops; she and I were in Cambridge at 
the chromosome 4 workshop I believe it was when there were difficulties and 
perhaps splinters between the group and talks about not sharing data, etc. We 
rang John Sulston up and said, ‘You’re on the Council of HUGO, John, go 
talk to these guys’. And he did. So I think there certainly was, over the years, 
274  Michael Ashburner FRS (b. 1942) was Professor of Biology at the University of Cambridge from 1991 
to 2009. 
Figure 17: Dr Susan Wallace
Human Gene Mapping Workshops c.1973–c.1991
87
strong support for the workshops and integration until such time as large-scale 
sequencing took off. That’s one memory I have of the connection between the 
two.
Bodmer: Who was the president of HUGO then, because I must have given up 
after 1991 I think?
Wallace: Yes, I think it was Tom Caskey by then. He was president when I came 
in.275
Rawlings: The only thing I can think that perhaps we haven’t given enough air 
time to is what was just briefly mentioned about the Human Gene Mapping 
Project Resource Centre the MRC had funded at Northwick Park, because that 
was also part of this transitional structure between the coordinated mapping 
internationally and the UK focus of that moving also to an EST and cDNA 
sequencing resource. And I also believe there was a linkage hotel activity as 
well, where again it was recognized that not everybody had the technical skills 
or weren’t sufficiently trained in the genetics to run the software needed so 
that the training component was there both in bioinformatics and in linkage 
analysis and then there was an opportunity to provide a sequence, a small 
DNA sequencing resource. If I remember, if you sent in your constructs they 
would do that sequencing and that was run partly by Martin Bishop and Tom 
Freeman for a while. I can’t remember who else was involved prior to that but 
that was quite important for a while, possibly for only three or four years before 
the whole, maybe for longer actually but obviously the whole Sanger Centre 
moving there and scaling up made a big difference to the basis for that centre. 
It closed at a time, I can’t remember when it finally closed its doors, probably 
late 1990s. Other people may know it better than I do; I just thought we hadn’t 
mentioned that enough perhaps.
Morgan: I wanted to pick up on something earlier: Walter made the comment 
about EMBL not really taking on a role early in this that could have been 
of great significance and you mentioned, Ian, about sequencing. It’s coming 
back to your point about the technology being very important. Now the 
LKB/Pharmacia machine, was that something that had been developed at 
EMBL and they commercialized it, or have I got the wrong machine?
Craig: I think they were, I’m not absolutely sure.
275  Professor Thomas Caskey was President of HUGO from 1993 to 1995; see http://hugo-international.
org/abt_hugopresidents.php (visited 20 January 2015). 
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Morgan: There were a lot of missed opportunities in Europe. The European 
Union never got involved in supporting large-scale sequencing.
Harper: Well I think we’ve given this topic a really thorough going-over actually, 
allowing for the folk who aren’t here and on the other side of the Atlantic, and I 
think it’s actually a pretty amazing story, how gene mapping has gone from very 
small, rather abstruse beginnings, and yet saying that it’s always had in mind the 
potential for important applications in prediction and other things. But how 
it’s developed and how really people have been able to see it in their lifetime 
start with the beginnings of the map and go on through to the sequence has 
been pretty amazing. I think people like myself who have been very peripherally 
involved have felt it a tremendous privilege to be even a very small part of 
the community. And it has been a community that has actually developed and 
survived despite a lot of stresses, perhaps from the inside as well as the outside. 
So I think it’s very important to document this as fully as possible. I do hope 
that Wellcome’s major initiative on the Genome Project doesn’t forget about 
the mapping phase. I’m sure it won’t, and I think, hopefully, those of us at this 
seminar will go back home and suddenly realise that we’ve got tucked away 
somewhere interesting photos, illustrative archival material, all of which, if you 
get in touch with Tilli’s team, can then be incorporated.
Tansey: Thank you very much, Peter. Well, thank you all very much for coming 
this afternoon. It’s been a privilege to listen to you all, and some very elucidating 
and entertaining stories. I’d like to pay a particular thank you to Peter, of course, 
for chairing this meeting so nicely as usual. He’s done so many of these and I 
think you now, with David Weatherall, hold the record, for the most Witness 
Seminars chaired. So particular thanks to Peter. [Applause]
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Appendix 1
Photographs of participants at HGM1, Yale; ‘New Haven Conference 1973: 
First International Workshop on Human Gene Mapping’276 
276  Reproduced from Ruddle et al. (eds) (1974a); pages 206–11.
Plate 1. 




P Meera Khan, P J McAlpine, J L Hamerton
F T Kao






K C Atwood, S Boyer
M Siniscalco
D Bootsma, E R Giblett, E H Y Chu
4th row
H J Evans, F H Allen Jr, M J Murnane, R S Kucherlapati
D Warburton, D Bootsma
L Coriell
5th row
L Langeler, C Tan
E R Giblett, C T Falk
W Bias
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Plate 2. 





H van Someren, P W Allderdice
J L Hamerton, P J McAlpine
2nd row
J German




E Nichols, G J Darlington, F Gilbert, G A Chase
F H Allen Jr, P J L Cook
4th row
P Meera Khan
P S Gerald, V A McKusick
C T Falk, K Hirschhorn
5th row
F A McMorris
D S Borgaonkar, MrsBorgaonkar, R S Kucherlapati
J A Tischfield, C Partridge
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Plate 3. 





P L Pearson, J Frézal
J H Edwards
2nd row
D M Steffensen, unidentified, H P Klinger
Participants
3rd row
H van Someren, R S Kucherlapati
G A Chase, G J Darlington, M J Murnane
L R Weitkamp, E A Nichols
4th row
G A Chase, J Ott
G J Darlington, F H Ruddle, R S Kucherlapati
5th row
E R Giblett, E A Nichols, J Mori, R Miller
T B Shows, J A Brown, P W Allderdice, C-C Lin 
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Appendix 2
Participants in the European Molecular Biology Organization (EMBO) 
workshop on ‘Cell Hybridization and  
Somatic Cell Genetics’, Oxford, 12–14 July 1973. Convened by 
Professor Walter Bodmer.

















16. Peter Goodfellow 










27. R T Johnston
28. –




33. unidentified, possibly Pat Gormley
34. Bette Robson
35. Ian Craig






























66. Anne Turner (later Anne Moir) 
67. Andries Westerveld 
68. Nguyen Van Cong
69. Harry van Someren
70. unidentified, possibly Liesbeth van 
Someren
* Peter Cook from the University of Oxford, 
not Peter Cook of the Galton Laboratory.
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Professor Egbert (Bert) Bakker
PhD (b. 1951) studied chemistry 
in Delft (BSc), continuing his 
studies at Leiden University 
(1975–1976) where he was also a 
technician (1977–1989). During 
this period he worked closely 
with Professor Peter Pearson 
and pioneered molecular genetic 
techniques, which led to the first 
prenatal diagnosis of Duchenne 
muscular dystrophy (DMD) in 
1985. In 1989 he completed his 
doctoral research on DMD (Bakker 
(1989)) and, the same year, was 
awarded the Lustrum Prize by the 
Dutch Human Genetics Society. 
In 1990 he became Head of the 
DNA diagnostic section in Leiden 
University’s Clinical Genetic Centre 
and became Associate Professor 
at the Department of Human 
Genetics. In conjunction with these 
roles, he was Head of the Forensic 
DNA-Laboratory at Leiden (1994–
2000). He was appointed Professor 
of Molecular Genetic Diagnosis at 
Leiden University Medical Center, 
where he is now Head of the 
Laboratory for Diagnostic Genome 
Analysis.
Professor Timothy Bishop
PhD FMedSci (b. 1953) was 
educated at the universities 
of Bristol and Sheffield, in 
mathematics and statistics, 
receiving his doctorate from the 
latter in 1978 in probability and 
statistics. In 1979, he moved 
to the University of Utah, Salt 
Lake City, where he commenced 
his postdoctoral research on 
investigating the links between 
data in the population records of 
Mormon families with Utah State’s 
cancer registration records and 
death certificates. Remaining in 
Utah, he became Assistant Professor 
at the Department of Medical 
Informatics (1979–1986) and then 
Associate Professor (1986–1989) 
and Adjunct Associate Professor 
(1989–1997). His research in the 
1980s was facilitated by the use 
of recombinant DNA technology 
to identify genetic variation and 
the production of genome maps 
to investigate the potential for 
identifying breast and colorectal 
cancer genes. Returning to the 
UK in 1989, he became Senior 
Scientist and Head of Laboratory 
at the Imperial Cancer Research 
Fund in Leeds, running a research 
Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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group in genetic epidemiology and 
familial cancer susceptibility. This 
group was a key research centre that 
contributed to international efforts 
to, eventually, map and identify 
the genes for breast and colorectal 
cancer. He is currently Director of 
the Leeds Institute of Cancer and 
Pathology (2011–).
Professor Sir Walter Bodmer
Kt FMedSci FRCPath FRS FSB 
(b. 1936) was educated at Clare 
College, Cambridge, UK; moving 
from a mathematics degree to 
population genetics for his doctoral 
research under R A Fisher, which 
was completed in 1959. As a 
postdoctoral fellow he worked 
with Nobel Laureate Joshua 
Lederberg at Stanford University’s 
Department of Genetics, USA, 
while training in molecular biology. 
At Stanford, he became Assistant 
and then Associate Professor 
of the Department of Genetics 
(1962–1968), and Professor 
(1968–1970), during which time 
he contributed to the discovery 
of the HLA system. From 1970 
he was Professor of Genetics, 
University of Oxford, until his 
appointment in 1979 as Director 
of Research at the Imperial Cancer 
Research Fund (ICRF), London. 
He became the first Director-
General of the ICRF (1991–1996). 
He was appointed Principal of 
Hertford College, University of 
Oxford (1996–2005), where he 
also became Head of the Cancer 
and Immunogenetics Laboratory 
at the Weatherall Institute of 
Molecular Medicine (funded by 
the ICRF, latterly, in part, by 
Cancer Research UK). His many 
distinguished awards and honorary 
positions include a Fellowship of 
the Royal Society, London, 1974; 
election to the National Academy 
of Sciences, USA, in 1981; (first) 
presidency of the International 
Federation of Associations for 
the Advancement of Science 
and Technology (1992–1994), 
and membership of the board 
of patrons, St Mark’s Hospital, 
London, since 1996 and, from 
2008 to 2014, Presidency of the 
Galton Institute. In 2013, he was 
also awarded a Royal Society Royal 
Medal ‘for seminal contributions to 
population genetics, gene mapping, 
and understanding of familial 
genetic disease’. He has published 
more than 700 papers and has also 
co-authored four books: Cavalli-
Sforza and Bodmer (1971); Jones 
and Bodmer (1974); Bodmer and 
Cavalli-Sforza (1976); Bodmer 
and McKie (1994). Sir Walter is 
credited as being one of the first 
people to propose the Human 
Genome Project.
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Professor Ian Craig
PhD (b. 1943) is Professor of 
Molecular Psychiatric Genetics and 
Head of the Molecular Genetics 
Section of the Social Genetic 
and Developmental Psychiatry 
Centre (SGDP), Kings College 
London, Institute of Psychiatry. 
He graduated in Biochemistry 
from the University of Liverpool 
and completed a PhD there 
in 1968, followed by a NATO 
Post-Doctoral Fellowship at the 
University of California, Santa 
Barbara. He returned to the UK 
with a position at the Genetics 
Unit at the Department of 
Biochemistry at Oxford University 
and was appointed to the titular 
post of Professor in Genetics there 
in 1996. His group was involved 
in one of the early positional 
cloning successes (a gene for 
X-linked blindness and mental 
retardation) and in the isolation 
and characterization of additional 
genes implicated in a range of 
human disorders. His interests in 
human gene mapping involved 
participation in the development 
of the Genome Database, GDB, 
as a Chromosome Editor and 
subsequently through election to 
the Human Genome Organisation 
(HUGO) Council (2000–2006) 
and appointment as Trustee to 
HUGO, London (2010). He 
moved to the SGDP Centre in 
1998 with interests in a variety of 
projects concentrating on searches 
for genes implicated in a range 
of behaviours and disorders. He 
also has a particular interest in 
the contributions of the X and Y 
chromosomes to sex differences 
in behaviour. Most recently, 
he has collaborated in whole 
genome association scans for genes 
implicated in the aetiology and 
pharmacogenetics of depression.
Professor John Hilton Edwards
FRCP FRS (1928–2007) held 
appointments in medicine, 
neurology, psychiatry, and 
pathology, in epidemiology and 
clinical genetics at Birmingham 
University from 1953 to 1979. He 
was Professor of Genetics and NHS 




FRCPath FRCP FMedSci FRSE 
FRS (b. 1931) is Emeritus 
Professor of Pathology, University 
of Cambridge, UK. He graduated 
in medicine at Glasgow University 
in 1955 and, while undertaking 
postgraduate training there in 
pathology, was introduced to 
research on sex chromatin under 
Bernard Lennox. An interest 
in Klinefelter’s syndrome that 
developed in the late 1950s led 
to his appointment as Fellow 
102
Human Gene Mapping Workshops c.1973–c.1991 – Biographical Notes 
in Medicine at Johns Hopkins 
University, Baltimore, in 1959, 
where he established the first 
chromosome diagnostic service 
in the USA and undertook 
cytogenetic research into Turner 
syndrome. Returning to Glasgow 
University in late 1961, he was 
appointed successively Lecturer, 
Senior Lecturer, Reader, and 
Director of the West of Scotland 
Regional Genetics Service before 
becoming Burton Professor of 
Medical Genetics in 1973. In 1987 
he was appointed Professor and 
Head of Pathology at Cambridge 
University and Director of the 
East Anglia Regional Genetics 
Service. Research interests include 
human gene mapping, molecular 
cytogenetics, karyotype evolution, 
vertebrate sex determination, and 
comparative genomics. In 1998, 
he moved to the Department of 
Veterinary Medicine to establish 
the Cambridge Resource Centre for 
Comparative Genomics. He is joint 
author of Essential Medical Genetics, 
6th edition (Tobias, Connor and 
Ferguson-Smith (2011)).
Professor Peter Goodfellow
PhD FMedSci FRS (b. 1951) 
studied at Oxford University, where 
his doctoral research was supervised 
by Professor Walter Bodmer. 
Between 1975 and 1979 he held 
postdoctoral fellowships at Oxford 
and Stanford Universities. He 
worked at the ICRF laboratories 
in Lincoln’s Inn Fields in London 
(now part of CRUK) for 13 years, 
becoming Principal Scientist 
(1986–1992), and then Balfour 
Professor of Genetics at Cambridge 
University (1992–1996). He 
was a member of the German 
Human Genome Project Advisory 
Board (1995–1999) and the UK 
Government’s Human Genetics 
Commission (2000–2002). 
From 1996 to 2006 he worked 
in the pharmaceutical industry as 
Worldwide Head of Research for 
SmithKline Beecham, and then as 
Senior Vice-President of Discovery 
Research at GlaxoSmithKline. He 
currently works for the venture 
capital company Abingworth, 
and is a board member of several 
companies and medical charities.
Professor Peter Harper
Kt FRCP (b. 1939) graduated 
from Oxford University in 1961, 
qualifying in medicine in 1964. 
After a series of clinical posts, he 
trained in medical genetics at the 
Liverpool Institute for Medical 
Genetics under Cyril Clarke and 
at Johns Hopkins University, 
Baltimore, under Victor McKusick. 
He was Professor of Medical 
Genetics at the University of Wales’ 
College of Medicine, Cardiff, from 
1971 until his retirement in 2004, 
when he was appointed University 
Research Professor in Human 
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Genetics, Cardiff University 
(Emeritus since 2008). He served 
on the UK’s Human Genetics 
Commission from 2000 to 2004 
and from 2004 to 2010 with the 
Nuffield Council on Bioethics. 
He has been closely involved with 
the identification of the genes 
underlying Huntington’s disease 
and muscular dystrophies, and 
with their application to predictive 
genetic testing. He has also been 
responsible for the development of 
a general medical genetics service 
for Wales. His books include 
Practical Genetic Counselling 
(Harper (1981)), Landmarks in 
Medical Genetics (Harper (2004)), 
First Years of Human Chromosomes 
(Harper (2006a)), and A Short 
History of Medical Genetics (Harper 
(2008)). For the past decade he 
has led an initiative, supported by 
the Wellcome Trust, to preserve 
and document the history of 
Human and Medical Genetics 
(www.genmedhist.org). He is 
a consultant to the ‘Makers of 
Modern Biomedicine Project’ for 
the History of Modern Biomedicine 
Research Group, Queen Mary, 
University of London.
Professor Harry Harris
FRCP FRS (1919–1994), 
biochemist and geneticist, 
qualified in medicine at Trinity 
College, Cambridge, served in 
the forces and joined the Galton 
Laboratory at UCL in 1947 where 
he pioneered the field of human 
biochemical genetics, became 
a lecturer in the Department 
of Biochemistry (1950–1953), 
Senior Lecturer (1953–1958), 
Reader in Biochemical Genetics 
(1958–1960), and Professor 
of Biochemistry, University of 
London (1960–1965). He was 
Honorary Director of the MRC 
Human Biochemical Genetics 
Research Unit (1961–1976), 
Professor of Human Genetics, 
University of London (1965–
1976), and Harnwell Professor of 
Human Genetics, University of 
Pennsylvania (1976–1990), later 
Emeritus. See Harris (1959).
Professor Veronica van Heyningen
CBE DPhil FRS FRSE FMedSci 
(b. 1946) studied at Cambridge 
(BA Cantab), Northwestern, Illinois 
(MS), and at Oxford (DPhil) with 
Professor Walter Bodmer as her 
supervisor. She was Beit Memorial 
Fellow at the Genetics Laboratory, 
Oxford (1973–1974), then the 
MRC Mammalian Genome Unit 
(1974–1976). She worked at the 
MRC’s Human Genetics Unit from 
1977, starting as a postdoctoral 
scientist, and becoming Head of 
the Cell and Molecular Genetics 
Section (now Medical and 
Developmental Genetics) in 1992, 
a post in which she remained until 
2012. In 1995 she was conferred 
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with an honorary professorship 
in the University of Edinburgh’s 
Faculty of Medicine, and from 
2000 to 2005 she was a member 
of the UK government’s Human 
Genetics Commission, chairing its 
Horizon-scanning subgroup. She 
served as President of the European 
Society of Human Genetics from 
2003 to 2004, and of the Genetics 
Society (UK) from 2009 to 2012, 
and was a member of the HUGO 
Council from 2006 to 2012. She is 
currently President of the Galton 
Institute.
Professor Maj Hultén
PhD MD FRCPath studied 
psychology at Stockholm 
University, then switched to 
genetics at the University of Lund, 
where she was inspired by Joe-Hin 
Tijo’s role in the identification of 
man’s 46 chromosomes, rather than 
48 as previously thought, during his 
visit to the university.277 She went 
on to study medicine, graduating 
from the Karolinska Institutet, 
Stockholm. In 1975, she moved 
to the UK to become the Head of 
the Regional Genetics Services at 
the East Birmingham/Heartlands 
Hospital, serving a population of 
5.5 million, a position she held 
until 1997. She was awarded an 
honorary professorial position at 
Birmingham University (1989–
1999) and at Warwick University 
(1996–2013). Since 2012, she 
has been Professor Emerita at the 
Karolinska Institutet, Stockholm. 
Her main research interests are 
the mechanisms of the origins of 
genetic disease and meiosis. She is 
also committed to the support of 
patient and carers’ associations for 
genetic disease, particularly as the 
Chief Medical Officer for Unique; 
www.rarechromo.org (visited 5 
March 2015).
Professor Victor McKusick
MD (1921–2008) qualified 
in medicine at Johns Hopkins 
University and completed his 
internship and residency in internal 
medicine there. He was Executive 
Chief of the Cardiovascular Unit 
at Baltimore Marine Hospital 
(1948–1950), while progressing 
through the ranks in the Johns 
Hopkins Department of Medicine. 
He also held joint professorships in 
epidemiology in the Johns Hopkins 
University School of Public Health 
and in biology. He founded the 
Division of Medical Genetics in 
1957, which he headed until 1973, 
when he became the William 
Osler Professor and Chairman 
of the Department of Medicine, 
and Physician-in-Chief of Johns 
277  See Hultén (2002) and Harper (2006b).
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Hopkins Hospital. He held these 
posts until 1985, when he was 
named University Professor of 
Medical Genetics.
Professor Sue Malcolm
PhD FRCPath was educated at 
Somerville College, University 
of Oxford, and at the Beatson 
Institute, University of Glasgow. 
Since 2002, she has been Emerita 
Professor of Molecular Genetics 
at the Institute of Child Health, 
University College London. She is 
also faculty member of the Faculty 
of 1000 Ltd. Her blog Me and My 
Genes takes a ‘light-hearted look at 
how genes rule your life’ and can 




PhD (b. 1942) was Director of 
Research Partnerships and Ventures 
at the Wellcome Trust and Chief 
Executive of the Wellcome Trust 
Genome Campus in Cambridge 
until his retirement in 2002. 
He joined the Trust in 1983, 
and was responsible for the 
development of new enterprises, 
such as DIAMOND, the new 
third generation synchrotron 
being built in partnership with 
the UK government and the SNPs 
Consortium (a partnership of the 
Trust and 12 private companies). 
He played a major role in the 
international coordination of the 
Human Genome Project and 
was also responsible for scientific 
establishments such as the 
Wellcome Trust Genome Campus. 
Following his retirement from the 
Trust, he was retained as a Director 
of DIAMOND and Chairman 
of the Structural Genomics 
Consortium, a partnership with 
Canadian and Swedish public 
entities and GlaxoSmithKline 
tasked with determining the 
structures of human proteins of 
importance to human health – 
Novartis and Merck joined the 
second phase of this enterprise. 
From 2006 until his retirement 
in 2009, he was Chief Scientific 
Officer of Genome Canada, where 
he instituted a new consultative 
process to determine strategic 
priorities for Canadian investments 
in genomic, proteomic, and allied 
research programmes. Morgan 
has also served as a Trustee of the 
Institute of Cancer Research, the 
Scottish Crop Research Institute, 
and the Transatlantic Harkness 
Foundation. He is a graduate 
of Trinity College, Dublin, and 
obtained his PhD from Leicester 
University.
Professor Sue Povey
MD MA (b. 1942) graduated 
in natural sciences (genetics) at 
Cambridge in 1964 and qualified 
in medicine in 1967. After brief 
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clinical experience at University 
College Hospital, London, 
Huddersfield, and working for 
Save the Children Fund in Algeria, 
she returned to University College 
London to join the MRC Human 
Biochemical Genetics unit under 
Harry Harris in 1970. Having 
obtained an MD in 1977, she 
became fascinated by human gene 
mapping and its many different 
techniques and was involved in all 
the HGM meetings between 1975 
and 1991. Her interests eventually 
focused on chromosome 9, for 
which she organized several Single 
Chromosome Workshops, pursuing 
the elusive TSC1 gene on 9q34 
(defective in some cases of tuberous 
sclerosis) for more than ten years 
until it was finally identified by 
international collaboration and 
intensive positional cloning in 
1997. From 1996 till 2007 she was 
Chair of the HUGO Human Gene 
Nomenclature Committee with 
a team supported by the MRC, 
NIH, and the Wellcome Trust. 
Elected a Fellow of the Academy 
of Medical Sciences in 2001, she 
was Deputy Director of the MRC 
Unit (1989–2000), then appointed 
Haldane Professor of Human 
Genetics at UCL and Editor of 
the Annals of Human Genetics 
until her retirement in 2007. As 
Professor Emeritus of Human 
Genetics her interest in tuberous 
sclerosis continues in the curation 
of the TSC1 and TSC2 locus-
specific mutation databases, and 
she has chaired a working group 
drafting ethical guidelines for such 
databases.
Professor Chris Rawlings
PhD (b. 1954) started his 
bioinformatics career at the 
Imperial Cancer Research Fund in 
1982 during which time he was the 
Project Manager for the computing 
infrastructure needed for the 
Human Gene Mapping Workshops 
(10.5 and 11). From 1991 to 1996, 
he led a group that researched 
the application of advanced logic 
languages to genetic mapping and 
protein structure bioinformatics. 
In 1996 he moved to SmithKline 
Beecham, where he was responsible 
for the bioinformatics platforms 
supporting human genetics, 
comparative genomics, and gene 
expression. From 2000 to 2004, he 
was the Director of Bioinformatics 
at Oxagen Ltd, where his group 
worked on the identification 
and validation of genes and drug 
targets from human genetics 
and genomics technologies. He 
moved to Rothamsted Research 
in 2004, where he now leads the 
Department of Computational and 
Systems Biology, which comprises 
over 30 staff and students engaged 
in research into, and application 
of, bioinformatics, mathematical 
modelling, and statistics to 
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problems from the agricultural 
sciences. His personal research 
interests are in the development 
and use of data integration systems 
for supporting systems biology 
and for candidate gene discovery 
from multi-omics datasets. He 
is a visiting Professor in the 
Department of Computing at 
Imperial College London, and 
was also one of the founding 
members and former Vice President 
of the International Society for 
Computational Biology.
Professor Frank Ruddle
PhD (1929–2013) studied 
zoology at the University of 
California, Berkeley. He conducted 
postdoctoral research at Guido 
Pontecorvo’s laboratory in Glasgow 
from 1960 to 1961, working with 
John Paul. He returned to the 
USA and worked at Yale for the 
remainder of his career, becoming 
a professor in 1972 and helping 
to found the University’s Human 
Genetics Department. In 1973 he 
convened the first Human Gene 
Mapping Workshop at Yale, New 
Haven (Connecticut, USA) and 
was joint Conference Scientific 
Editor for HGM1–3. He also 
developed the first computerized 
database of human gene mapping 
data. For an obituary see 
Kucherlapati and Leinwand (2013).
Professor Ellen Solomon
PhD FMedSci (b. 1943) studied 
biological chemistry at Harvard 
University. Her postdoctoral 
fellowship at the Institut Pasteur 
(1971–1973) was followed by 
fellowships at the University 
of California Medical Center 
(1973–1974) and at the Genetics 
Laboratory at Oxford’s Department 
of Biochemistry (1974–1976). 
From 1976 to 1979 she was 
Senior Scientist at the Imperial 
Cancer Research Fund, London, 
then Principal Scientist from 
1986 to 1995. At King’s College 
London School of Medicine, from 
1995 to 2009, she was Head of 
the Department of Medical and 
Molecular Genetics and of the 
Division of Genetics and Molecular 
Genetics. At King’s, at present, 
she is Prince Phillip Professor of 
Human Genetics (since 2004); 
Research Dean of the London 
School of Medicine (2004–2013), 
and Dean for International Affairs 
(2008–2013). She was a member 
of the Executive Committee of the 
Human Gene Mapping Committee 
from 1991 to 1995, and co-
organized HGM11 with Professor 
Sir Walter Bodmer. She was also 
Chairman of the Chromosome 
17 Committee for HGM9.5, 
10.5, and 11, and co-organized 
the Chromosome 17 Single-
Chromosome Workshops in 1990, 
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1991, and 1992. In 1992 she was 
elected to EMBO and in 1995 to 
the HUGO Council. She was on 
the editorial board of Cytogenetics 
and Cell Genetics from 1980 to 
1985, and currently serves on 
the editorial boards of Human 
Genomics.  
Professor Tilli Tansey
OBE PhD PhD DSc HonFRCP 
FMedSci (b. 1953) graduated in 
zoology from the University of 
Sheffield in 1974, and obtained her 
PhD in Octopus neurochemistry 
in 1978. She worked as a 
neuroscientist in the Stazione 
Zoologica Naples, the Marine 
Laboratory in Plymouth, the MRC 
Brain Metabolism Unit, Edinburgh, 
and was a Multiple Sclerosis Society 
Research Fellow at St Thomas’ 
Hospital, London (1983–1986). 
After a short sabbatical break at 
the Wellcome Institute for the 
History of Medicine (WIHM), 
she took a second PhD in medical 
history on the career of Sir Henry 
Dale, and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History of 
Modern Medical Sciences at UCL 
in 2007 and moved to Queen Mary 
University of London (QMUL), 
with the same title, in 2010. With 
the late Sir Christopher Booth she 
created the History of Twentieth 
Century Medicine Group in the 
early 1990s, now the History of 
Modern Biomedicine Research 
Group at QMUL.
Dr Susan Wallace
PhD (b. 1960) is Lecturer of 
Population and Public Health 
Sciences in the Department of 
Health Sciences at the University 
of Leicester. Her research interests 
include the legal and policy 
implications of population-based 
and disease-based longitudinal 
cohort studies and biobanks; the 
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